The effects of chronic methamphetamine treatment on amine metabolism in rat brain in vivo. by Bardsley, Maria E.
        
University of Bath
PHD









If you require this document in an alternative format, please contact:
openaccess@bath.ac.uk
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 18. Sep. 2021
THE EFFECTS OF CHRONIC METHAMPHETAMINE 
TREATMENT ON AMINE METABOLISM IN RAT 
BRAIN IN VIVO
Submitted by Marie E. Bardsley 
for the degree of Ph.D. 
of the University of Bath 
1978
COPYRIGHT
Attention is drawn to the fact that copyright of this thesis rests 
with its author. This copy of the thesis has been supplied on 
condition that anyone who consults it is understood to recognise 
that its copyright rests with its author and that no quotation 
from the thesis and no information derived from it may be published 
without the prior written consent of the author.
This thesis may be made available for consultation within the 
University Library and may be photocopied or lent to other libraries 




INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest.
ProQuest U442557
Published by ProQuest LLC(2015). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States Code.
Microform Edition © ProQuest LLC.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
TO MY PARENTS
The Gods did not reveal, from the beginning.
All things to us, but in the course of time 
Through seeking we may leam and know things better. 
But as for certain truth, no man has known it.
Nor shall he know it, neither of the gods 
Nor yet of all the things of which I speak.
For if by chance he were to utter
The final truth, he would himself not know it:
For all is but a woven web of guesses.
Xenophanes
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Rats were chronically treated with methamphetamine over a seven 
week period during which time their weights, food consumption and 
drinking rates were recorded. The effects of chronic treatment 
with, and withdrawal from, methamphetamine on amine metabolism 
in selected brain regions was investigated. Three groups of 
experimental animals were studied; chronically treated rats, rats 
which had been withdrawn from the drug for 36 h and controls.
The parameters chosen to reflect changes in catecholamine 
metabolism in the brain were: tyrosine hydroxylase activity and the 
levels of noradrenaline, dopamine and their non-O-methylated meta­
bolites and of phenylalanine and tyrosine. The metabolism of 
serotonin was studied by measuring the levels of "free" tryptophan 
in the plasma,and the levels of tryptophan and serotonin in the brain.
Initially the methamphetamine was administered in the drinking 
water at doses of 5, 10, 20 and 40 mg/kg/24 h increasing in a 
stepwise manner over a period of 20 days. This dose was found to 
produce toxic reactions in the rats and it was found that it was 
not possible to control the intake of the drug. In subsequent 
experiments the rats were given 5, 10 and 15 mg/kg/24 h i.p. 
increasing in a stepwise manner over a period of 15 days.
The first set of injected animals did not develop tolerance to 
the anorexic effects of methamphetamine and the chronically treated 
and withdrawn animals showed changes in tyrosine hydroxylase 
activity and in the levels of noradrenaline and dopamine.
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The three other sets of injected animals did develop tolerance 
to the anorexic effects of methamphetamine. Tyrosine hydroxylase 
and the levels of noradrenaline, dopamine, their non-O-methylated 
metabolites and of tryptophan and serotonin did not change in 
these chronically-treated or withdrawn animals, but changes were 
seen in the levels of "free" tryptophan in the plasma and the levels 
of most amino acids in the brain.
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II. INTRODUCTION
A. CLINICAL ASPECTS OF AMPHETAMINE USE
Historically the study of amphetamines began in 1887 when Edeleano pre­
pared the volatile^amine phenylisopropylamine (amphetamine). Barger 
and Dale (1910) found that it was related to adrenaline in its pharma­
cological actions (see Connell, 1970). In 1927 Allés synthesized 
amphetamine in the course of a search for a substance to replace ephe- 
drine, which was difficult to obtain from its natural sources. This led 
to an exploration of the clinical uses of this group of drugs and even­
tually to the production of an amphetamine sulphate inhaler in 1932.
Further studies led to the separation of amphetamine into dextro and laevo 
isomers, the former being now well known as dexamphetamine. Emde (1929) 
prepared the drug now known as methylamphetamine.
There are more than fifty preparations of amphetamine substances either 
alone or in combination with other drugs (notably barbiturates), on the 
market at the present time, the well known ones including amphetamine 
itself ('durophet'), dexamphetamine ('dexedrine'), methylamphetamine 
('methedrine') and phenmetrazine ('preludin'). Some of the structures, 
together with the catecholamines are shown in Figure 1.
The amphetamines are a group of structurally related compounds with 
sympathomimetic and central stimulant properties. They were first used 
in medical practice in the early 1930's for the treatment of allergies 
(specifically those involving bronchial spasms), depression, fatigue, 
obesity and Parkinson's disease. Owing to their wide range of actions 
they rapidly came onto the general market as a general panacea to 
'cure all ills' . When the addictive properties of the amphetamines were 
realised they were rapidly removed from the market.
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Owing to the undesirable side-effects of the amphetamines which, 
apart from leading to dependence, have been suggested to produce be­
havioural and other physical pathology with prolonged use at high 
doses, their clinical use has been curtailed (Honigfeld and Howard,
1973; A.M.A. Drug Evaluations, 1973). Their efficacy in the 
treatment of depression and Parkinson's disease is also questionable.
It appears that only certain forms of depression are relieved by amphe­
tamine treatment. Amphetamine or amphetamine-barbiturate combinations 
have been used on a variety of depressed patients (General Practitioner 
Research Group, 1964; Hare et ai., 1962; Overall et ai., 1962). In 
all studies amphetamine was found to be no more effective than placebo, 
and, in some cases, patients treated with amphetamine became worse. 
However, Weii-Malherbe and Szara claim that amphetamine is "undoubtedly 
an effective antidepressant" (Weil-Malherbe and Szara, 1971), but as 
no reference is given to any clinical trials it is impossible to assess 
this statement.
Studies carried out by Finkelman and Shapiro (1937) and Davis and 
Stewart (1938) on patients with post-encephalitic Parkinson's disease 
showed that although subjective improvements in mood and energy were 
observed together with reversal of disordered sleep rhythms, there was 
no objective evidence for any improvement in the motor disturbances 
characteristic of Parkinson's disease. Amphetamines however did have 
a dramatic effect on the oculogyric crisis of post-encephalitic 
Parkinsonism, which was often abolished (Davis and Stewart, 1938;
Matthews,1938). It is perhaps interesting to note that patients with 
post-encephalitic Parkinson's disease showed no signs of developing 
tolerance or becoming addicted to amphetamine (Solomon at ai., 1937).
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The amphetamines are still used clinically in the treatment of 
narcolepsy, obesity, epilepsy, depression and various psychological 
disturbances which do not respond to other forms of treatment. Narco­
lepsy was probably the first condition for which amphetamine was used 
clinically (Prinzmetal & Bloomberg, 1935). It revolutionized therapy 
in the condition, and although not curative, in that it does nothing 
to eradicate the underlying disturbance, the drug may enable the patient 
to become symptom-free. Amphetamine was first used in epilepsy because 
of its action in antagonizing the sedative effects of narcotics. It 
was later found that amphetamine itself may have beneficial effects, 
particularly in the milder epileptic states. However, owing to 
differing responses, when given it is usually in combination with other 
anticonvulsant drugs (Connell, 1968).
The property of amphetamine sulphate in modifying antisocial be­
haviour " in children was reported by Bradley & Bowen (1941). Children 
who were withdrawn or lethargic became more alert and sociable, and 
aggressive, noisy children who were hyperactive tended to calm down.
Large doses were readily tolerated and as much as 60 mg of amphetamine 
sulphate a day was used. More recently the use of amphetamines in the 
treatment of hyperkinetic syndrome in children with presumed "minimal 
brain dysfunction" (Klein & Davis, 1969) in America has evoked contro­
versy and the accusation that the children are being "controlled for the 
classroom". The possibility of side-effects from large, daily doses of 
amphetamine has also been raised. The apparently paradoxical effects of 
the amphetamines on the children had been noticed previously with psycho­
pathic patients. The current explanation given by behavioural pharma­
cologists of this apparent paradox is that the hyperactive
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children have a different baseline of activity from normal children, 
and the dose-response curve for amphetamine on locomotor activity is 
an inverted U-shaped function. The reason for the decrease in loco­
motor activity at high doses is the onset of stereotypy. Consequently 
the hypothesis is that the hyperkinetic children may be developing a 
mild form of stereotypy, which is seen as increased focussing of 
attention and an increased ability to perform the simple repetitive 
tasks demanded of children in school. Associated with this is the 
prediction that these children would have problems with tasks demanding 
a wider span of attention. This theory is, however, still purely 
hypothetical.
Methylamphetamine has been used in psychiatric practice as an ab- 
reactive agent in the treatment of neurotic conditions and also as an 
aid in the diagnosis of psychiatric disorders. However the frequency 
of its use in psychiatric therapy is diminishing.
The general effects of amphetamine include anorexia, although 
tolerance occurs rapidly to this effect, and within 2 - 3  weeks of daily 
treatment the drug no longer depresses food intake. Amphetamine is 
a strong central stimulant, decreasing sleeping, fatigue and stimulating 
the medullary respiratory centre. The sympathomimetic properties 
induce a general stimulation of the sympathetic nervous system, the 
effects of which include increased heart rate and dilation of the 
bronchioles. Amphetamine can produce repetitive motor activity 
(stereotyped behaviour) e.g. the assembling and disassembling of a 
piece of mechanical equipment. It is also reported to improve attention, 
especially after prolonged sleep deprivation. Subjective reports in-
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dicate that amphetamine causes euphoria and an increased ability to 
concentrate (Goodman & Gilman, 1970; Klein & Davis, 1969).
Research into the effects of the amphetamines has undoubtedly been 
catalysed by the outbreaks of amphetamine taking which occurred in 
Sweden around 1965, and in Japan in the 1950's. While the amphetamines 
were still generally available, young people in America started to use 
benzedrine-containing inhalers for their euphoriant effects. As early 
as this the paradoxical effects of amphetamine were noted, as some 
reports suggested that a form of self-medication occurred, in the sense 
that the amphetamines suppressed certain forms of agitated, juvenile 
'psychopathic' behaviour (Eisenberg, 1963; Pasamanick, 1951).
The Swedish outbreak of amphetamine abuse began with oral amphe­
tamine consumption by bohemian artists, writers and actors in Stockholm 
in the 1940's. It spread downwards in terms of status so that anti­
social and criminal groups had adopted it by the 1950's. In 1958 
an increased illicit supply, brought in from Spain, allowed further 
non-medical use, at which time other urban centres became involved 
and younger people became interested. In 1965 one out of every ten 
people arrested in Stockholm was taking phenmetrazine intravenously.
Use was largely amongst males in the twenty to thirty age-group 
(Bejerot, 1966).
About the same time a similar situation existed in Japan (Masaki, 
1956). Here, use was attributed to the availability after the war 
of large military supplies of amphetamine, and to marked changes in 
social life following defeat in war, and democratization of government.
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Young people began to use amphetamine in such numbers that a survey 
in one city showed that 5% of people in the 16 to 25 age-group had used 
amphetamines; among these non-medical users about one quarter of the 
group were considered dependent or suffering ill-effects. By 1954 
it was estimated that there were about half a million users, with 
half showing dependence. Even children of 12 were giving themselves 
intravenous injections of methylamphetamine (V7H0,- 1956) . A later report 
suggested that there were one and a half, million users, almost all of whom were 
young people (Ministry of Health and Welfare, Japan, 1964). Again a 
high concentration of use was reported amongst delinquents and artists.
England also experienced an increase in non-medical and disapproved 
amphetamine use among young people (Bewley, 1966; Scott & Wilson, 1965),
In response to public concern,generated in part by newspapers, a Drug 
Misuse Act was passed in 1964, making it an offence to possess amphet­
amine without medical authority. However, medical prescription does 
not guarantee limited use. A study by Kiloh & Brandon (1962) showed 
that five hundred people in an English town of 250,000 had become 
dependent on amphetamine (most of these were middle-aged women). An 
extrapolated estimate gives a rate of 1/1000 or 2/1000 in England 
for such iatrogenic dependency. As for illicit use, Bewley estimated 
it to be approximately the same order of magnitude.
The side effects which have been noted when therapeutic doses of 
amphetamine are taken include mild gastro-intestinal disturbance, 
anorexia, dryness of the mouth, tachycardia, cardiac arrhythmias, 
insomnia and restlessness (Meyler, 1966). Headache, palpitations, 
dizziness, vasomotor disturbances, agitation, confusion, dysphoria,
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apprehension and delirium are also mentioned (Goodman & Gilman, 1966). 
Other side effects have been noted (Rudolph, 1955) such as flushing, 
pallor, sensation of swaying, excessive sweating, muscular pains. 
Tiredness and sleepiness, lethargy and listlessness may occur when 
the effect wears off, together with mild depression of mood. Side- 
effects on withdrawal in a patient who has taken large quantities of 
the drug include excessive tiredness and sleepiness, but, more import­
ant, may include severe depression with suicidal ideas and the danger 
of suicidal attempts.
Many amphetamine addicts have been misdiagnosed as paranoid 
schizophrenics; this was very common during the Japanese outbreak of 
amphetamine use. This psychosis, which most frequently developed in 
people with a long history of amphetamine abuse (Kalant, 1973), was 
first described by Connell (1958). Connell's study was based on a 
study of 42 patients who took amphetamine alone. Essentially the 
psychosis is a paranoid psychosis in a setting of clear consciousness; 
the experiences of the patient are well remembered by the patient and 
will include ideas of persecution and hallucinations, which may be 
both visual and auditory. The psychosis remits quickly in a few days 
and before the drug has been fully excreted.
In Sweden, where young people were injecting phenmetrazine intra­
venously, the symptomology included ideas of persecution by the police 
and was called, by the Swedish workers 'police paranoia’. It was the 
situation in Japan which, by virtue of the large numbers of people 
involved, really drew attention to the dangers of dependence, and the 
occurrence of the amphetamine psychosis.
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Oswald & Thacore (1963) referred to the ubiquity of amphetamine 
addiction, and demonstrated by the use of electroencephalographic 
methods that the normal sleep pattern was altered on withdrawal of 
these drugs and that disturbance of sleep continued some days or weeks 
after the drug could have been assumed to have been totally excreted 
(but see Discussion). Many of the drug-dependent adults are first put 
on amphetamine by their doctor; Connell (1958) noted that 11 of the 
42 patients he studied had been prescribed the drug initially by 
doctors. Doses the patients built up ranged from 30 - 975 mg a day. 
Higher doses have been reported.
In summary, the amphetamines are commonly abused drugs. Epidemics 
of amphetamine use have centred around the 15 - 30 age group in Japan, 
Sweden, England and America (four of the most technically advanced 
nations). Methedrine, or methamphetamine,was the most common compound 
taken. However there is no evidence that use in itself leads to ill- 
effects; some who take amphetamine in excessive doses do show toxic 
reactions, while others taking them on a chronic basis show dependency. 
Either situation may precipitate a psychosis, which has come to be 
known as the amphetamine psychosis.
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B. BIOCHEMICAL EFFECTS OF AI^HETAMINE IN VIVO AND IN VITRO
A report by Burn and Rand (1958) suggested that amphetamine and 
a series of other phenylethylamine derivatives exerted their peripheral 
sympathomimetic actions indirectly via the catecholamines. Since 
then there has been a plethora of literature on the biochemical effects 
of amphetamine on adrenergic neurons. It has now become clear that 
amphetamine affects storage, uptake, release and metabolic degradation 
of the catecholamines in both the peripheral and central nervous systems 
I feel that it is important to consider the effects of amphetamine on 
the periphery as well as the brain, as it is easy to rationalize or 
explain changes in the brain as though it were not connected to the 
rest of the body.
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1. structure-Activity Relationships
The amphetamines are a group of synthetic compounds whose basic 
structure is shown in Figure 1, together with those of the catecholamines; 
adrenaline, noradrenaline and dopamine. Amphetamine, methamphetamine 
and the catecholamines, noradrenaline and adrenaline, have asymmetric 
centres giving rise to optical activity. In the case of amphetamine, 
rotation occurs around the a-methyl group, and with noradrenaline and 
dopamine, around the 3-hydroxy group. The two carbon side-chain 
between the phenyl and amino acids is common to the amphetamines and 
the catecholamines.
Daly et al, (1966) studied the release of {]̂ h] - noradrenaline from 
mouse heart induced by pharmacological agents structurally related to 
the catecholamines. Their experiments showed the ability of (+)- and 
(-)-amphetamine and methamphetamine to release noradrenaline from 
the mouse heart. Daly showed that progressive méthylation either of 
the amino group or of the side-chain progressively decreases the 
characteristic actions of amphetamine. Shifting the a-methyl group 
to the 3 position abolishes essentially all of the central and anorexic 
effects of amphetamine (Biel, 1970).
Amphetamine has been shown to be a potent inhibitor of nor­
adrenaline uptake systems (Burgen & Iversen, 1965). Iversen (1965) 
showed that, in rat heart, there are two separate uptake mechanisms for 
noradrenaline and adrenaline. Uptake^ operates at low concentrations 
of the perfused amine and Uptake^ at high concentrations of the perfused 
amine. The kinetic parameters of the uptake mechanisms showed that 
they were two distinct processes. Iversen that Uptake^
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might be brought into action after the release of noradrenaline 
into the synaptic cleft. The local high concentrations of nor­
adrenaline could be rapidly removed so as to terminate its neuro­
transmitter actions.
Burgen & Iversen (1965) studied the inhibition of noradrenaline 
uptake by sympathomimetic amines. They demonstrated the importance 
of the a-methyl group of amphetamine in inhibiting Uptake^. The 
(-) form was shown to be one twentieth as potent as the (+) form , and 
(+) methamphetamine was 0.3 times less potent than (+) amphetamine.
The ability of the various amines to inhibit Uptake^ correlates well 
with the potency of these drugs in eliciting the characteristic be­
havioural responses.
Uptake^ showed radically different affinities for the various 
inhibitors tested. Opposite effects were found with 3-hydroxylation
and a-methylation. 3-Hydroxylation increased the affinity slightly
and no difference was observed between the two optical isomers. The 
a-methyl group on amphetamine reduced its affinity. It was interesting 
that the 0-methylated metabolites of adrenaline and noradrenaline 
(metanephrine and normetanephrine) were potent inhibitors of Uptake^r 
but relatively poor inhibitors of Uptake^.
Most of the structure-activity relationships between the amphe­
tamines have been elucidated using the sympathetic innervation of 
the heart as the model system, and comparing the relative abilities 
of the various compounds tested to bring about the release of nora­
drenaline or to inhibit the uptake of noradrenaline (e.g. Daly et ai., 
1966; Burgen & Iversen, 1965) .
-13-
2. Storage of Catecholamines and other putative neurotransmitters
In this section on storage I am going to limit myself to those 
studies which have been carried out on rats, owing to the large number 
of disparate reports not only within species but between species, and 
in view of the fact that my studies have been carried out on rats.
(i) Catecholamines in peripheral tissues
Acute injections of amphetamine, administered i.p., s.c., or 
i.v. to rats, caused a decrease in noradrenaline in the heart (Axelrod 
& Tomchick, I960: Axelrod et ai., 1962; Potter & Axelrod, 1963;
Lewander, 1968 a,b; Brodie et ai., 1970). Noradrenaline was also 
found to be depleted in the stomach (Brodie et ai., 1970). Adrenaline 
and noradrenaline are depleted in the adrenal gland; the extent varies 
with the dose. A 3.5 mg/kg injection of (+)-amphetamine tartrate has 
been reported to decrease adrenaline,levels by 70% and noradrenaline 
levels by 60% (Beauvallet et ai., 1962a).
The chronic administration of (±)-amphetamine sulphate caused a 
maximal depletion of heart noradrenaline to 40 - 50% of the control 
value (Lewander, 1968b, 1971a). Similar results were reported by 
Brodie et al. (1970) for the heart and stomach. Tolerance to this 
effect has been shown to occur in the adrenal gland. Lewander (1968a, 
b) showed that a single injection of 20 mg/kg of (±)-amphetamine 
sulphate decreased the levels of adrenaline in the adrenal gland to 
80% of the control value, but after chronic administration of the drug, 
the levels were unchanged.
(ii) Brain catecholamines
Acute experiments in which a single dose of amphetamine is
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administered (i.p., s.c. or i.v.) caused a decrease in brain noradren­
aline (Moore & Lariviere, 1963, 1964; Baird & Lewis, 1963, 1964;
Carlsson et al., 1965; Corrodi et al., 1967; Lewander, 1968 a, b;
Baird, 1968; Brodie et al., 1969; Groppetti & Costa, 1969b; Taylor 
& Snyder, 1970, 1971; Costa & Groppetti, 1970; Simon et al., 1970b; 
Lewander, 1971 a, b; Leonard & Shallice, 1971; Leonard, 1972;
Costa et al., 1972; Click et al., 1974). The decrease in brain 
noradrenaline is dose dependent (Moore & Lariviere, 1963; Baird &
Lewis, 1964; Leonard & Shallice, .1971). After sublethal doses 
(10 - 20 mg/kg of (+)-amphetamine sulphate) the maximal noradrenaline 
depletion is about 50% of the control level and doses of (+)- or 
(-)-amphetamine below 2 mg/kg seem to produce little, variable or no 
effects, (Baird & Lewis, 1964; Littleton, 1967; Corrodi et al., 1967; 
Brodie et ai., 1970; Leonard and Shallice, 1971). Intracisternal 
injection of 40 pig of (+)-amphetamine does not change brain noradrenaline 
or.dopamine levels (Breese et ai., 1970; Taylor & Sulser, 1973). 
Comparisons of the effect of different doses of (+)-and (-)-amphetamine 
show that the (+) isomer is 2 to 3 times more effective than the (-) 
isomer with respect to the depletion of brain noradrenaline levels.
(Baird & Lewis, 1964; Taylor & Snyder, 1970, 1971; Brodie et ai.,
1970; Lewander, 1971a; Costa et ai., 1972). The racemic mixture 
((±)-amphetamine) gives an intermediate response (Lewander, 1971a).
The decrease in noradrenaline levels seems to be variable between 
different brain areas (Taylor & Snyder, 1970). The time response 
curves show that the noradrenaline depletion persists for 1 to 4 days, 
depending on the dose, after single injections of (+)- or (-)-amphetamine, 
(Brodie et al., 1969; Groppetti & Costa, 1969b; Brodie et ai., 1970; 
Costa & Groppetti, 1970; Lewander, 1970a, 1971a). The duration of
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the depletion of noradrenaline levels after (-)-amphetamine is 
shorter (Brodie et al., 1970).
Amphetamine, in combination with grid shock stress (Moore & 
Lariviere, 1963, 1964), forced muscular work (Beauvallet et al.,
1962b), cold stress (Salama & Goldberg, 1969) or increasing the room 
temperature to 33°C (Beauvallet et al., 1967; Beauvallet, 1968), caused 
a more pronounced decrease in the levels of noradrenaline in the brain 
than amphetamine alone.
Methamphetamine also depleted the levels of noradrenaline in the 
brain (Cook & Schanberg, 1970; Leonard, 1972), and abolished the 
daily rhythm of hypothalamic noradrenaline (Asano & Moroji, 1974)
Reports on the acute effects of amphetamine on whole brain, or 
striatal dopamine are not consistent. Some authors have reported 
unchanged or slighlydess than 15%) decreased levels (Moore &
Lariviere, 1963, 1964; Baird & Lewis, 1963, 1964; Carlsson et al., 
1965; Gunne & Lewander, 1967; Corrodi et al., 1967; Baird, 1968; 
Breese et al., 1970; Taylor & Snyder, 1970. 1971; Leonard & Shallice, 
1971; Leonard, 1972; Costa et al., 1972; Click et al., 1974), while 
others have reported an increase by up to 24%, (Littleton, 1967; 
Lewander, 1968a, b, 1971a, b) with doses of between 10 - 20 mg/kg 
about 3 h after the administration of either of the isomers or the 
racemate of the drug. The increase in the levels of dopamine in 
the brain after amphetamine administration was potentiated by keeping 
the animals at 33°C, which induced hyperthermia (40°C colonic temp­
erature; Beauvallet, 1968). Lesioning the nigrostriatal dopaminergic
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pathway abolished the amphetamine-induced increase in the levels of
dopamine in the brain (Boulu et al., 1972). Various forms of stress
(grid shock, restraint, swim, sound) in combination with amphetamine 
had no additional effect on the levels of dopamine in the brain 
(Moore & Lariviere, 1963). Injection of 40 yg of amphetamine into 
the cerebral cisternae did not affect the concentrations of dopamine 
in the brain (Breese et ai., 1970).
Methamphetamine (15 mg/kg) caused no change ■ in the levels of 
dopamine in the brain initially but the levels decreased on repeated admini­
stration of the drug. (Koda and Gibb, 1978) .
(iii) Effects of chronic amphetamine administration on brain.catecholamines
Repeated injections of amphetamine of as much as 20 mg/kg of 
the (±)-isomer of the drug once or twice daily for as long as 1 month 
have been shown to induce an additional decrease in the levels of 
noradrenaline in the brain but never exceeding 40 to 50% of control 
levels (McLean & McCartney, 1961; Gunne & Lewander, 1967; Beauvallet, 
1968; Javoy et ai., 1968; Lewander, 1968b, 1971b; Brodie et ai.,
1970). The noradrenaline levels in the brain stem and hippocampus 
were reduced, but unchanged in other areas of rat brain after giving 
3 mg/kg of (±)-amphetamine sulphate daily in the food for 6 months 
(Herman et ai., 1971a). No difference between controls and chronically- 
treated rats was found after 9 months of the same drug regime (Herman 
et ai., 1971b). Acute and chronic treatment with methamphetamine 
caused reduced noradrenaline levels in the brain, (Cook & Schanberg,
1970; Schanberg & Cook, 1972).
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Chronic administration of (±)-amphetamine sulphate, 20 mg/kg 
twice daily for 1 week or 16 to 32 mg/kg twice daily for 1 month, 
caused a decrease to 85% and 50% respectively of the control level 
of dopamine in the whole brain (Gunne & Lewander, 1967; Lewander 
1968b, 1971e). Daily administration of 3 mg/kg of (±)-amphetamine in 
the food for 6 months decreased the levels of dopamine in the hippo­
campus to 60% of the control level but did not change the dopamine 
levels in any other region including the striatum (Herman et al.,
1971a). According to histochemical studies, the depletion in 
dopamine levels after chronic treatment with amphetamine seemed to be 
confined to the nigrostriatal dopaminergic system and not to involve 
the hypothalamic dopaminergic neurons (Fuxe & Ungerstedt, 1970).
(»v) The effects of amphetamine on the levels of serotonin in the brain 
Reports on the effects of amphetamine on 5-hydroxytryptamine 
levels are inconsistent. In rats (+) or (±)-amphetamine , in doses 
of between 0.6 and 30 mg/kg given 0.5 to 16 h before killing the 
animals did not, in most studies, affect the levels of 5-hydroxytryp- 
tamine in the whole brain, (Pletscher et al., 1964; Carlsson et al., 
1965; Beauvallet et al., 1967; Salama & Goldberg, 1969; Ganguli, 
1969; Costa & Groppetti, 1970; Maickel et al., 1970; Reid, 1970 a, 
b; Simon et al., 1970b; Tagliomonte et al., 1971a, b; Leonard & 
Shallice, 1971; Gdrlitz & Frey, 1972; Morgan et al., 1972a;
Fuller et al., 1972b). Salana & Goldberg (1969) and Leonard 
(1972) reported a decrease in 5-hydroxytryptamine levels after amphe­
tamine treatment. Beauvallet et ai. (1969, 1970) found an increase 
in 5-hydroxytryptamine levels in the whole brain or in the striatum.
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pons and mesencephalon but no change in the cortex and medulla oblongata 
after giving 15 mg/kg of amphetamine.
Methamphetamine in doses of 7 to 14.5 mg/kg given 1 - 6 h 
before death reduced the levels of 5-hydroxytryptamine in the brain 
by 25 - 47%; (+)- and (-)-methamphetamine were equally effective in
this respect (Morgan et al., 1972a; Leonard, 1972). Determination 
of 5-hydroxytryptamine in different brain areas (Ott et ai., 1971) 
showed that methamphetamine (5 mg/kg, 40 min before death) caused a 
reduction in the cortex, olfactory bulb and hippocampus, while no 
change occurred in six other regions. Ganguly (1969) reported an 
increase in the levels of 5-hydroxytryptamine in the brain after meth­
amphetamine treatment which was abolished by chlorpromazine pretreatment.
McLean & McCartney (1961) reported a 20 - 30% increase in 5- 
hydroxytryptamine levels after repeated administration or chronic 
treatment with (+)-amphetamine (16 - 32 mg/kg). Similar results 
were later reported by Diaz & Huttunen (1972) . The administration 
of 3 mg/kg of amphetamine daily did not change the levels of 5- 
hydroxytryptamine in the brain (Herman et al., 1971b).
(v ) The effects of amphetamine on the levels of brain acetylcholine
Aqjtylcholine levels in the brain have been reported to be 
decreased after giving 2 mg/kg of amphetamine (Domino & Olds, 1972; 
Domino & Wilson, 1972) but only in young or very old animals (Vasko 
et al., 1974). The acetylcholine levels increased after amphetamine 
treatment (10 to 20 mg/kg) in striatal tissue
from adult female rats (Consolo et all, 1974; Click et al., 1974).
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(vi )The effect of amphetamine on the levels of y-amino butyric acid
and substance P
Levels of brain y-aminobutyric acid (GABA) and substance P have 
recently been shown to change on acute administration of amphetamine.Lynch & 
Leonard (1978) found that acute administration (5 mg/kg) of (+)- 
amphetamine caused an increase in the GABA content of the brain stem, 
thalamus and olfactory lobes. I îr\8.ij found that although chlorpromazine 
antagonized the stereotypy induced by amphetamine, the combination of 
the two drugs increased the GABA content of all brain regions studied.
This study is an example of the dangers of correlating biochemical 
observations with gross behaviour. Here it appears that GABA levels 
do not correlate with behaviour. Fortunately enough is known about 
the actions of amphetamine to say that GABA must be playing an 
ancillary role.
Pettibone et al. (1978) reported a decrease in immunoreactive 
substance P in the rat striatum (20 - 35% after the administration of 
high doses of (+)-amphetamine (10 mg/kg i.p.)) .
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3. Uptake of Catecholamines and 5-Hydroxytryptamine
(i) Peripheral noradrenergic neurons
Axelrod and Tomchick (1960) first demonstrated (+)-amphetamine 
to "prevent the protective binding" of intravenously-injected radio­
labelled noradrenaline and adrenaline in mice. In cats amphetamine pre­
vented uptake-and retention of -noradrenaline in the heart, 
spleen, adrenal gland and liver but not in skeletal muscle (Axelrod 
et al., 1961; Hertting et al., 1961). Similar results were obtained 
with the rat heart (Axelrod et al., 1962). Amphetamine also inhibited 
the uptake of -me tar ami no 1, a catecholamine analogue, into mouse 
heart (Carlsson & Waldeck, 1965). Similarly, the depletion of 
noradrenaline levels in the rat heart by guanethidine and bretylium 
(drugs which are taken up across the axonal membrane) was prevented by 
amphetamine pretreatment (Chang, 1965). Later, in vitro studies showed 
that noradrenaline uptake across the neuronal membrane was inhibited
in the cat spleen by concentrations of amphetamine of approximately 
— 710 M (I.D. 50) (Dengler et al., 1961), in isolated rat heart (Burgen 
*& Iversen, 1965 ), or heart slices from rats and rabbits (Hendley 
& Snyder, 1972), slices of vas deferens from reserpine-nialamide 
pretreated rats (Carlsson at al., 1965, 1966a, b; Haggendel &
& Hamburger, 1967), isolated iris from rats and rabbits (Hamburger 
& Malmfors, 1967; Hendley & Snyder, 1972), and rabbit aortal strips 
(Ferris et ai., 1972; Hendley & Snyder, 1972).
Leitz (1970) showed that (+)-amphetamine inhibited metaraminol- 
induced release of noradrenaline from the heart by inhibiting the
e
*Uptake2  ̂ according to Iversen (1967) was also inhibited by 
amphetamine at an ID50 concentration of 10“^M.
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uptake of metariminol. Uptake of noradrenaline into isolated bovine 
splenic nerve noradrenergic storage granules was inhibited by 
amphetamine and by methamphetamine (Euler & Lishajko, 1968).
(ii) Noradrenergic neurons in the brain
Inhibition of the uptake mechanism of noradrenergic neurons in 
the brain for noradrenaline in vivo by amphetamine has been shown by 
different procedures. The uptake and retention of intraventricularly- 
labelled noradrenaline into different brain regions was reduced in 
amphetamine-pretreated rats (Glowinski & Axelrod, 1964; Glowinski 
et al., 1966a,b; Fuxe & Ungerstedt, 1968, 1970; Strada et ai., 1970). 
Methamphetamine showed the same property (Cook & Schanberg, 1970; 
Schanberg & Cook, 1972). In these studies an increased uptake of 
noradrenaline was observed 3 to 5 h after the methamphetamine injection. 
X+)-Amphetamine was found to be a more potent inhibitor of noradrenaline 
uptake in various brain areas than the (-)- isomer (Taylor & Snyder, 
1970, 1971). Amphetamine also antagonised the depletion of nora­
drenaline in the brain caused by 4,a-dimethyl-m-tyramine (H77/77), which 
indicates that the uptake of this compound into rat brain noradrenergic 
neurons was inhibited (Carlsson et al., 1969). In contrast,.a po­
tentiation of the H77/77-induced noradrenaline-depletion was reported 
by Leonard & Shallice (1971). This difference in results might be 
explained by different dosage schedules; however I feel that there 
is insufficient knowledge about the actions of such a drug to allow 
its use as a tool to determine the actions of another.
Slices from mice treated in vivo with amphetamine, which were then 
incubated in vitro, took up less noradrenaline than slices from control
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mice (Ross & Renyi, 1966a, 1967b).
Various in vitro systems have been used for studies on the.effects 
of amphetamine on noradrenaline uptake. Thus (+)-, (-)-and (±)- 
amphetamine have been shown to inhibit the uptake of noradrenaline 
into slices of cerebral cortex in mice (Ross & Renyi, 1964, 1967b;
Reitz et ai., 1972) and rats (Carlsson et ai., 1965, 1966a, b; Haggendal 
& Bamberger, 1967; Rutledge et ai., 1972a; Ziance & Rutledge, 1972;
Ferris et ai., 1972), in chopped cortex (Ziance et ai., 1972) in 
homogenates of cerebral cortex, hypothalamus, medulla oblongata and 
cerebellum (Coyle & Snyder, 1969b), and in synaptosomal preparations 
from cortex and hypothalamus (Horn et ai., 1971; Horn & Snyder, 1972;
Ferris and Maxwell, 1972; Ferris et ai., 1972; Harris & Baldessarini, 
1973a. Thornburg & Moore, 1973 ). Methamphetamine inhibited the 
uptake of noradrenaline into slices from the hypothalamus and brain 
stem but not from the telencephalon of rats (Morgan et ai., 1972b).
(iii) Dopaminergic neurons in brain
Amphetamine has been shown to inhibit the reserpine-resistant 
uptake of dopamine and noradrenaline into the tuberoinfundibu ]ar 
dopaminergic neurons in reserpine-nialamide treated rats in vivo (Fuxe 
et ai., 1967). The uptake of intraventricularly-administered dopamine into 
nigro-striatal dopaminergic cell bodies and terminals was inhibited 
by amphetamine (Fuxe & Understedt, 1968, 1970). Taylor & Snyder,
(1970, 1971) showed that (+)-but not (-)-amphetamine (10 mg/kg s.c.) 
inhibited the uptake of intraventricularly-administered -nor­
adrenaline into the striatum. However, in a previous study by 
Glowinski et ai. (1966a), (+)-amphetamine (15 mg/kg i.p.) did not
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affect the uptake of intraventricularly-administered -noradrenaline
or -dopamine into the striatum. A series of in vitro studies 
shows unequivocally that (+>- and (-)-amphetamine inhibit the uptake 
of dopamine into rat brain slices from striatum (Carlsson et ai., 1966a, 
b; Haggendal & Hamberger, 1967), homogenates of striatum (Coyle & 
Snyder, 1969 a, b) and synaptosomal preparations of striatal tissue 
(Horn et ai., 1971; Horn & Snyder, 1972; Ferris & Maxwell, 1972; 
Ferris et ai., 1972; Harris & Baldessarini, 1973a; Thornburg & Moore, 
1973 .). Methamphetamine has similar actions (Morgan et ai., 1972b). 
Amphetamine inhibits the uptake of dopamine (and noradrenaline) into 
isolated synaptic vesicles from striatal tissue of pig brain (Philippu 
& Beyer, 1973).
Kinetic analysis of the inhibition of uptake exerted by amphetamine
showed it to be competitive and reversible in both hypothalamus and
striatum (Horn et al., 1971). Ki values for amphetamine are in the 
-7order of 10 M in in vitro studies.
Controversial findings with regard to the differential potencies 
of (+)- and (-)-amphetamine as uptake inhibitors on noradrenergic and 
dopaminergic neurons have been reported. Coyle & Snyder (1969b) and 
Taylor & Snyder (1970, 1971) in in vitro and in vivo experiments, 
reported (+)-amphetamine to be up to 10 times more potent than 
(-)-amphetamine as uptake inhibitors for noradrenergic neurons in 
the brain, while the two isomers were equipotent with regard to 
striatal dopaminergic neurons. In contrast, Ferris et ai. (1972), 
Harris & Baldessarini (1973a) and Thornburg & Moore (1973 ) reported 
(+)- and (-)-amphetamine to be about equipotent in inhibiting
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noradrenaline uptake into brain noradrenergic neurons and (+)-amphet­
amine to be 4 - 5  times more effective than (-)-amphetamine on brain 
dopaminergic (striatal) neurons. A four- to six-fold difference 
between (+)- and (-)-amphetamine was found with regard to dopamine 
uptake into mesolimbic and striatal dopaminergic nerve terminals 
(Horn et ai., 1974). Differerences in experimental conditions, e.g. 
the use of reserpine-treated rats (Coyle & Snyder, 1969b; Hendley 
& Snyder, 1972), might explain the differences in these results.
However, Harris & Baldessarini (1973a) point out that reserpine does 
not affect the "(+)/(-)-quotient" but reduces , the total amounts of 
catecholamines taken up, which makes the results unreliable.
I
Other important factors affecting the outcome of stereoselective 
mechanisms are: thickness of slices, linearity of the kinetics and
nonsaturating concentrations of amines (Hendley & Snyder, 1972). Thus, 
these authors found (+)-amphetamine to be more potent than (-)-amphe­
tamine as inhibitors of uptake over the neuronal cell membrane of 
noradrenergic neurons in the rat heart, rabbit vas deferens, and 
iris; (+)- to be equal to (-)-amphetamine in rabbit heart and retinal(dopamin­
ergic cells) and (-)-amphetamine to be more potent than (-1-)-amphetamine 
in rabbit thoracic aorta. Ferris et al., (1972) reported that the 
isomers were equipotent in the thoracic aorta of rabbits not treated 
with reserpine; all animals were pretreated with reserpine in the 
study by Hendley & Snyder (1972).
(iv) The effects of amphetamine on the 5-hydroxytryptamine into neurons
and platelets
Total body uptake and retention of 5-hydroxytryptamine in the
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mouse was not affected by amphetamine (Axelrod & Inscoe, 1963). Up­
take and accumulation of 5-hydroxytryptamine into mouse cortex
slices in vitro were inhibited by amphetamine in a concentration of 
—510 M (Ross & Renyi, 1967a). Similarly, Wong et al. (1973) found 
that amphetamine competitively inhibits the high affinity uptake of 
5-hydroxytryptamine into isolated rat brain synaptosomes. In vivo 
models for uptake studies include histochemical evaluations of 5-hydroxy­
tryptamine accumulation into tubero infundibular dopaminergic neurons 
in reserpine treated rats, which was blocked by amphetamine (Fuxe 
et ai., 1967) and accumulation of 5-hydroxytryptamine into central 
neurons after intraventricular administration of 5-hydroxytryptamine, 
which was not blocked by amphetamine.. (Fuxe & Ungerstedt, 1968) . De­
pletion of serotonin in the brain by 4-methyl-a-ethyl-m-tyramine (H75/
12; Carlsson et ai., 1969; Leonard, 1972) or (+)-p-acetyldeoxyephedrine 
(Dubnick et ai., 1973) was not blocked by (+)- or (-)-amphetamine. 
Methamphetamine, on the other hand, caused a decrease in the accumulation 
of 5-hydroxytryptamine into striatal slices, but not in slices of 
telencephalon, hypothalamus, or brain stem (Morgan et ai., 1972b).
In summary, amphetamines seem to affect the uptake mechanism for
5-hydroxytryptamine in vitro but a higher concentration is required 
-5(>10 M) than is required for the inhibition of catecholamine uptake 
—6(greater than 10 M,Ross & Renyi, 1967a).
Blood platelets have been used as models for 5-hydroxytryptamine 
uptake, storage and release mechanisms. Amphetamine has been reported 
not to inhibit the accumulation of 5-hydroxytryptamine into rabbit 
platelets (Da Prada et al., 1965) but to inhibit competitively the
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uptake of 5-hydroxytryptamine into human platelets (Ki = 10~^ M) 
(Lemmer, 1973).
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4. Release of Catecholamines, 5-hydroxytryptamine and acetyl choline
(i) Peripheral catecholamines
Amphetamine has been shown to release noradrenaline or - nor­
adrenaline previously taken up into the mouse or rat heart in vivo 
(Axelrod et al., 1962; Potter & Axelrod, 1963; Benington & Morin , 
1968) and - noradrenaline, a-methyl-noradrenaline or metaraminol
from the mouse heart (Carlsson & Waldeck, 1966a, b). The releasing 
action of amphetamine does not seem to be due to inhibition of the
uptake mechanisms, since more potent uptake inhibitors, like desmethyl-
e/imipramine (DMI) (Carlsson and Waldeck, 1968; Lui^org, 1969) or 
protriptyline (Carlsson & Waldeck, 1966a; Lundborg & Waldeck, 1972), 
do not release ^ ^  -noradrenaline from the mouse heart. Amphetamine 
has to be transported into the noradrenergic neuron in order to exert 
its action (Lundborg & Waldeck, 1972), and it has been claimed that it 
releases mainly, but not exclusively, extravesicular monoamines from 
the mouse heart (Lundborg, 1969).
Studies’ in vitro showed that amphetamine increases the release 
of unchanged noradrenaline from isolated rat heart by reducing nora­
drenaline metabolism by deamination (Leitz & Stefano, 1971). The 
effect of amphetamine was inhibited by 6-hydroxydopamine pretreatment 
or guanethidine, a-methyl-noradrenaline or amantadine added to the 
slices before amphetamine, indicating that amphetamine releases 
noradrenaline from an extragranular storage pool. Electric field 
stimulation was without releasing effect in the reserpine plus mono­
amine oxidase inhibitor (MAOI) preparations; thus amphetamine and 
nerve-impulse-induced release of noradrenaline seems not be be 
identical (Enna & Shore, 1974). In heart slices, amphetamine caused
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the release of -noradrenaline newly synthesized from [ ^  -dopamine
(Chevillard at al., 1971) and this effect was potentiated by angio­
tensin II (Chevillard & Alexandre, 1972). Amphetamine also releases
newly-synthesized noradrenaline from heart (Rapin at al., 1972) and
-4spleen slices (Rapin at al., 1973b). Rather high (10 M) concentrations 
of amphetamine are needed for the release of noradrenaline from 
isolated bovine splenic nerve vesicles (Euler & Lishajko, 1968).
Catecholamines in adrenal glands from cats (Rubin & Jaanus,
1966) but not rats (Cession-Fossion, 1967) are released on perfusion 
with amphetamine. In this tissue amphetamine has a acetylcholine­
like action, since the presence of hexaméthonium or denervation does 
not inhibit this effect. Both in perfused cat and cow adrenals, 
amphetamine also causes the release of nucleotides, protein and dopa­
mine- 3-hydroxylase in addition to the catecholamines, indicating 
exocytosis
release by ' at certain drug concentrations (Rubin & Jaanus,
1967; Schneider, 1972). This release is dependent on the presence 
of calcium ions (cf. Rubin, 1970). At high concentrations of 
amphetamine a direct effect on the catecholamine storage vesicles seems 
to be operating (Schumann & Philipp ü., 1962; Rubin & Jaanus, 1967; 
Schneider, 1972; Wagner et ai., 1973, 1974).
(ii) Plasma catecholamines
An amphetamine-induced increase of noradrenaline and adrenaline 
in plasma has been reported in dogs (Chidsey et ai., 1962; Harvey et 
ai., 1968). In the study by Chidsey et ai. (1962), noradrenaline was 
shown by coronary sinus cannulation to be released from the heart and 
in the study by Harvey et ai. (1968), increased concentrations of
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adrenaline in the cannulated adrenal veins were observed after 
amphetamine. Dose-response relationships were established for 
the increase in plasma catecholamines and the effects of amphetamine 
on the blood pressure (Harvey et al., 1968).
(iii) Urinary excretion of catecholamines
The urinary excretion of noradrenaline and adrenaline reflects 
primarily the release of these substances from peripheral noradreœrgic 
neurons and the adrenal medulla brought about by nerve impulses or 
drugs, and also the release of catecholamines from non-innervated 
chromaff in cells.
An increase in the urinary excretion of noradrenaline and adrena­
line in the rat after acute administration of amphetamine has been 
demonstrated (Biscardi et al.,1964; Beauvallet et ai., 1966 ; Gunne 
& Lewander, 1967; Lewander, 1968a, b; Beauvallet, 1968; Basso et 
ai., 1970). The ganglion blocking agent, mecamylamine, blocked 
the effect of amphetamine on the excretion of noradrenaline but not 
on the excretion of adrenaline; adrenal demedullation did not 
completely block the increase in the excretion of adrenaline after 
amphetamine treatment (Biscardi et ai., 1964). The increase in 
urinary adrenaline excretion was, however, absent after bilateral 
cutting of the splenchnic nerves (Gunne & Lewander, 1967; Lewander, 
1968b). Later, Basso et ai. (1970) could show that the adrenal 
demedullation could be performed more efficiently if the whole gland 
was removed and pieces of its cortex were grafted under the capsule 
of the kidney. Amphetamine administered to rats demedullated in 
this manner did not cause an increase in the urinary excretion of
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adrenaline. It was also found (Lewander, 1968b; Basso et al., 1970) 
that the amphetamine-induced increase in the urinary excretion of 
noradrenaline was more pronounced in rats with denervated or 
demedullated glands than in intact rats.
During chronic administration of ( ±)-amphetamine, 16 - 32 mg/kg 
twice daily for approximately 14 days per dose level, there was an 
initial increase in the urinary excretion of both adrenaline and 
noradrenaline followed by a successive decrease toward control 
excretion values (Lewander, 1968b). This pattern was most evident 
at the two higher dose levels and.was considered to be a sign of 
tolerance to these effects of amphetamine in rats.
Amphetamine caused a decrease in the urinary excretion of 
dopamine in rats between 4 and 8 h after administration.
(iv) Noradrenaline and dopamine in the brain
Various methods have been used to demonstrate amphetamine-induced 
release of catecholamines in the brain in vivo. Several of these 
approaches utilize the hitherto accepted view that extraneuronally- 
liberated catecholamines are metabolized by catechol-O-methyl transferase 
(COMT) to the 3-0-methylated amines, which are subsequently deaminated 
by MAO to neutral or acidic metabolites (see reviews by Axelrod,
1959, 1965; Copin, 1964; Carlsson, 1966; Iversen, 1967; Andén 
et al. , 1969).
(v) Measurement of endogenous catecholamines and 3^0-m3thyl5ted 
catecholamine metabolites after MAO inhibition 
Amphetamine causes an increase of brain normetanephrine and 3-
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methoxytyrosine, after a single dose or chronic administration in 
rats (Gunne & Lewander, 1967, 1968). The levels of normetanephrine 
and 3-methoxytyrosine are more easily detected by conventional methods 
in control rat or guinea pig brain after pretreatment of the animals 
with a monoamine oxidase inhibitor, i.e., nialamide. Administration 
of amphetamine after nialamide pre-treatment causes a marked increase 
in the normetanephrine and 3-methoxytyrosineaccumulation in the brains 
of rats (Randrup & Jonas, 1967; Gunne & Lewander, 1968; Jonas & 
Scheel-Krüger, 1969; Scheel-Krüger, 1971, 1972 ), mice (Svensson,
1971), and guinea pigs (Lewander, 1971c) indicating extraneuronal 
release of both noradrenaline and dopamine in the brain.
In another series of reports, rats were pretreated with reserpine 
plus nialamide plus L-DOPA in order to study selectively the extra- 
vesicular ly but intraneuronally located catecholamines (Carlsson et 
ai.,1965, 1966a, b). In these rats very low doses of amphetamine 
(0.1 to 1 mg/kg) caused a depletion of the catecholamines, as shown 
with biochemical and histochemical methods, and an increase in the 
levels of normetanephrine and 3-methoxytyrosine in the brain indicated 
that amphetamine has a marked releasing effect on such an artificially 
enlarged pool of extravesicular catecholamines. Similar results 
have been reported by Andën and Svensson (1973) in several brain 
regions in reserpine-nialamide pretreated rats. Histochemical 
evidence for the amphetamine-induced decrease in a-methyl-noradrenaline 
and a-methyl-dopamine was reported in mts given tetrabenazine plus 
a-methy1-DOPA (Carlsson et al., 1968). Potent and selective uptake 
inhibitors like desmethylimipramine do not cause depletion of the 
a-methylated amines in similar experiments (Carlsson et al., 1966b).
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Sectioning of dopaminergic neurons in the brain or treatment of 
rats with y-hydroxybutyric acid causes an increase in the levels of 
dopamine in the brain. Amphetamine given before or after these 
treatments counteracts this increase, which indicates that amphetamine 
releases dopamine from the dopaminergic neurons in the brain (Andën 
et ai., 1973; Roth et ai., 1973). The effects of (+)-and (-)- 
amphetamine on the accumulation of normetanephrine and the reduction 
of noradrenaline, i.e., release of noradrenaline, were equal. While 
(+)-amphetamine was 1.7 times more potent than (-)-amphetamine on 
the accumulation, of 3-methoxytyrosine, i.e., on the release of dopamine 
(Scheel-Krüger, 1972 )
(vi) Levels of homovanillic acid
One to two hours after an acute dose of amphetamine (10 - 20 mg/kg 
i.p.X homovanillic acid levels increase in cats (Laverty & Sharman, 
1965), rats and mice (Jori & Bernadi, 1969, 1972; Bizzi et ai., 1970; 
Roffler-Tarlov et ai., 1971; Fuentes & Del Rio , 1972; Jori &
Dolfini, 1974). (+)-Amphetamine was more potent than (-)-amphetamine
in this respect (Jori et ai., 1973; Jori & Dolfini, 1974). In some 
mouse strains brain homovanillic acid levels do not increase after 
amphetamine treatment (Jori & Garattini, 1973; Caccia et ai., 1973). 
The increase in homovanillic acid levels in the striatum in mice 
was antagonized by amantadine (Menon et ai., 1973), and y-hydroxy- 
butyric acid (Menon et ai., 1974). However, reduced levels of homo­
vanillic acid after amphetamine treatment have been found in dogs 
(Laverty & Sharman, 1965) and guinea pigs (Lewander, 1971c)-
Rats, chronically treated with amphetamine (but not mice), became 
tolerant to the effect of amphetamine on homovanillic acid (Joii &
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Bernadi, 1972); chronically treated guinea pigs had lower homovanillic 
acid concentrations in the brain as compared with a single dose 
(Lewander, 1971c).
(vii) Accumulation of P h] -normetanephrine and *3-methoxytyrosine 
synthesized from PlQ -DOPA
Amphetamine (20 mg/kg i.p.) injected before or after i.v. 
injection of -DOPA, increases the accumulation of -normeta­
nephrine and [̂ h]-3-methoxytyrosine in the rat brain (even without 
MAO inhibitors), indicating an amphetamine-induced release of cate­
cholamines (Lewander, 1970a, 1973d ).
(viii)Fate of noradrenaline and dopamine taken up into brain cate­
cholamine neurons after intraventricular injection
-noradrenaline or nj-dopamine inj ected into the lateral 
ventricle or cisterna magna of rats ts taken up primarily by central 
noradrenergic and dopaminergic neurons. Subsequent administration 
of (+)-amphetamine (10 - 15 mg/kg) accelerates the disappearance of 
the labelled noradrenaline and causes an< [increase in -normeta­
nephrine, and a decrease in deaminated catechol metabolites (Glowinski 
& Axelrod, 1964; Glowinski et ai., 1966a, b; Strada et ai., 1970; 
Tilson & Sparber, 1972). Very similar findings were reported for 
methamphetamine (Cook & Shanberg, 1970). Chronic methamphetamine 
treatment did not change this pattern of deaminated metabolites 
(Schanberg & Cook, 1972). Small doses (5 mg/kg) of amphetamine 
have no effect on the levels of hJ -normetanephrine except after 
repeated injections (Glowinski, 1970b). The levels of labelled 
3-methoxy-4-hydroxyphenylglycol, however, were increased after 3 mg/kg
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of amphetamine in such experiments (Ladisch et al., 1970 ); 
progesterone mitigated this effect of amphetamine (Ladisch &
Baumann, 1971).
Intraventricular administration of amphetamine also caused a 
decrease in labelled noradrenaline and an increase in -normeta­
nephrine (Taylor & Sulser, 1973). Intraventricularly-administered 
unlabelled catecholamines to reserpine-nialamide pretreated rats 
are also released from catecholaminergic neurons by amphetamine as 
demonstrated by histochemical methods (Fuxe & Ungerstedt, 1968, 1970).
(ix) Perfusion of the cerebral ventricular system
Carr & Moore (1969, 1970a, b) perfused the ventricular system 
in cats with -noradrenaline, which was assumed to be taken up 
primarily by catecholaminergic neurons in the brain. Administration 
of amphetamine (25 - 400 yg/ml) added to the perfusion fluid, or 
injected i.v. (1 mg/kg), was followed by increased amounts of nj- 
noradrenaline and -normetanephrine in the perfusate indicating 
an amphetamine-induced noradrenaline release. (-)-Amphetamine was 
less effective than (+)-amphetamine in this respect. Release ;of 
noradrenaline has been reported in rats which have a push-pull cannula 
fitted on top of the skull and reaching to the ventricular system 
(Sparber & Tilson, 1972b). Later, ventricular perfusion experiments 
in cats have shown that ^-dopamine previously taken up or newly 
synthesized from -tyrosine or -DOPA is released by amphetamine 
(Chiueh & Moore, 1973, 1974b). (+)-Amphetamine was 3 to 4 times
more potent than (-)-amphetamine (Voigtlander & Moore, 1973a,b;
Chiueh & Moore, 1974a).
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Amphetamine-induced release of dopamine was reduced by sectioning 
the nigro-striatal dopaminergic neurons. It was also demonstrated 
that amphetamine potentiated the release of dopamine by electrical 
stimulation of the nigrostriatal bundle (Voigtlander & Moore, 1973b) 
Haloperidol did not antagonize amphetamine-induced dopamine release 
(Voigtlander & Moore, 1973a). The effect of amphetamine on catecholamine 
release in these experiments was not changed by a-methyl-p-tyrosine 
(Chiueh & Moore, 1974c) or amantadine (Gudetsky et ai., 1974). The 
lack of inhibition of amphetamine-induced release of dopamine is 
not in agreement with the study of Enna et al. (1973).
(x) Perfusion or superfusion of different brain areas in vivo with 
push-pull cannulas or cups
The output of endogenous dopamine from cat striatium was found 
to increase after the addition of amphetamine (0.5 mg/ml) to the
perfusate through a push-pull cannula (McKenzie & Szerb, 1963).
pl4 —1 [14 1Increased amounts of newly-synthesized I cj-dopamine from [ Cj-
DOPA or -tyrosine was found in the perfusate after the
administration of amphetamine.in similar experiments (Riddell &
Szerb, 1971). In rats, Stein and Wise (1967, 1969) showed that 
amphetamine (3 mg/kg i.p.) increased the output of -noradrenaline 
in push-pull cannula perfusates placed in the amygdaloid nucleus 
and in the hypothalamus. Glowinski (1970b) and Besson et al.
(1971 ) superfused the caudate nucleus of cats with -tyrosine
by use of the cup technique in order to label the stores of dopamine 
with -dopamine. Addition of amphetamine (10 ^ M) to the
superfusate or i.v. injection of (-)-amphetamine (2 mg/kg) caused 
a release of -dopamine into the superfusate. This result was
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confirmed in a similar study in monkeys (Gauchy et ai., 1974).
(xi) Release of newly synthesized catecholamines in In vitro systems 
Isolated corpus striatum (Besson et ai., 1969a) or slices of
striatum or medulla oblongata (Besson et ai., 1969b; Glowinski,
1970b) from rats were superfused or incubated in the presence of ^ ~ 
tyrosine. -Catecholamines synthesized during the incubation were
measured in the tissues and in the media. Amphetamine, either given 
to the animals before killing or added to the incubations, caused 
a release of newly synthesized ^ -catecholamines from the tissue 
into the superfusion fluid or media.
(xii) Release of catecholamines previously taken up into in vitro 
tissue preparations
Ng et al. (1970) showed that (+)-amphetamine was more potent 
than (-)-amphetamine in releasing ^ -noradrenaline taken up by 
rat striatal slices. Farnebo (1971) demonstrated that (+)-amphetamine 
(10 ^ M) release d[^H|-noradrenaline taken up into cortical slices 
and -dopamine taken up into neostriatal slices. Ebstein et al. 
(1972) have reported that amphetamine caused a release of noradrenaline 
more efficiently in slices from the amygdaloid nucleus than from the 
hypothalamus. The effect was more evident when slices from reserpine 
plus nialamide pretreated rats were used (Farnebo, 1971). Electrical 
stimulation of brain slices caused an increased overflow of -cate­
cholamines in the presence of (+)-amphetamine than in its absence 
(Farnebo, 1971).
The release of -catecholamines taken up into synaptosomal
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preparations from rat cerebral cortex, hypothalamus and striatum
was four times greater with (+)-amphetamine than with (-)-amphetamine
- 5(Ferris & Maxwell, 1972; Ferris et ai., 1972). (-)-Amphetamine (10 M)
caused the release of ^ ^  -noradrenaline taken up either by chopped
tissue, homogenates or synaptosomes from rat hypothalamus (Phillipu
et ai., 1974) and cerebral cortex- (Rutledge et ai. 1972a, b, 1973;
Ziance et ai., 1972; Ziance & Rutledge, 1972; Azzaro & Rutledge,
1973; Azzaro et ai., 1974; Tseng et ai., 1974). (-)-Amphetamine was
less active than (+)- or (±)-amphetamine. The release was temperature
dependent and amphetamine did not cause unspecific release of , e.g.,
inulin or urea. The release process was calcium-dependent only at
—3amphetamine concentrations below 10 m ; at or above that concentration 
release could be demonstrated in calcium-free media. Thus, amphe­
tamine-induced release differs from electrically-induced, potassium- 
induced, and tyramine-induced release, in not being completely calcium 
dependent (cf. Rubin, 1970).
Only a slight releasing effect of amphetamine was noticed when 
synaptosomes from rat brain were superfused with a solution containing 
amphetamine., (Raiteri et ai., 1974). These authors concluded that 
the main action of amphetamines in the brain is uptake inhibition.
The amphetamine metabolites, p-hydroxyamphetamine and p-hydroxynorephed- 
rine, . also released noradrenaline from chopped cortex tissue in 
vitro: p-hydroxyamphetamine was weaker in effect than amphetamine 
and p-hydroxyamphetamine (Wegler & Rutledge, 1974).
Enna et al. (1973) found that a-methyl-p-tyrosine inhibited the 
amphetamine-induced release of noradrenaline and some catecholamine 
analogues from brain slices . Cocaine and desipramine prevent
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amphetamine-induced release of noradrenaline from chopped brain tissue 
by inhibiting the uptake of amphetamine into the neurons (Rutledge et 
al., 1973; Azzaro et al., 1974). Incorporation of a-methy-m- 
tyramine into dopaminergic neurons in the brain occurs after admini - 
stration of a-methyl-m-tyrosine (Dorris & Shore, 1974). Amphetamine 
caused a depletion of this false transmitter, indicating release, 
but by a mechanism different from release by nerve impulses (Dorris 
& Shore, 1974). Amantadine prevented amphetamine-induced release 
of a-methyl-m-tyramine (Dorris & Shore, 1974).
(xiii)The effects of amphetamine on the release of 5-hydroxytryptamine
Only a few techniques for the demonstration of amphetamine-induced
release of brain 5-hydroxytryptamine in vivo have been applied. Fuxe
and Ungerstedt (1970) reported that amphetamine caused a change toward
extraneuronal accumulation of 5-hydroxytryptamine in reserpine-treated
rats, as evaluated bya histochemical fluorescence microscopic technique
for the visualization of monoamines. The use of intraven-
tricularly located push-pull cannulae in rats showed that after a
single dose of amphetamine there was no increase in the release of 
rl4 1L Cj-5-hydroxytryptamine, previously taken up into the serotonergic 
neurons,into the perfusion fluid (Sparber & Tilson, 1972a). However 
in rats chronically treated with amphetamine, further amphetamine caused 
a release of 5-hydroxytryptamine.
Superfusion of isolated corpus striata from rats in vivo has been
used for the demonstration of release of catecholamines after amphetamine
-4treatment. In similar experiments, 10 ' M concentrations of amphetamine 
in the perfusate caused a small release of 5-hydroxytryptamine 
(Glowinski, 1970a, b). (+)-Amphetamine but not (-)-amphetamine was
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shown to release 5-hydroxytryptamine taken up into central cortex
-4slices (Ng et al., 1970). (+)-Amphetamine, 10 M, also induces
release of 5-hydroxytryptamine from chopped pieces of tissue from the 
caudate nucleus, medulla oblongata and cortex of the rat brain 
(Rutledge et al., 1972b; Azzaro & Rutledge, 1973). Amphetamine- 
induced liberation of 5-hydroxytryptamine from rabbit blood platelets 
has been reported by Da Prada et al. (1955) and from human blood 
platelets by Lemmer (1973).
(xiv)The effects of amphetamine on the release of acetylcholine
Acetylcholine release has been measured by the superfusion of an 
area of cat cerebral cortex in vivo by a cup technique. By this 
method amphetamine has been shown to increase the release of acetyl­
choline from the cat cortex (Pepeu & Bartolini, 1967; Beani et ai., 
1968; Hemsworth & Neal, 1968a, b). This effect of amphetamine seems 
to be due to an indirect activation of cholinergic neurons rather than 
to a direct presynaptic effect, since no effect of amphetamine was 
obtained after undercutting of the cerebral cortex (Deffenu et ai., 
1970; Pepeu et ai., 1970) or septal lesions (Nistri et ai., 1972). 
Administration of chlorpromazine (Pepeu & Bartolini, 1968; Nistri 
et ai., 1972) blocks the amphetamine-induced release of acetylcholine, 
while a-receptor blocking agents like phenoxybenzamine or phentolamine 
are without effect (Deffenu et ai., 1970; Pepeu et ai., 1970) and the 
3-receptor blocking agent, propranolol, has varying effects (Bartolini 
& Pepeu, 1970; Deffenu et ai., 1970; Pepeu et ai., 1970). These 
findings suggest that amphetamine-induced release of acetyl­
choline is a catecholamine-mediated phenomenon. The release of 
acetylcholine, as measured with a caudate nucleus cup in cats, was not 
altered by amphetamine given i.p. (5 mg/kg) or in the superfusing
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medium (Jones et al., 1973).
Amphetamine inhibits neuromuscular transmission in isolated 
nerve-muscle preparations (Anderson & Amman, 1963; Peterson at al., 
1964; Gerald & Hsu, 1975). Recently Skau & Gerald (1978) found 
that a- and 3-receptor blockers failed to alter the blocking effects 
of amphetamine on the isolated rat phrenic nerve diaphragm and 
pretreating the rats with reserpine did not modify the response.
Thus, the effects of the amphetamine isomers do not seem to be mediated 
by catecholaminergic interactions. The blocking of neuromuscular 
transmission by amphetamine resembled the non-depolarizing blockade 
produced by tubocurarine.
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Biochemical Effects of Amphetamine on Metabolism
1. Degradation of the catecholamines
(i) Monoamine oxidase
Since early reports (Blaschko et al., 1937; Pugh & Quastel, 1937)
that amphetamine is not a substrate for monoamine oxidase (MAO) and
that it inhibits the enzyme competitively and reversibly (Mann &
Quastelf 1940; of. review by Blaschko, 1952), a number of studies
have confirmed this finding for a variety of species and tissues.
Preparations from rat, mouse and rabbit brain (Grana & Lilia, 1959;
Glowinski et ai., 1966a; Nielson et ai., 1967; Green, 1971; Moller-
Nielson & Dubnik, 1970; Morgan et ai., 1972bJ, human brain and
salivary gland (Blaschko & Stromblad, 1960) and other tissues including
liver, kidney and heart have been studied . Concentrations of amphet-
""5 “ 2 'amines ranging from 10 to 10 M seem to be required for inhibition 
of deamination of typical MAO substrates: adrenaline, noradrenaline,
tyramine, oxedrine, kynuramine, benzylamine, serotonin, tryptamine, 
and phenethylamine. Comparative studies have shown that I.C. 50 
concentrations are lowest with serotonin, tryptamine and tyramine as 
substrates, while phenethylamine requires 25 to 50 times higher 
concentrations (Everett & Yellin, 1971; Fuller, 1972).
Parmer (1966) made the observation that amphetamine protects 
MAO in rat liver mitochondria from other MAO inhibitors like iproniazid, 
tranylcypromine and nialamide. (+)-Amphetamine is generally a 
more potent MAO inhibitor in vitro than (-)-amphetamine (Pratesi & 
Blaschko, 1959; Grana & Lilia, 1959; Blaschko & Strdmblad, 1960;
Fuller & Walters, 1964; Parmer, 1966; Moller-Nielson & Dubnik, 1970) 
except in the rabbit liver where the two isomers are equally active 
(Pratesi & Blaschko, 1959).
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Kinetic studies on MAO from rat liver suggest that the enzyme 
exists in two major forms, A and B (Johnston, 1968). Serotonin and 
noradrenaline have been shown to be substrates for the A form, benzyl­
amine and phenethylamine for the B form and tyramine and dopamine 
as substrates for both forms. Tryptamine has been reported as a 
substrate for the B form and as a substrate for both forms of the 
enzyme, (Houslay & Tipton, 1974; Neff & yang  ̂ 1974; Hall et al., 
1969; Mantle et al., 1975; Johnston, 1968). The kinetic studies 
of Mantle et al. (197 6) show that, in rat liver, amphetamine inhibits 
the A form of the enzyme. Therefore if MAO inhibition is of physio­
logical importance, one would expect to see a differential effect 
between noradrenaline and dopamine metabolism. There is reason to 
suggest that rat liver MAO may be an adequate model for brain MAO 
(see Mantle et al., 1976), consequently this differential effect should 
be seen in the brain. Glowinski et al. (1966) showed that, after 
acute injection of amphetamine there was a decrease in MAO activity; 
this inhibition was only mild when tryptamine was used as a substrate, 
but marked when noradrenaline was used as the substrate.
Salama & Goldberg (1969) found that systematically-administered 
amphetamine in combination with cold stress, but not other forms of 
stress, caused a reduced MAO activity in rat brain.
After 50 days of chronic treatment of methamphetamine to guinea- 
pigs there was a decrease in brain MAO activity to 75% of the controls. 
After withdrawal there was a compensatory increase over control levels 
in MAO activity (Utena et al., 1959).
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Rutledge (1970) and Rutledge at al. (1972b), have shown that amphe­
tamine, in addition to causing release of -noradrenaline and - 
dopamine previously taken up into brain slices or chopped tissue, 
reduces the oxidative deamination of the catecholamines. Rutledge
(1970) also found that amphetamine does not inhibit rat brain MAO from 
lysed synaptosomes or mitochondria from the rat brain and concluded 
that amphetamine causes a functional MAO inhibition by inhibiting 
access of the catecholamines to intraneuronal MAO by blocking the 
uptake mechanisms for catecholamines. In addition, the metabolic 
pattern of catecholamine metabolites is changed toward non-deaminated 
metabolites after amphetamine (Glowinski et ai., 1966a, b; Cook & 
Schanberg, 1970; Tseng et ai., 1974), methamphetamine (Strada et ai., 
1970), and p-hydroxyamphetamine (Wenger & Rutledge, 1974), Similar 
findings were.reported with the isolated perfused rat heart. It 
has been concluded that amphetamine protects intraneuronal catechol­
amines from degradation.
Studies on the endogenous concentrations of homovanillic acid, 
the 3-0-methylated and the deaminated product of dopamine in the 
brain, as an indicator of the in vivo importance of MAO inhibition 
in brain caused by amphetamine, have given conflicting results. Thus, 
amphetamine causes an increase in brain homovanillic acid in cats 
(Laverty & Sharman, 1965), rats and mice (Jori & Bernardi,
1969, 1972; Bizzi et al., 1970); Puentes & Del Rio, 1972;
Menon et ai., 1973; Jori & Dolfini, 1974), while amphetamine causes 
a reduction of the levels of homovanillic acid in the dog (Laverty 
& Sharman, 1965) and the guinea-pig brain (Lewander, 1971c). (+)-
Amphetamine was more potent than (-)-amphetamine in increasing the 
levels of homovanillic acid in rat brain (Jori et al., 1973; Jori &
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Dolfini, 1974). Roffler-Tarlov et ai. (1971) confirmed that amphe­
tamine increased the levels of homovanillic acid in mouse brain and 
showed that 3,4-dihydroxyphenylacetic acid, the deaminated metabolite 
of dopamine, was decreased. 3,4-Dihydroxyphenylacetic acid levels 
in the rat brain were also decreased after amphetamine (Roth et ai., 
1973; Bunney et ai., 1973 ). Tolerance to the amphetamine-induced 
increase in homovanillic acid after repeated administration of amphet­
amine has been shown to occur in rats, but not in mice (Jori &
Bernadi, 1972). . Chronic administration of amphetamine
to guinea-pigs caused a more pronounced fall in the levels of homo­
vanillic acid in the brain than a single injection of the drug (Lew­
ander, 1971c).
It appears that the concentration of homovanillic acid in the 
brain might be influenced in two directions by amphetamine : a)
increased by release of dopamine from dopaminergic neuron terminals 
and b) decreased as a result of functional MAO inhibition and/or a 
negative feed-back modulation of dopamine synthesis. The resultant 
effective homovanillic acid concentration may thus be dependent on 
the concentration of amphetamine within the brain and, possibly, also 
on the animal species.
The early suggestion by Mann &, Quastel (1940)that the central 
stimulant effect of amphetamine should be due to MAO inhibition is 
not compatible with the fact that other, more efficient MAO inhibitors 
do not share the central stimulant action of amphetamine (Pratesi & 
Blaschko, 1959; Grana & Lilia, 1959). However, recent evidence 
(Glowinski et ai., 1966a; Green, 1971; Rutledge, 1970; Leitz &
-45-
Stefano, 1971? Rutledge et al., 1972b) suggest that any interpretation 
of the mechanism of action of amphetamine in relation to central 
stimulation that ignores the effect of high tissue concentrations of 
the drug on deamination of central and peripheral catecholamines might 
be incomplete. An experiment by Green et al. (1978) demonstrated, 
using a labile irreversible inhibitor of MAO (phenelzine), that 
MAO is inhibited in vivo to about 50% of its original activity.
(ii) Catecho1-0-methyl transferase (COMT)
Amphetamine has been found not to change COMT activity in vitro 
(Axelrod & Tomchick, 1950). The increase in 3-0-methylated metabolites 
of catecholamines in various tissues is thought to be due to the 
increased concentration of substrate available to COMT caused by the 
amphetamine-induced release of catecholamines.
The interpretation of changes in 0-methylated and deaminated 
metabolites in terms of intra-and extra-neuronal metabolism (implicit 
in these considerations are other considerations such as neuro­
transmitter release and reuptake), rests on the assumption that 
COMT degrades extraneuronal catecholamines, and MAO degrades 
intraneuronal catecholamines. MAO is certainly intracellular (bound 
to mitochondrial membranes inside glial and neuronal cells) , and COMT 
is a soluble, cytoplasmic enzyme. The situation may not be as simple 
as we are led to believe.
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2. Synthesis of the catecholamines
(i) Tyrosine hydroxylase
Tyrosine hydroxylase, partly purified from beef or cat brain
(Bagchi & McGeer, 1964; Besson et al., 1973), or in a crude homo-
genate of rat brain (McGeer & McGeer, 1967), was not inhibited by
-4(+)-amphetamine in vitro in concentrations of 10 M. Tyrosine
hydroxylase activity was decreased in striatal slices in vitro by 
— 7 —410 to 10 M concentrations of amphetamine (Besson et al., 1971b).
In other studies rats have been injected with amphetamine and 
the tyrosine hydroxylase activity has been determined in tissue 
homogenates or brain slices in vitro, either as the formation of - 
H^O from ^3,5- sj-tyrosine or as the accumulation of ^ -catechol­
amine from the precursor. Thus Besson et al. (1969b) found that 5 mg/ 
kg of (+)-amphetamine increased catecholamine synthesis in brain slices 
from the striatum and the brain stem, while in later studies (Besson 
et al., 1971 , 1973) a reduction of the tyrosine hydroxylase activity 
was reported. No effect was found-in the accumulation of -nora­
drenaline from ^ -tyrosine after chronic administration of 1 mg/kg 
of (+)-amphetamine for 8 days (Besson et al., 1973). The amphetamine- 
induced inhibition of tyrosine hydroxylase was non-competitive for 
tyrosine (Besson et al.,1973). Amphetamine has been reported to 
change the physical state of striatal but not mid-brain tyrosine 
hydroxylase, i.e., it becomes more membrane-bound and is thereby 
inactivated (Mandell et al., 1972).
Harris & Baldessarini (1973b) reported that in vivo administration 
of amphetamine (5 mg/kg) to rats caused a decrease in tyrosine 
hydroxylase activity in striatal homogenates for 0.5 to 2 h. This
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effect of amphetamine was blocked by chlorpromazine or bicuculline 
pretreatment, indicating that it might be secondary to indirect 
stimulation of dopaminergic and GABA receptors. Amphetamine added 
in vitro did not cause a decrease in the activity of the enzyme.
Administration of amphetamine in the drinking water for 3 to 
7 days did not change tyrosine hydroxylase activity in the rat fore­
brain structures (Hulme et ai., 1974).
By another in vivo technique, i.e., interstriatal injection of 
labelled tyrosine and subsequent determination of -H^O and 
dopamine in the striatal tissue, amphetamine was found to decrease 
the synthesis of dopamine at the tyrosine hydroxylase step (Javoy 
et al., 1974).
Fibiger & McGeer (1971) found that methamphetamine (10 mg/kg) 
had no effect on tyrosine hydroxylase in brain and adrenal gla,nds 
except after repeated injection, when the activity of the caudate 
nucleus decreased and that of the adrenal gland increased. Similar 
results were reported by Koda & Gibb (1973). These changes in 
tyrosine hydroxylase activity in the caddate nucleus and a,drenal 
gland could be antagonized by haloperidol (Buening & Gibb, 1974). 
Chlorpromazine antagonized the actions of amphetamine in the striatium 
but not in the adrenal gland (Buening & Gibb, 1974). Mandell &
Morgan (1970) and Mandell & Knapp (1972) also reported increased 
tyrosine hydroxylase activity in adrenal glands of thicken after 
repeated administration of methamphetamine.
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(ii) Aromatic amino acid decarboxylase (DOPA decarboxylase)
If amphetamine has any effect on this enzyme it has not, to 
my knowledge, been reported.
(iii)Dopamine-6-hydroxylase
Dopamine-6-hydroxylase has been reported to be inhibited by 
amphetamine, (+)-amphetamine and (±)^amphetamine (Goldstein et al., 
1964). Similarly dopamine-6-hydroxylase in homogenates of spleen 
was inhibited by amphetamine, methamphetamine and p-hydroxyamphetamine 
(Jacquot et al., 1974).
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3. Turnover of the Catecholamines
Glowinski & Axelrod (1965) injected -noradrenaline intra- 
ventricularly into the rat brain and found that (+)-amphetamine 
(20 mg/kg) retarded its disappearance. As reported by Javoy et al. 
(1968) and later reviewed by Glowinski (1970a), smaller doses of 
amphetamine (5 mg/kg) accelerated the turnover of noradrenaline in 
the brain, while repeated or higher doses have no effect on nora­
drenaline turnover as measured by this method.
Determination of the rate of disappearance of catecholamines 
after inhibition of catecholamine synthesis at the tyrosine hydroxylase 
step, by giving a-methyl-p-tyrosine (Corrodi et al., 1967; Andén,
1970) or 3-iodotyrosine, or at the dopamine-g-hydroxylase step , 
using diethyldithiocarbamate (Littleton, 1967) have also been used 
as methods for turnover measurements. In these.studies 2 mg/kg of 
(+)-amphetamine accelerated noradrenaline depletion after diethyl­
dithiocarbamate and retarded the depletion of dopamine after 3-iodotyro­
sine (Littleton, 1967). Large doses of (+)-amphetamine (15 - 20 mg/kg) 
accelerated the depletion of noradrenaline in the whole rat or mouse 
brain (Corrodi et al., 1967; Alhava, 1973), but had no effect on 
noradrenaline in the rat spinal cord (Andén, 1970). In the two rat 
studies, dopamine depletion in the brain was not affected by amphet­
amine. No change in the degree of depletion of noradrenaline or 
dopamine was found after amphetamine in a-methyl-p-tyrosine-pretreated 
rats (Andén et al., 1967). Methamphetamine, but not amphetamine 
has been reported to antagonize a-methyl-p-tyrosine-induced depletion 
of noradrenaline (Leonard, 1972).
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A third method for the determination of brain catecholamine 
turnover is the accumulation of labelled catecholamines after i.v. 
injection of ~ or -tyrosine or of DOPA. By this
technique Costa & Groppetti (1970, 1972), Persson (1970), Costa at 
ai. (1972) and Groppetti et al. (1972 ) found that small doses of 
amphetamine caused an increase in dopamine turnover in the striatum 
but had no effect on noradrenaline turnover, Fulginiti & Orsingher
(1971), however, reported an increased accumulation of labelled 
noradrenaline after giving 2 mg/kg of (±)-amphetamine. In mice 
implanted with amphetamine containing pellets there was an increased 
accumulation of both noradrenaline and dopamine from -tyrosine.
A large dose (10 mg/kg) of amphetamine counteracted this effect 
(Hitzemamet al., 1973).
Acute or chronic administration of large doses of the drug 
(16 - 32 mg/kg i.v.) reduced the accumulation of labelled noradrenaline 
in rat heart and brain synthesized from tyrosine or DOPA, which was 
suggested to be due to release of the newly synthesised noradrenaline 
(Lewander, 1971d). There was no effect on dopamine levels in the 
brain (Lewander, 1970a, 1971d). When amphetamine was given 2 h 
after the catecholamine stores of the rat brain had been labelled 
by -tyrosine administration, it was found that the disappearance 
of ^ ^  -noradrenaline was accelerated and that of -dopamine 
retarded (Lewander, 1970a). Javoy et al. (1970) injected 
tyrosine into various parts of the rat brain and measured the 
accumulation of -catecholamines. (+)-Amphetamine (5 mg/kg)
caused an increase in the accumulation of dopamine in cell bodies 
(substantia nigra) and a decrease in the terminals (Caudate nucleus)
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of dopaminergic neurons, while no effect on noradrenaline accumulation 
in the ventromedial nucleus of the hypothalamus was found.
Levels of tyrosine in the brain after amphetamine administration
In the aforementioned turnover studies where labelled tyrosine 
was used, neither plasma nor brain levels of -tyrosine were 
affected by amphetamine; the same was found to be true of 
endogenous (unlabelled) tyrosine, (Rapin et al., 1971). However 
Leonard & Shallice (1971) have reported decreased levels of tyrosine 
in rat brain and plasma in contrast to an increase in brain tyrosine 
reported by Tagliamonte et al. (1971a, b).
This brief summary on the reported effects of amphetamine on 
catecholamine turnover show that the results are contradictory. The 
differences may be due to the different doses of amphetamine used. It seems 
that low doses of amphetamine in rats cause an increase while higher 
doses cause a decrease or no change in brain catecholamine turnover.
This is probably due to the fact that one or another of the effects 
of amphetamine on either uptake, release, synthesis or degradation 
of the catecholamines or feedback modulation of catecholamine neuron 
impulse flow may predominate at certain dose levels. Regional varia­
tions in turnover within the brain might be added to the list of 
causes for the differences in results.
Critical evaluation of methods used to measure catecholamine turnover
From the descriptions of the methods used to measure the 'turnover' 
of noradrenaline and dopamine it can be seen straight away that the 
methods which involve labelling of noradrenaline or dopamine by
-52-
injecting a labelled precursor are assuming that the label is 
incorporated evenly in noradrenaline/dopamine stores throughout 
the brain. For physical (i.e. access from the site of injection 
and "free" and "bound" amine interconversion) and 'compartmental'
(i.e. transport mechanisms) reasons this is extremely unlikely.
Therefore what is being studied is the turnover of a particular 
'pool' of amine, which may vary with the precursor used and the site 
of injection.
Inhibition of tyrosine hydroxylase and of dopamine-6-hydroxylase 
have been found to be associated with different rates of noradrenaline 
depletion, (Persson & Waldeck, 1970). The disappearance of both 
^ -noradrenaline and endogenous noradrenaline was more rapid when 
dopamine-6-hydroxylase was inhibited (Goldstein & Nakajima, 1967).
Persson & Waldeck (1970) have presented some experimental support 
for the view that the activity of noradrenaline-containing neurons 
is affected by the activity in the dopaminergic neurons when the synthesis 
of both dopamine and noradrenaline are inhibited, the turnover of 
the latter amine appears to be slower. When only dopamine-6-hydroxy­
lase is inhibited, the influence of the dopaminergic . on the 
noradrenergic neurons is undisturbed (Persson & Waldeck, 1970).
The tyrosine hydroxylase inhibition as a method for the 
estimation of noradrenaline turnover therefore appears to have the 
disadvantage of slowing noradrenaline turnover. On the other hand, 
when isotope precursor methods are used the extent to which the 
isotopically-labelled amines are replaced by remaining labelled 
precursors is not known. Both methods therefore will show too slow
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a turnover of noradrenaline. The other possible source of error, 
which has already been mentioned, is the unequal labelling of 
storage pools, since much experimental work (Hillarp, 196o: Lundborg,
1963; Haggendal & Lindqvist, 1963; Andeh & Henning, 1966; see 
Kopin et al, 1968) indicates the presence of a small,
functionally-active pool with a high turnover and a large pool from 
which the amines are released slowly. During the comparatively long 
time intervals used for estimating the disappearance of the labelled 
amines in these experiments, only the turnover of the large slow pool 
would then be reflected in the half-lives obtained with -tyrosine. 
Although Persson & Waldeck (1970) found no significant differences 
between the turnover of ^ ^  -dopamine with or without inhibitors of 
its synthesis, the limitations of the methods discussed above may 
also apply to the estimations of dopamine turnover.
In summary, it is not surprising that there is a great disparity 
in the results obtained for the turnover of noradrenaline and dopamine 
in the brain and the changes seen on administration of amphetamine 
since the estimations of the catecholamine turnover in the brain with 
the present methods are not very accurate, and may not actually measure 
turnover in the usually accepted sense of the word.
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4. Degradation of 5-hydroxy tryptamine. _ _
Tagliamonte et al. (1971a, b) showed that amphetamine induces 
an increase in the concentrations of 5-hydroxyindoleacetic acid in 
the brain. In chicken, Schrold and Squires (1971) obtained similar 
results. Leonard (1972), however, found no change in the levels of 
5-hydroxyindoleacetic acid in rat brain after a single injection 
or after chronic administration of amphetamine (Diaz & Huttunen,
1972). The effect of amphetamine on the levels of 5-hydroxyindole- 
acetic acid in the brain might be dependent on several factors 
including dose, time and environmental temperature. Thus, Scheel- 
Krüger & Hasselager (1974) reported an increase in 5-hydroxyindole­
acetic acid levels in rat brain at 3 h after 5 to 15 mg/kg of 
o oamphetamine at 21 C but not at 13 C .ambient temperature. An initial
(1 h) decrease and a late (4 h) increase in 5-hydroxy indole acetic
acid levels in the rat brain was observed after giving 10 mg/kg of
(+)-amphetamine; these fluctuations were absent in chronically-
treated rats (Lewander, 1974b). A time dependency of the effect of
amphetamine on the levels of 5-hydroxyindoleacetic acid in the brain
might explain the inconsistent results in the earlier literature.
No change in 5-hydroxyindoleacetic acid concentrations was found
in the brains of dogs and cats (Laverty & Sharman, 1965). Rutledge et al.,
(1972b) found that amphetamine decreased the deamination of 5-hydroxy-
tryptamine in vitro after incubating chopped brain tissue in the 
— 3presence of 10 M amphetamine. Amphetamine also inhibited the 
deamination of 5-hydroxytryptamine in aggregated rabbit blood 
platelets (Da Prada et al. , 1965).
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5. Synthesis and turnover of 5-hydroxytryptamine
In rats, (+)-amphetamine (5 mg/kg x 2)has been shown to cause an 
increase in 5-hydroxytryptamine turnover as measured by the slope of 
the decrease in 5-hydroxyindoleacetic acid levels in the brain after 
inhibition of MAO by pargyline (Reid, 1970b). This effect of 
amphetamine was interpreted as possibly being an effect of amphetamine- 
induced hyperthermia. Amphetamine (1 mg/kg) decreased the rate of 
accumulation of 5-hydroxyindoleacetic acid after probenecid, indi­
cating a decrease in brain 5-hydroxytryptamine turnover in rats 
(Gorlitz & Frey, 1972).
In mice, Schuberth et al. (1970) found that amphetamine (15 mg/kg)
reduced the accumulation of 5-hydroxytryptamine in the brain after i.v. 
administration of labelled tryptophan. Amphetamine also retarded 
the disappearance from the brain of -5-hydroxyindoleacetic acid 
after intracerebral injection of labelled tryptophan in amphetamine- 
treated mice (Hitzemann et al., 1970) and rats (Diaz & Huttunen,
1972). In contrast, determination of the decrease in the levels of 
5-hydroxytryptamine in the brain after inhibition of its synthesis 
by p-chlorophenylalanine showed that amphetamine and methamphetamine 
accelerated the turnover as measured by this method (Leonard, 1972). 
Schuberth et al. (1970) were the first to report that amphetamine 
causes an increase in the brain tryptophan concentration at 3 h after 
its administration in mice. This finding was confirmed with dose- 
and time-response curves and extended to include rats as well (Schuberth 
& Sedvail, 1972). In addition there was an increase in plasma 
tryptophan concentration after amphetamine treatment, while there
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was no change in the liver. Independently, Tagliamonte et ai.
(1971a, b) and Leonard & Shallice (1971) have confirmed that 
amphetamine-induced increased brain and plasma tryptophan concentra­
tions, especially in rats which reacted with extreme hyperthermia.
This effect on brain tryptophan is not restricted to amphetamine 
but is seen after a number of various drugs (Tagliamonte et ai.,
1971b). Methamphetamine is also effective in this respect (Leonard 
& Shallice, 1971; Morgan et ai., 1972b). No definite explanation
for the effect of amphetamine on brain tryptophan has been put 
forward. However, the amphetamine-induced changes in brain tryptophan 
complicate measurements of 5-hydroxytryptamine turnover.
Reports on the in vitro determination of tryptophan hydroxylase 
activity in brain tissue showed that methamphetamine or amphetamine 
had no effect (Morgan et ai., 1972b; Knapp et ai., 1974). Chronic 
administration of amphetamine in the drinking water for 3 to 7 days 
did not change the tryptophan hydroxylase activity in the rat fore­
brain tissue (Hulme et ai., 1971). However, striatal synaptosomes 
from amphetamine-treated rats showed a reduced conversion of trypto­
phan into 5-hydroxytryptamine when assayed in vitro (Knapp et ai.,
1974).
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6. Metabolism of acetylcholine
Single doses of amphetamine (5 mg/kg) to rats did not change 
the activities of brain choline acetylase or acetyl cholinesterase 
(Ho & Gershon, 1972; Mandell & Knapp, 1972). In cats an increase 
in acetyl cholinesterase activity in the substantia nigra has been 
reported (Ellinwood & Escalante, 1970a). The choline acetylase 
activity in the adrenal glands of chicken increased after metham­
phetamine administration (Mandell & Morgan, 1970; Mandell & Knapp, 
1972).
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D. Effects of Amphetamine on the Cyclic Nucleotides and Glycogenolysis
Since brain cAMP levels are increased by noradrenaline in brain 
slices, it might be e^qpected that amphetamine should induce an increase 
in brain cAMP via the release of noradrenaline. However, several 
authors have been unable to show an amphetamine-induced increase in 
whole brain cAMP in mice or rats, in spite of sophisticated methods 
of rapid killing using coagulation or freezing of the brain (Paul 
et ai., 1970; Schmidt et ai., 1972; Ferendelli et ai., 1972).
In fact, amphetamine and p-hydroxyamphetamine, its main metabolite 
in the rat, were found to inhibit noradrenaline-induced activation 
of adenylcyclase in brain slices in vitro (Palmer, 1973). Costa et 
ai. !(1973), however, reported that amphetamine increased cAMP in 
the rat caudate nucleus simultaneously with an increase in the dopa­
mine turnover in that brain area.
cQlP was increased in mouse cerebellum after the injection of 
10 mg/kg of amphetamine (Ferendelli et ai., 1972).
Phosphorylase b kinase and phosphorylase activity (enzymes which 
are thought to be important in the g-receptor mediated glycogenolysis; 
Sutherland & Rail, 1960) in brain have been reported to be increased 
by amphetamine (Breckenridge & Norman, 1965; Drummond & Bellward,
1970). (+)- And (-)-amphetamine were equipotent in increasing
phosphorylase activity in the rat heart (McNeill & Muschek, 1972).
High doses of the drug, however, blocked the stimulating effect of 
noradrenaline or isoprenaline on this cardiac enzyme (McNeill & Muschek,
1972).
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Amphetamine is a potent glycogenolytic agent (Hutchins & Rogers,
1973). Hutchfhs & Rogers (2-970) hypothesized that if the glycogen­
olysis is mediated by the release of endogenous catecholamines, then 
it should be possible to antagonize this glycogenolytic effect 
with drugs which impair the storage or synthesis of catecholamines.
The drugs used were: p-chlorophenylalanine, diethyldithiocarbamate 
sodium, a-methyl-p-tyrosine and reserpine. Each of the drugs 
which caused depletion of the catecholamines (diethyldithiocarbamate, 
a-methyl-p-tyrosine and reserpine) resulted in an increase in the 
concentration of brain glycogen, whereas p-chlorophenylalanine, which 
depleted 5-hydroxytryptamine levels to less than 20% of the control 
values did not alter the glycogen content. These results suggest 
that a chcinge in the metabolic activity of the catecholamine,containing 
neurons of the central nervous system can influence cerebral glycogen 
metabolism. After treatment with a-methyl-p-tyrosine or diethyl­
dithiocarbamate the increase in the concentration of glycogen bore 
a closertemporal relationship with the loss of noradrenaline than 
with the change in concentration of dopamine.
None of the monoamine depleting agents, when administered 
individually was able to antagonize the glycogenolytic or central 
stimulant effect of amphetamine completely, which may be due to small 
amounts of catecholamines left in the neurons and able to be released 
by amphetamine. However, Glowinski et al. (19$6b) found that the amount of 
radioactivély labelled noradrenaline retained in the brains of 24 h 
reserpinized rats was resistant to release by amphetamine. Thus . 
a direct stimulation of receptors by amphetamine is possible. However, 
Hutchins & Rogers (1973) were able to Onttnjorvir-C CP'infUUlij the effects
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of amphetamine on glycogenolysis by using a combination of reser­
pine and a-methyl-p-tyrosine. Similar results were obtained in 
hypothermic mice and in mice whose body temperature had been 
maintained, and they are consistent with the hypothesis that 
amphetamine depletes brain glycogen by the release of central 
catecholamines rather than by a direct action at the receptors.
Although p-chlorophenylalanine did not affect the glycogeno­
lytic effect of amphetamine, it did prevent the characteristic 
secondary increase in glycogen to a value greater than the control 
This suggests that 5-hydroxytiryptamine may play a secondary role 
in the replenishment of glycogen.
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E. General Metabolic Effects of Amphetamine Administration.
(i) Oxygen consumption
Amphetamine increases oxygen consumption, probably via its 
peripheral actions, as isolated tissues incubated with amphetamine 
in vitro will take up oxygen, increased oxygen consumption is seen 
in decapitated rats, and only brain tissue seems to be insensitive 
to amphetamine in vitro (see Waterman, 1949; Andres, 1967; Weis, 
1973; Utena et al., 1959). Amphetamine has been found to reduce
respiration (Lewis & Pollack, 1965).
The activity of the thyroid gland seems to have a profound 
effect on the stimulation of oxygen consumption produced by 
amphetamine, since this effect is enhanced in hyperthyroid rats 
and almost abolished in hypothyroid rats (Chu, 1969). However 
Chu's studies showed that amphetamine did not have a releasing
action on the thyroid gland. It appears therefore that peripheral
adrenergic mechanisms and the action of thyroid hormones on target 
cells are necessary for the effect of amphetamine on oxygen con­
sumption .
(ii) Brain adenosine nucleotide and phosphate metabolism.
Most of the early studies can be discounted, as they do not 
agree with those which have been carried out recently and this is 
almost certainly due to post-mortem changes.
Nahorski & Rogers (1973) measured the concentration of glucose, 
glycogen, glucose-6-phosphate, lactate, ATP and phosphocreatine 
in the brains of mice at various intervals after the injection of
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5 mg/kg of (+)-amphetamine. During the initial 30 min, amphet­
amine induced a fall in cerebral glycogen and phosphocreatine and 
an elevation of;lactate. Changes in glucose and brain/blood 
glucose were less marked. The metabolite levels returned to
control values at 60 min. The cerebral metabolic rate showed a
biphasic change an initial depression of energy flux over the 
first 15 min following amphetamine injection was followed by an 
increase that appeared to be closely associated with the increase 
in locomotor activity over this period.
(iii) Lipid metabolism
Amphetamine in doses greater than 2 mg/kg causes an increase 
in free fatty acids levels in rats, the peak effect occurs after 
1 h. Both isomers are active, but (+)-amphetamine is up to 10 times 
more potent than (-)-amphetamine (for a review see Lewander, 1977). 
It has been suggested that amphetamine has at least two actions 
on adipose tissue and lipolysis; one indirect via the sympathetic 
nervous system and a second via release of a lipolytic compound 
released from the hypothalamus, (Fassina, 1966; Opitz, 1970; Shaw 
et al., 1972). Indirect evidence for the last proposal has been 
provided by Bolt et ai. (1974), who found that the increase in 
free fatty acids could not be abolished by spinal transection in 
cats, thus excluding the possibility of a centrally elicited 
increase in the efferent innervation of the adipose tissue. 
Amphetamine does not have a direct action on fat tissue cells.
Neuronal membrane lipids
The turnover of phosphatidylcholine (a component of membranes
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in nerve endings and vesicles) has been studied after acute and 
chronic administration of amphetamine and found to be inhibited 
in several brain areas (Hitzemann & Loh, 1973). Jn vitro it was 
found that amphetamine inhibited one specific enzymatic step in 
the synthesis of phosphatidylcholine (diphosphorylcholine di­
glyceride transferase; Hitzemann & Loh, 1973) .
(ivj Protein and nucleic acid metabolism
These have been looked at to a small extent, but these 
results are contradictory (see Lewander, 197 7).
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F . Summary of the Biochemical Effects of Amphetamine
The early research into the neurochemical effects of amphet­
amine led to the suggestion that amphetamine might exert its 
action by inhibiting MAO. While this action cannot be 
discounted at present, there is substantial evidence that the 
pharmacological actions of amphetamine are mediated by the release 
of catecholamines from neurons in the central nervous system. The 
exact mechanism for the release is not known, but it seems to be 
different from the release induced by nerve impulses. In addition, 
amphetamine blocks the (re-) uptake of noradrenaline and dopamine; 
this together with, perhaps a similar situation existing at the 
intraneuronal vesicular membranes, might contribute to the increase 
in the concentration of catecholamines in the synaptic cleft 
(therefore increasing the concentration of catecoholamines at the 
receptor). Similarly, decreased inactivation of the catecholamines 
by deamination, where there is a high tissue concentration of amphet­
amine, leads to the same results.
Increased stimulation of pre- and/or postsynaptic catechol­
amine receptors caused by the increased amount of extraneuronal 
catecholamines might affect the rate of synthesis and turnover of 
noradrenaline and dopamine in the brain catecholamine neurons by 
negative feedback regulatory mechanisms.
The action of amphetamine is thought to be indirect, since 
cunphetamine itself is not thought to act on receptoirs, but that its 
action is mediated by the release of catecholamines. There is 
evidence that amphetamine-induced release of catecholamines is
“55“
dependent on newly synthesized catecholamines(or that this pool is 
preferentially released).
The effects of amphetamine on 5-hydroxytryptamine storage, 
uptake, release and metabolism are not very clear. The effects 
are far less pronounced than those on the catecholamines, suggesting 
that 5-hydroxytryptamine may play a secondary role. The increase 
in brain tryptophan on treatment wi-th amphetamine is the most pro­
nounced effect with respect to the metabolism of 5-hydroxytrypt­
amine, and one of the more interesting as it has yet to be fully 
investigated.
There is evidence that amphetamine, at least in high tissue 
concentrations, causes a release of 5-hydroxytryptamine,an increase 
in 'turnover' (perhaps due to the increased levels of tryptophan)!, 
and a change in the 5-hydroxytryptamine synthesizing capacity of 
striatal synaptosomes.
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G. ’Catecholamines in the Brain as Mediators of the Amphetamine
Psychosis *
The amphetamine psychosis has already been mentioned in section 
A of the Introduction. Snyder (1972) put forward a hypothesis 
that catecholamines mediated the amphetamine psychosis, and 
that research in this area could lead to a biochemical model of the 
paranoid state or paranoid schizophrenia. I do not feel that this 
model, although interesting, is very convincing. In order to 
introduce the catecholamine theory, Snyder analyses a study on 
human subjects carried out by Griffith et al. (1970) and Angrist 
& Gershon (1970) and says that they show that the psychosis is not 
due to sleep deprivation or to a 'latent' schizophrenic tendency 
in the patients. I do not think that it is possible to make the 
latter statement from these clinical studies, but the main point 
is that both sleep deprivation and personality disorder are charac­
teristic features of chronic amphetamine users (and therefore of 
the psychosis); these behavioural features almost certainly involve 
changes in the catecholamines in the brain. He is confusing the 
relationships between the various disciplines involved in the 
study of brain function. Any discipline is potentially capable 
of describing and explaining an aspect of brain function but the 
biochemical changes occurring at the same time as the behavioural 
do not necessarily indicate a causal relationship. Another 
important aspect to bear in mind is that there is a many-to-one 
relationship (homomorphism) between the disciplines of biochemistry 
and behaviour.
Despite this criticism of the way in which Snyder presents his
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case, I do feel there is good reason to believe that catecholamines 
may be the primary mediators of the amphetamine psychosis. I do 
not believe there is a good reason for extrapolating the bio­
chemical changes which may precipitate the amphetamine psychosis 
to paranoid schizophrenia for the aforementioned reasons.
Crow et al. (1976) also proposed that the catecholamines may 
be involved in schizophrenia for the same reason. ~TKc»j point out 
that the psychosis occurs in most, if not all, volunteers when a 
sufficiently large dose is given (Griffith, 1972). This psychosis 
can be reversed with chlorpromazine, (Espelin & Done, 1968).
I do not doubt that the catecholamines are involved in schizophrenia, 
but I cannot see any reason for believing at this stage that they 
necessarily play a primary role. It is impossible to disturb 
the function of one neurotransmitter in the brain without affect­
ing others.
Animal models, by definition, are based on our preconceived 
ideas and therefore may not be able to provide any understanding of
tlie cause of a particular dysfunction in man.
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H, Metabolism and the Metabolites of Amphetamine
I. Uptake into and release from adrenergically innervated
tissues of amphetamine itself
Amphetamine accumulates in slices of the mouse heart (Ross & 
Renyi, 1966b) and perfused rat heart (Thoenen et al., 1968). 
Subcellular fractionation of the mouse heart showed that only 12% 
of the total amphetamine content is particle-bound 1 h after the 
injection of amphetamine (Obianwu et al., 1968). Slices of cerebral 
cortex from mice (Ross & Renyi, 1966c; Ross et al., 1968) and 
rat brain homogenate (Baldessarini & Vogt, 1971) also accumulate 
amphetamine in vitro. Subcellular fractionation of rat brains 
by differential or gradient centrifugation after systemic admini­
stration of amphetamine showed that amphetamine is found mainly in 
the high-speed supernatant (Pfeiffer et al., 1969; Wong et ai.,
1972; Fuller et ai., 1972b); only 7% is located in the synapto­
somal fraction and less than 3C% is particle bound (Wong et ai.,
1972).
Several studies indicate that the accumulation of the drug 
in the tissues might be largely extraneuronal. Thus, denervation 
(Thoenen et ai., 1968; Obianwu et ai., 1968), incubation temperature 
(Baldessarini & Vogt, 1971), and metabolic inhibitors like 
ouabain (Ross & Renyi, 1966c; Thoenen et ai., 1968) do not affect 
amphetamine accumulation. Efficient neuronal membrane pump 
blockers for noradrenaline uptake like cocaine, desmethylimipramine 
and protriptyline have little or no effect on the uptake of 
amphetamine (Ross & Renyi, 1966b, c; Ross et ai,, 1968; Thoenen 
et ai.,1968; Obianwu et ai., 1968). Amphetamine-induced nora­
drenaline depletion in the rat brain and heart in vivo is poorly
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inhibited by desmethylimipramine (Brodie et ai., 1968; Lewander, 
1968a). Protryptyline only partially prevents amphetamine 
induced release of a-methyl-noradrenaline from mouse heart in 
vivo (Lundborg & Waldeck, 1972). However, more recently it has 
been found that cocaine and desmethylimipramine inhibit the uptake 
of amphetamine into central noradrenergic neurons, at low concen­
trations of amphetamine (Rutledge et ai., 1973; Azzaro et ai.,
1974). It appears that amphetamine is, to a small extent, 
dependent on the noradrenaline transport mechanisms for its uptake 
by the adrenergic cell membrane.
Adrenal gland chromaffin vesicles take up amphetamine but
to a lesser extent than tyramine and by a mechanism which is
3different from adrenaline (Wagner et ai., 1974). H-Amphetamine
taken up into peripheral tissues or cerebral cortex slices was only 
poorly released by electrical stimulation (Kopin & Gordon, 1963; 
Baldessarini, 1971).
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2. Storage of amphetamine in the body.
S. Sparber (personal communication) has found that amphetamine 
is stored in the adipose tissue on long term treatment of rats with 
amphetamine. These stores of amphetamine are mobilized on subjecting 
the animal to cold stress. It is interesting to note that the 
familiar phrase 'after the drug had been eliminated from the body' 
may not be true. If amphetamine is stored in adipose tissue 
(and perhaps in other tissues) and only mobilized on stress, then 
measurements of blood levels of the drug may be meaningless.
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3. Metabolism of amphetamine
Partridge & Conner (1973) claim there is a carrier-mediated trans­
port mechanism for amphetamine which shows saturability, competitive 
inhibition with other amines and pH dependence. These authors report 
that a large fraction of the drug enters the brain by a non-specific
free diffusion process. This free diffusion is unusual as amphetamine 
Hence.
has a pKa of 9.9,j(at an arterial pH of 7.4 99.7% of the plasma
amphetamine will be protonated and in its lipophobic form. They 
postulate that the rapid onset of central nervous system stimulation 
could be due to this faster, carrier-mediated mechanism.
The metabolism of amphetamine is subject to large species 
variations. In rats amphetamine is metabolized mainly by p-hydroxy- 
lation in the liver and by B-hydroxylation in noradrenergic neurons.
The p-hydroxylation step does not seem to be stereoselective, but 
hydroxylation in the B-position is stereospecific to the (+)-isomer 
of amphetamine in vivo (Goldstein & Anagnoste, 1965; Goldstein et 
al., 1964; Lewander, 1971a). Direct B-hydroxylation of amphetamine 
can be detected in vivo (Goldstein et al., 1964; Taylor, 1974), 
but is only detected in very small amounts in tissues in vivo and 
has not, so far, been found to be important for the pharmacological 
actions of amphetamine (Goldstein & Anagnoste, 1965; Thoenen et al., 
1966; Groppetti & Costa, 1969b; Brodie et al., 1970; Lewander, 1971a)
The presence of p-hydroxynorephedrine was first demonstrated 
in the rat heart (Goldstein & Anagnoste, 1965) and cat spleen 
(Thoenen et al., 1966). Later this metabolite was also demonstrated
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in adipose tissue (Gessa et al., 1969), and in the rat brain after
larger doses of amphetamine ( > 1 - 2  mg/kg) or repeated admini­
stration of small doses of the drug (Groppetti & Costa, 1969a, b; 
Costa & Groppetti, 1970; Brodie et ai., 1970; Lewander, 1970a, b, 
1971a; Clay et al., 1971; Freeman & Sulser, 1972). p-Hydroxy-
norephedrine is believed to be present in noradrenergic neurons
and stored in noradrenergic storage vesicles. This is based 
on the findings that this metabolite of amphetamine is not detected 
in the rat liver (Gcildstein & Anagnoste, 1965) , that it can be 
liberated from the splenic nerve by sympathetic nerve stimulation 
in cats (Thoenen et ai., 1966), and that reserpine inhibits its 
accumulation into rat brain and heart, whether it is formed in 
vivo from amphetamine (Lewander, 1971a) or frcxn p-hydroxyampheta­
mine (Lewander, 1971b) . Intraventricular administration
of 6-hydroxydopamine reduces the brain content of p-hydroxynore­
phedrine after amphetamine (Cattabini et al., 1973). Methamphet- 
amine is dealkylated to amphetamine which in turn is p-hydroxylated 
in the rat. No evidence of the presence of p-hydroxynorephedrine 
or of p-hydroxyephedrine was found in the rat brain following 
administration of methamphefamine (Morgan et al., 1972a).
Studies on the duration of the noradrenaline depletion after 
(+)- or (±)-amphetamine in rats showed that control levels of nora­
drenaline were not reached until several hours or days after the 
disappearance of amphetamine from the tissues and it was demon­
strated that a maintained noradrenaline depletion correlated in 
time with the presence of p-hydroxynorephedrine in the brain, heart
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and fat tissues (Brodie et al., 1969, 1970; Groppetti & Costa, 
1969b; Costa & Groppetti, 1970; Lewander, 1970a, 1971a).
Lewander (1970a ,1971a) and Brodie et al. (1970), were the 
first people to suggest that p-hydroxyamphetamine and p-hydroxy­
norephedrine were responsible for the increase in the duration 
of noradrenaline and dopamine depletion after chronic amphetamine 
treatment. Also that p-hydroxynorephedrine acts as a false trans­
mitter and is involved in the development of tolerance to amphet­
amine during chronic treatment. I will present Lewander's 
case, as he sees it (1977) for p-hydroxynorephedrine playing a 
key role in the development of tolerance to amphetamine.
Investigation of the detailed stochiometric relationship^ 
between noradrenaline depletion and the amount of p-hydroxynore­
phedrine present in rat brain and heart showed that these parameters 
were related after, but not before, the first 24 h after the 
amphetamine injection (Groppetti & Costa, 1969b; Costa &
Groppetti, 1970; Lewander, 1971a). Thus the initial decrease 
in tissue noradrenaline levels seemed to be caused by mechanisms 
other than noradrenaline displacement due to p-hydroxynorephedrine 
accumulation, while the persistent noradrenaline depletion may 
be caused exclusively by the presence of this metabolite. The 
supporting evidence for this theory is :
(i) (-)-amphetamine, which is not converted to p-hydroxynorephe­
drine, causes only a transient (-̂ 24 h) and less pronounced 
noradrenaline depletion than (+)-amphetamine (Brodie et al., 
1970; Lewander, 1971a; Clay et al., 1971).
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(ii) after pretreatment of rats with drugs that inhibit p-hydroxy­
lation of amphetamine in the rat liver, e.g. desmethyl­
imipramine (Lewander, 1959, 1971a; Groppetti & Costa, 1959a, 
b; Costa & Groppetti, 1970), no p-hydroxynorephedrine
was present in the tissues after (+)- or (±)-amphetamine 
administration and the noradrenaline depletion was of shorter 
duration (< 24 h), than after (+)- or (±)-amphetamine alone.
(iii)in the guinea-pig p-hydroxylation of amphetamine does not 
occur. Thus, p-hydroxynorephedrine is not formed in this 
species and the brain noradrenaline depletion after amphet­
amine corresponds in time with the presence of amphetamine 
itself (Costa & Groppetti, 1970; Lewander, 1970b, 1971c).
(ivj in peripheral noradrenergically innervated tissues, p-hydroxy­
norephedrine follows the noradrenaline containing vesicular 
fraction in density gradients, while amphetamine is found in 
the supernatant (Jaquot et al., 1971).
Administration of p-hydroxyamphetamine to rats and mice causes 
depletion of heart, spleen, adipose tissue and brain noradrenaline 
(Maitre & Brunner, 1967; Lewander, 1969, 1971b; Groppetti &
Costa, 1969b; Gessa et al., 1969; Brodie et al., 1969, 1970;
Costa & Groppetti, 1970; McCullough et ai., 1970; Clay et al., 
1971; Rapin et al., 1973b). In rats chemically sympathomimecto- 
mized by 6-hydroxydopamine, less p-hydroxynorephedrine accumulated 
in peripheral sympathetically innervated tissues (Jacquot et al., 
1973a). Inhibition of noradrenaline uptake inhibits the accumu­
lation of p-OH-amphetamine into peripheral noradrenaline neurons 
(Jacquot et al., 1973b).
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p-Hydroxynorephedrine does not seem to accumulate in dopaminergic 
neurons, which may not be surprising, as they do not contain 
dopamine-B-hydroxylase. However, p-hydroxyamphetamine is found 
in the highest concentration in the caudate nucleus (Cattabeni at 
al., 1973). This metabolite is present in rat brain for only a 
short (less than 24 h) period of time after administration of 
amphetamine (Costa & Groppetti, 1970; Lewander, 1971a). Levels 
of dopamine in the brain are decreased after p-hydroxyamphetamine 
administration in rats (Lewander, 1969, 1971b), and mice (McCullough 
et al., 1970) and therefore p-hydroxyamphetamine may be important 
for the decrease in: brain dopamine, particularly after chronic 
treatment of rats (Lewander, 1968b, 1971a). Rat brain homo- 
vanillic acid concentrations do not change after peripheral p- 
hydroxyamphetamine injections (Jori & Bernardi, 1972; Jori &
Dolfini, 1974). After methamphetamine injections brain and 
heart noradrenaline is decreased, but the depletion does not last 
for several days as after amphetamine. Further, there is no 
evidence for the presence of g-hydroxylated metabolites of metham­
phetamine in the rat brain (Morgan, 1972a).
Intracisternally injected p-hydroxyamphetamine or p-hydroxy­
norephedrine causes a sustained decrease in brain noradrenaline 
(Breese et al., 1970; McCullough et al., 1970; Hitzemann &
Loh, 1972; Taylor & Sulser, 1973) and, in some experiments, in 
the brain dopamine concentration (Hitzemann & Loh, 1972). Re­
lease of brain noradrenaline and dopamine by intracisternally 
administered p-hydroxynorephedrine has been shown by a decrease 
in labelled catecholamines and an increase in methylated .
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deaminated catecholamine metabolites (Hitzeman & Loh, 1972).
Similar results were obtained for brain noradrenaline after 
intraventricular administration of both p-hydroxynorephedrine 
and p-hydroxyamphetamine by Taylor & Sulser (1973). In their 
experiments however,deaminated noradrenaline metabolites decreased. 
The tyrosine hydroxylase activity was reported to increase in the 
rat brain after p-hydroxynorephedrine (Hitzeman & Loh, 1972). 
Noradrenaline synthesis was, however, decreased in vivo after p- 
hydroxynorephedrine alone or in combination with amphetamine 
(Hitzeman & Loh, 1974). In this study, marked effects of 
p-hydroxynorephedrine on both synthesis, release and metabolism 
of brain noradrenaline were observed. The half-life of p- 
hydroxynorephedrine in the rat brain after intracerebral injections 
appears to be shorter (1.5 to 5 h; El-Guedri et al., 1973';
Taylor & Sulser, 1973) than after peripheral administration of 
the drug or its precursor (about 22 h; Costa & Groppetti, 1970; 
Lewander, 1971a).
It is unlikely that the formation of p-hydroxyamphetamine or 
p-hydroxynorephedrine are required for amphetamine to exert its 
acute catecholamine-mediated effects on, e.g., blood pressure, 
body temperature, motor activity. However, p-hydroxynorephedrine 
can be released from noradrerergic - neurons by nerve impulses 
(Thoenen et al., 1966) and by amphetamine itself (Brodie et al., 
1970; -Lewander, 1971b) as a false transmitter.
Looking at the evidence critically, the hypothesis that p- 
hydroxynorephedrine is acting as a false neurotransmitter and is
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involved in the development of tolerance to amphetamine must 
remain hypothetical. If p-hydroxyamphetamine is a substrate for 
dopamine-3-hydroxylase, it is not surprising that the product of 
the enzymic reaction remains in the dense-cored vesicle which 
contains the enzyme and noradrenaline or that it is released along 
with the contents of the vesicle.
Tolerance to a drug is defined behaviourally, therefore this 
theory that p-hydroxynorephedrine, which has weaker receptor 
stimulating properties than noradrenaline, may displace' the trans­
mitter from the noradrenergic storage granules and, following 
chronic (+)-amphetamine treatment is preferentially released 
resulting in diminished behavioural and physiological effects 
has to be subjected to behavioural tests. Lewander (1974) found 
that there was cross tolerance between the (+)- and (-)- isomers cf 
amphetamine for the anorexic effect. Recently Kokkinidis and 
Anisman (1978) found cross-tolerance between the two isomers using 
a free-running Y-maze. Acute amphetamine treatment induces 
stimulus perseveration, i.e. animals tend to visit only two arms 
of the Y-maze successively (naive animals tend to enter the armu 
which was least recently visited). The stimulus perservation 
decreases after chronic treatment (10 mg/kg for 5 days resulted 
in tolerance to this effect). Tolerance occurred with (+)- and 
with (-)-amphetamine and symmetrical cross-tolerance (i.e. from 
(+)- to (-) and from (-)- to (+)-) was found. This suggests 
that p-hydroxyamphetamine is not playing a critical role in the 
tolerance to perserveration, even though there is evidence that 
suggests a noradrenergic mediation of perseverative behaviour 
(Anisman & Kokkinidis, 1975).
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In summary, the amphetamine metabolite p-hydroxynorephedrine 
has been proposed to be involved in the development of tolerance to 
amphetamine. This has been studied extensively from a biochemical 
point of view. However tolerance to a drug is a behaviourally 
defined phenomenon, therefore investigation should be carried 
out, or theories confirmed in this discipline. Octopamine has 
been proposed as another candidate for a false transmitter by 
Kostopoulus and Yarbrough (1975).
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J. Aim of the Research
From the above review of the literature on the actions of 
amphetamine it can be seen that the biochemical aspects of with­
drawal have not been considered. This is because very little 
work has been done on this aspect of amphetamine administration.
Seiden et ai. (1976) observed, in monkeys, that the depletion 
in catecholamine concentration observed in the brain after chronic 
treatment with methamphetamine persists for long periods of 
withdrawal. Herman et ai. (1973b) treated rats chronically 
(3 mg/kg/24 h) with (±)-amphetamine for 9 months and found no 
change in 5-hydroxytryptamine, but a decrease in noradrenaline.
After 12 days of withdrawal there were decreases in noradrenaline 
and 5-hydroxytryptamine in the pons.
A feature of the literature on catecholamine metabolism after 
chronic treatment with amphetamine is that no one appears to have 
attempted to look at the situation from a metabolic viewpoint.
Thus, the aim of my research was to look at the metalDolism - of 
the catecholamines and 5-hydroxytryptamine during chronic treatment 
with, and withdrawal from, methamphetamine.
I chose to measure the levels of amines and those enzymes 
or transport processes which are thought to be rate-limiting steps 
in their synthesis (i.e. tyrosine hydroxylase and the uptake of 
tryptophan into the brain). The object was to see if an adaptation 
to the presence of the drug, via the regulatory mechanisms, occurred, 
and how any such adaptations reacted to the withdrawal of the drug.
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The initial experiments were carried out using the same drug
regime as Manning et al. (1973). In chronically-treated rats they
pl4 Tobserved that initial decreases in brain lactate and I Cj-glucose 
incorporation had returned to control levels (suggesting tolerance). 
Interestingly, the changes observed in these parameters after 
acute treatment were reversed after withdrawal of methamphetamine.
In summary, I chose to look at the regulation of catecholamine 
and serotonin metabolism after chronic treatment with, and with­
drawal from, methamphetamine, following the drug regime of 
Manning et al. (1973).
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FIGURE 1 Chemical structures representative of 
the amphetamines and catecholamines
a, ephedrine; b, amphetamine; c, metham­
phetamine; d, phenmetrazine; e, adrenaline; 
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SECTIONS III AND IV
MATERIALS, METHODS AND RESULTS
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III. ADMINISTRATION OF METHAI^IPHETAMINE IN THE DRINKING WATER
A. Treatment of animals and behavioural monitoring
1. Materials and Methods 
Materials
DL-]SBthamphetamine hydrochloride was obtained from Sigma (London) Chemical 
Company Ltd, The experiments were performed on remote Wistar rats (CHFB) 
of both sexes (Anglia Laboratories).
Methods
The rats were thirty days old on commencement of treatment. They 
were kept under constant conditions, i.e. light/dark cycles (12h), temp­
erature (21°C), and diet (Oxoid rat, mouse breeding diet). Four experi­
mental animal groups were set up as follows:
(i)'Acute' animals were injected (i.p.) with methamphetamine hydro­
chloride (5 mg/kg body weight), dissolved in 0.9% (w/v) sodium 
chloride, one hour before death.
(ii)'Chronic' rats received methamphetamine in their drinking water in 
concentrations calculated to give 5 mg/kg/24h initially. This was 
doubled every five days to a final intake of 40 mg/kg/24h at the 
end of the experimental period.
(iii)'Withdrawn' rats were treated identically to those in the chronic 
group, except that the methamphetamine was removed and they were 
given drug-free water 24h prior to death.
(iv)Control animals. There were two groups of control rats, one of 
which ('injected controls') received an i.p. injection of saline Ih 
prior to death. The other group ('controls') received no treatment.
The rats were housed in groups of five.
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2. Results
The weights and drinking rates of the rats were recorded. A 
graph of the weight changes is shown in Figure 2. It can be seen 
that the chronic male rats gained weight steadily up to 24 days at a 
rate slower than that of the control males, but higher than that of 
the control females. Between 24 and 43 days the chronic males in­
creased in weight only very slowly, contrasting with the control males 
who continued to gain weight rapidly. The chronic females did not 
appear to gain weight at all, and at 24 days they started to lose 
weight. This was the only group of rats which lost weight over the 
experimental period.
The drinking rates are shown in Figure 3. It can be seen that 
they varied considerably over :the experimental period not only between 
groups but within groups. The control males consistently drank more 
than the chronic males and control females. The chronic females con­
sumed approximately the same as the last two groups until 20 - 22 days 
when the drinking rate fell to around 4 ml/24h/rat.
Behavioural monitoring
During the experimental period attempts were made to apply rating 
scales to the various stereotyped behaviours observed, and to monitor 
the activity of the animals. To do this a modified hole-board cage 
was used (File & Wardill, 1975). The size of the cage was 58 cm x 
60 cm X 40 cm with 16 holes (4x4), diameter 2.5 cm, spaced equally 
apart. A representative set of figures obtained after 24 days of 
chronic treatment is shown in Table 1. The rats had been previously
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habituated to the cage. It was observed that the chronic rats were 
readily disturbed by external noises; they responded with a period 
of immobility (about 30s ), followed by a period of hyperactivity.
Table 1.
The figures represent the ratio of line-crossing (activity); 
climbing the sides of the cage and head-dipping (exploratory behaviour); 
rearing ; over a 3 min period.
Control males Chronic males
Rat Wt.(g) rating Rat Wt.(g) rating
1 250 68:25:2 1 220 88:12:0
2 290 73:23:1 2 210 76:11:0
3 245 94:18:0 3 235 90:28:4
4 245 29:13 :1 4 195 71:11:0
5 245 52:24:0 5 185 85:23:0
6 190 57:12:4 6 215 120:20:6
7 200 137:34:1
It can be seen that the chronically-treated males appeared to be 
more active than the control males. There is no obvious difference 
between exploratory behaviour and rearing. The data was not analysed 
statistically for reasons which will become apparent later.
From subjective observations, between 0 - 3  weeks hyperactivity 
was marked in the chronic rats from the commencement of treatment.
After 1 week an abnormal gait (recorded on film) similar to "mud-walking" 
was observed. This was especially prominent in the females. With-
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drawal of the rats after 3 weeks of chronic treatment appeared to have 
a relatively depressing effect on motor activity.
Between 3 and 7 weeks of treatment the hyperactivity decreased 
in the chronic males and females, and the abnormal gait became less 
prominent, but was still observed after five weeks. At approximately 
5 weeks the females showed marked wasting, and engaged in pointless, 
apparently stereotyped, behaviour (they clustered around the water 
bottle and continually rattled the ball, but the drinking rates showed 
that they were consuming hardly any water). By 5 weeks all the females 
had died; on death it could be seen that they had bitten through their 
skin in two, almost stereotaxically defined, positions on the upper 
and lower abdomen. However no bleeding was apparent.
Between 6 and 7 weeks the abnormal gait could no longer be ob­
served in the males, neither was there any marked hyperactivity. How­
ever, they started to engage in stereotyped grooming behaviour and 
self-mutiliation of their claws (in some cases the claws were bitten 
away to the skin, which was bleeding). Withdrawal from methamphetamine 
at this stage appeared to have no obvious behavioural effects.
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FIGURES 2 and 3 The weights and drinking rates of
chronic and control rats over the 
experimental period
The weights of the control males 
(•— •), chronic males (a— -a) , control (■— u) and chronic 
females ($-4) are shown in Figure 2.
Arrows on the abscissa mark the day on 
which the dose of methamphetamine was 
doubled. Figure 3 shows the drinking 
rates of the same animals; the key is the 
same as for figure 2.
The first chronically-treated female 
died on day 24; only one was left by day 37.
All the chronically-treated females had died 
by day 42.














B. Choice of brain regions
This was determined by our knowledge of the distribution of the
amines likely to be affected by the treatment. The regional distribution
in the brain of the monoamines, noradrenaline (Vogt, 1954), dopamine 
(Carlsson et al., 1958) and serotonin (Twarog & Page, 1953) led to the 
hypothesis that they were acting as neurotransmitters in the brain. Pharma­
cological manipulation of the monoamines has led to their implication in 
various neurological and psychiatric disturbances in man. Most of the 
dopamine in the brain was found to be localized in the neostriatum 
(Bertler & Ros engren, 1959a,b). Reserpine was demonstrated to deplete 
the stores of serotonin in the body (Shore et al., 1956), and the cate­
cholamine stores both centrally and peripherally (Holzbauer & Vogt, 1956;
Carlsson & Hillarp, 1956; Bertler et al., 1956). An injection of the 
catecholamine precursor dihydroxyphenylalanine (DOPA) resulted in a re­
versal of the behavioural changes brought about by reserpine administration, 
but the serotonin precursor 5-hydroxytryptophan lacked this effect (Carlsson 
et al., 1957). The injection of DOPA caused a considerably greater rise
in dopamine levels than in noradrenaline levels. The emergent hypothesis 
was that Parkinson's disease may be caused by changes in dopamine levels
or its properties as a neurotransmitter (Carlsson, 1959). Other examples 
of drugs introduced into psychopharmacology as substances found to act by 
manipulating monoamine levels are chlorpromazine (Delay et al., 1952), ipro- 
niazide (Loomer et ai., 1957; Kline, 1959) and imipramine (Kuhn, 1957). 
These drugs are still used as potent antipsychotic and antidepressant drugs, 
respectively.
The criteria for noradrenaline, dopamine and serotonin functioning 
as transmitters in the central nervous system have to considerable 
extents been experimentally established (Andén, 1964; Andén et al., 1969).
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The distribution of the monoamines in the central nervous system 
has been localized biochemically (Vogt, 1954; Bertler & Rosengren,
1959; Carlsson, 1959; Bertler, 1960) and mapped histochemically (Fuxe 
et ai., 1969).
The Falck and Hillarp histochemical technique provided the first 
evidence for the intraneuronal localization of noradrenaline, dopamine 
and serotonin in specific systems of cell bodies and nerve terminals 
(Carlsson et ai., 1962). Dahlstrôm and Fuxe were able to make a 
detailed description of the exact localization of the noradrenergic, 
dopaminergic and serotonergic cell groups and nerve terminal areas 
(Dahlstrom & Fuxe, 1964, 1965; Fuxe, 1965 a, b). It is possible to 
increase the intraaxonal monoamine levels by lesioning the axons, as 
the interruption of axonal flow causes a pile up of fluorescent material 
proximal to the lesions thus making it possible to trace the axons by 
serial sectioning. By studying the axonal pile up and the terminal 
degeneration after lesions it was possible to outline the ascending 
monoamine pathways in the brain (Andén et al., 1966). The detailed 
anatomy of the dopaminergic and noradrenergic pathways was elucidated 
by Ungerstadt (1971c ) who, by superimposing his sections
on the K5nig and Klippel stereotaxic rat brain atlas (1963), made the 
monoamine pathways accessible to stereotaxic techniques.
Major monoamine pathways in mammalian brain
(i) Noradrenaline
Noradrenergic cell bodies, found in the brain stem, send projections 
via the dorsal and ventral noradrenergic bundles to innervate forebrain 
structures. The ventral bundle is believed to project to the hypo­
thalamus, while the dorsal bundle innervates regions of the cerebral
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cortex and mesolimbic nuclei. The locus coeruleus contains the 
major noradrenergic cell group. This is located in the pons in the 
floor of the IV th ventricle, and sends fibres mainly via the dorsal 
bundle.
(ii) Dopamine
Dopaminergic cell bodies are found predominantly in the mid­
brain. Three major dopaminergic pathways have been established:
Nigro-neostriatal pathway. This originates in the cell bodies of the 
substantia nigra and the fibres project to the neostriatum (caudate 
nucleus-putamen complex).
Mesolimbic pathway. This originates in cell bodies medial to the sub­
stantia nigra and projects through the median forebrain bundle to 
areas of the mesolimbic system (nucleus accumbens septi, tuberculum 
olfactorium, amygdaloid complex).
Tubero-infundibular dopaminergic systan. The cell bodies are found 
in the acunate nucleus of the hypothalamus and project fibres to the 
terminal region of the median eminence.
(iii) 5-hydroxytryptamine (serotonin)
Major serotonergic cell groups are found in the region of the 
Raphé nuclei (dorsal and ventral) of the upper brain stem. Other minor 
serotonergic cell groups are found in the pons/medulla, giving rise to 
various ascending and descending tracts. Fibres from the Raphe nuclei
project to various forebrain structures; these fibres eventually run
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with the median forebrain bundle and innervate regions of the neostriatum, 
cerebral cortex and mesolimbic nuclei. There are also more caudal 
projections to the hypothalamus and hippocampus.
A diagrammatic summary of the noradrenergic, dopaminergic (Unger- 
stedt, 1971b)and serotonergic (Dahlstrom & Fuxe, 1964, 1965) pathways 
is shown in Figure 4.
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Figure 4. 4a shows the major noradrenergic pathways and 
the nigrostriatal dopaminergic pathway.
4b shows the major serotonergic pathways and a 
more detailed diagram of the dopaminergic pathways
Fig. 4a
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C. Regional dissection of the brain
Post-mortem changes are obviously an important consideration at 
this stage. The three methods most commonly used to minimize these 
are: -
(i) Subjecting the rat to a short, intense burst of microwave irradiation.
(ii) Decapitation followed by dissection over ice or on a freezing block.
(iii)Decapitation followed by freezing the whole brain in liquid 
nitrogen (or, alternatively, killing the rat by dropping it into 
liquid nitrogen).
Method (i) has recently been shown to disrupt the structural in­
tegrity of the nerve fibres (Meyerhoff et al,, 1978). Method (iii) 
poses practical problems for a regional dissection of the brain, as 
the architecture of the brain is destroyed by freezing, and the various 
regions loose their colouration and texture. This means that di­
ssection of specific regions would have to be carried out solely on 
their stereotaxic positions. Frozen brains are very difficult to 
mount on a cryostat chuck, and would have to be cut before commencing 
dissection. Thin blocks buckle and break more easily than the whole 
brain, making clean, consistent dissection hard. Palkovits (1973) 
has described a method employing cryostat dissection. Brain nuclei 
were 'punched out' of slices of frozen brain cut with a microtome.
The slices were placed on a microscope slide and the required nuclei 
removed with a special needle, under a stereomicroscope.
I found it was not possible to raise the temperature of the brain in 
a cryostat to a temperature at which it could be dissected without fract­
uring the brain. This can only be done at O^C when the ice has melted and
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the brain is no longer firm; therefore dissection is difficult.
For the above reasons Method (ii) was chosen as being the most 
practical. Two recent papers (McKay et al., 1978 a, b) have reviewed, 
amongst other things, the stability of monoamine oxidase, tyrosine 
hydroxylase, dopamine-3-hydroxylase, dopa decarboxylase, noradrenaline, 
dopamine, serotonin, homovanillic acid and 5-hydroxyindoleacetic acid 
in the brain post-mortem. Tyrosine hydroxylase has been shown to be 
very unstable at room temperature, and only moderately stable at 4°C.
The activity of this enzyme falls by approximately 50% over 3 post­
mortem hours in rat brain (Black & Geen, 1975). The order of in­
creasing stability is:- dopamine-3-hydroxylase, dopa decarboxylase 
and monoamine oxidase (which appears to be stable even at room temp­
erature) . Noradrenaline is the most unstable of the amines mentioned, 
although data on the metabolites are sparse, i.e. limited to those 
mentioned here. Post-mortem changes using Method (ii) are likely to 
be minimal with the exception, perhaps, of tyrosine hydroxylase. This 
will be considered in the Discussion. After dissection, the regions 
were weighed and dropped into liquid nitrogen. The regions were stored 
at -20°C.
The regions dissected were:-
(i) Cortical slice (0.33 mm slice of neocortex).
(ii) Medulla. Cuts were made in front of the superior colliculi and 
behind the IVth ventricle.
(iii)Striatum (including caudate nucleus - putamen and globus pallidus).
(iv) Mesolimbic regions. The tuberculum olfactorium, nucleus accumbens 
and amygdala were pinched out using fine forceps.
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(v) Hypothalamus. This was pinched out using fine forceps.
The pinching out of regions was found to be the most rapid way 
of selectively obtaining these small regions, rich in nerve terminals. 
Precision was, to some extent, sacrificed for rapidity. The consist­
ency of dissection was monitored by weight. The time from decapitation 
to the stage where all regions had been frozen in liquid nitrogen 
varied from 6 - 8  min. Figure 5 shows the positions of the various 
brain regions.
Throughout this thesis the names given to the regions do not corre­
spond to their precise anatomical definition therefore should be pre­
faced by "the regions containing...", and these are defined by the 
dissection technique.
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Fig.5 Drawing of the rat brain
The regions of the brain that were dissected out (see text) 
are indicated.
Key:- hypothal. - hypothalamus
caudate n. - caudate nucleus (striatum, globus
pallidus and putamen) 
tub.olfatorium - tuberculum olfatorium 
n. accumbens - nucleus accumbens. 













D. Fluorometric determination of noradrenaline^ dopamine, serotonin 
and histamine 
1. Materials and Methods 
Materials
All reagents were of Analar grade. Noradrenaline bitartrate, 
dopamine hydrochloride, serotonin creatinine sulphate, histamine hydro­
chloride, orthophthalaIdialdehyde and Dowex SOW (x4; h "̂ form; 100 -
200 mesh) ion-exchange resin were obtained’from Sigma (London) Chemical 
Company Ltd.
Potassium hydroxide phthalate reagent was made by adding 1.021 g 
of potassium hydrogen phthalate to 40 ml of water. The solution was
then adjusted to pH 3.0 with 2 M hydrochloric acid. To this, 3.96 g 
of potassium hydroxide was added, and the final volume adjusted to 50 ml.
Narrow-range indicator paper (pHydrion paper pH 3.0 - 5.5) was 
obtained from Micro Essential Laboratory, Brooklyn, N.Y., U.S.A.
An Aminco Bowman spectrophotofluorometer (American Instrument 
Company Inc., Silver Spring, Maryland, U.S.A.) was used for all the 
fluorometric determinations.
Methods
The first method for the extraction and purification of the amines in 
brain tissue was performed according to the method of Atack & Magnusson 
(1970). The procedure followed was:- homogenization, neutralization 
and ion-exchange chromatography.
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Homogenization. Each region was homogenized in 10 vol. of perchloric 
acid (0.4 M) containing 1 mM ethylene diamine tetraacetic acid (EDTA) 
and 10 mM ascorbic acid. The EDTA and ascorbic acid were added to 
minimize oxidation of the amines. Homogenization was carried out 
using 'Uniform' glass to glass homogenizers. The procedure was 
standardized to ensure maximal, consistent extraction of the amines.
The homogenate was kept at 0°c in an ice bath, then centrifuged at 
8,000 X g (16 X 15 ml head) for 15 min in an MSE 18 centrifuge. The 
supernatant was pipetted off, the volume measured and stored at -20°c 
overnight. Immediately before the amines were separated by ion- 
exchange chromatography, the homogenate was neutralized.
Neutralization. The extracts were adjusted to pH 4 by the addition 
of 1 M acetic acid (0.1 ml: 1ml extract), at 0°C, followed by the 
potassium hydroxide phthalate reagent (approximately 0.4 ml: 1 ml 
extract). The potassium hydroxide phthalate reagent was added with 
mixing to avoid high local pH changes. The precipitated potassium 
perchlorate was removed by centrifugation at 3,000 xg for 10 min at 
0°C. The pH of each extract was tested using narrow-range indicator 
paper.
Ion-exchange chromatography. Dowex SOW (x4; H^ form; 100 - 200 mesh) 
resin was prepared by washing ten times with water, with subsequent 
decanting, to remove fine particles. The resin was washed in 2 M 
sodium hydroxide (10 vol.) containing 0.1% EDTA,followed by three washes 
with distilled water. Finally the resin was washed with 10 vol. of •
2 M hydrochloric acid, followed by three washes in distilled water.
This cycle was repeated three times, and the resin was stored in 0.1 M
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sodium phosphate buffer, pH 6.5, containing 0.1% EDTA.
The columns (15 mm x 6 mm) were packed with freshly-prepared 
Dowex resin. The column was washed with 10 ml of 0.1% EDTA in order 
to remove any fluorescent material or metal ions which may have been 
left on the resin. A known volume of neutralized extract was then 
loaded onto the column and washed with 10 ml of 0.1 M sodium phosphate 
buffer, pH 6.5. This preliminary washing removed compounds which had 
not bound to the resin e.g. 5-hydroxyindoleacetic acid, 5-hydroxytryp­
tophan and histidine. The eluate was collected and discarded. The 
column was then washed with 5 ml of distilled water. The amines 
were eluted in a stepwise manner, and the elution pattern is shown 
in Figure 6. This took about 6 h and the recovery was low; con­
sequently this stage was modified.
Modified method
The method was modified as follows: noradrenaline, dopamine and
histamine were eluted with 4 ml of 2.5 M hydrochloric acid, then the 
serotonin was eluted with 5 M hydrochloric acid in 50% methanol.
Initially it was assumed that the original order of elution 
corresponded to the decreasing pKa values of the amines ; therefore all 
should elute with 4 ml of 2.5 M hydrochloric acid. However, serotonin 
was found to elute very slowly even using concentrated hydrochloric 
acid, implying that the nature of its binding to the ion-exchange resin 
is not simply ionic. Serotonin was eluted with 8 ml of acid and the 
elution pattern was independent of the concentration of acid used be­
tween 2.5 M and 11.45 M. On using 1 M hydrochloric acid in 50%
“106“
methanol or ethanol, serotonin Wos eluted in 2 ml. In practice
5 M hydrochloric acid in 50% methanol was used, as the fluorometric 
assay requires strongly acidic conditions. Therefore the subsequent 
addition of hydrochloric acid in the assay procedure could be omitted, 
thus effectively doubling the sensitivity of the assay. It was found 
necessary to dry the methanol and redistill it immediately prior to 
use; if this was not done the blank values were very high. Methanol 
was chosen, rather than ethanol, as the assay for serotonin involves 
heating in a boiling water bath for 15 min. The evaporation of the 
methanol increased the sensitivity of the assay, and could be the 
reason why the purity of the methanol was found to be so crucial.
The flow rate of the columns using glass“wool plugs was found to 
be very variable. This was standardized by using polyethylene plugs.* 
Light was partially excluded from the resin, as a precautionary measure, 
with opaque tape.
Each fluorometric assay was found to be specific. Methamphet- 
amine and the major metabolites of amphetamine,norephedrine and p-hydroxy- 
amphetamine were found not to interfere with any of the assays.
This modified procedure cut down the elution time by one third, 
and minimized the loss of amine due to altered elution patterns.
Quenching of the fluorescence by other compounds present in the eluate,
was found not to be significant (based on the use of internal standards).
Simulated assays were carried out to test the recovery of each 
amine at different stages in the overall procedure.
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A diagrammatic summary of these, and the percentage recoveries, 
are shown in Figure 7 and Table 2. This was done for the pure 
compounds only.
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Fig. 6 Elution pattern of amines from
ion-exchange chromatography*
The stepwise elution of standard solutions ofj 
noradrenaline, serotonin, dopamine and histamine 
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1 85% 1 52%
2 89% 2 52%
3 100% 3 54%
4 100% 4 88%






















The assays were carried out in triplicate. The assays had to be 
repeated for dopamine, as the first set of results showed low recovery 
and high interference. The second set of results are shown here.
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Fluorometric determination of the levels of noradrenaline, dopamine, 
serotonin and histamine in brain regions
(i) Dopamine and noradrenaline
Both the noradrenaline assay (Laverty & Taylor, 1968) and the 
dopamine assay (Atack, 1973) are based on the formation (by oxidation) 
of the fluorescent trihydroxyindole derivatives. The trihydroxyindole 
derivative of dopamine was measured at an excitation wavelength of 
330 nm, and an emission wavelength of 375 nm. The corresponding ex­
citation and emission wavelengths for the noradrenaline derivative were 
395 nm and 475 nm.
(ii) Serotonin and histamine
Both assays involve condensation with orthophthalaldialdehyde (OPT) 
to give a fluorescent product. In the case of serotonin the reaction 
takes place on heating in acid conditions, (Maickel et al., 1968) to 
give a product which fluoresces at excitation and emission wavelengths 
of 295 nm and 550 nm respectively. Histamine reacts with OPT under 
alkaline conditions to give a fluorescent product with excitation and 
emission wavelengths of 350 nm and 460 nm (von Redlich & Click, 1974).
In all fluorescent studies the excitation and emission peaks are un­
corrected.
Modification of fluorometric assays
The assays were modified to allow for the assay of small volumes 
and the higher acidity of the column eluate. In all the assays the 
pH has to be correct at the critical stages in the reactions to ensure 
maximal formation of the fluorophore.
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For the assay of noradrenaline, potassium bicarbonate (2.5 M) 
containing potassium hydroxide (2.5 M) was added, on mixing,to 0.3 ml 
of eluate until the pH reached 6.5 (approximately 0.2 ml). Iodine 
reagent (0.1 ml of 0.02 M iodine in 5% w/v sodium iodide) was added, 
the solution mixed and allowed to stand for 3 min. Alkaline sulphite 
reagent (0.3 ml) was added on mixing and the solution left to stand 
for 4 min (alkaline sulphite reagent: 40% (w/v) Na^SO^; 1% mercaptoethanol; 
5 M NaOH). Finally the solution was acidified with 0.2 ml of 10 M 
acetic acid.
The dopamine assay was modified as follows: EDTA (50 yl of 8%,
pH 7) was added to 0.5 ml of eluate. Potassium ferricyanide (50 ul of
0.25%) was added on mixing and the solution was left to stand for 5 min. 
Alkaline metabisulphite (6.3 M NaOH containing 0.125 M sodium meta­
bisulphite) was added until the solution reached a pH of 13.1 (approx­
imately 0.2 ml). After allowing to stand for 5 min, 0.2 ml of glacial 
acetic acid was added.
In both these assays it was important to add the alkaline solutions 
on mixing on a vortex mixer to try to minimize high local pH changes 
which would result in oxidation of these amines. The blanks used for 
the noradrenaline and dopamine assays were: reagent (no amine sample) 
and completely reversed (acid, antioxidant and then oxidant).
Serotonin was assayed by taking 0.5 ml of eluate
and adding 50 yl of 0.02% (w/v dissolved in methanol) OPT.
The solution was mixed and incubated in a boiling water bath for 15 min.
The tubes were left to cool before reading them in the fluorometer.
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The histamine assay was carried out by adding 0.12 ml of 5 M NaOH 
to 0.2 ml of column eluate. The NaOH was added, on mixing, to bring 
the solution to a pH of 12.4 to 12.5. OPT (50 yl of 0.02% w/v 
dissolved in methanol) was added, the solution mixed, and allowed to 
stand for 4 min before adding H^PO^ (50 yl of 3 M) to bring the final 
solution to a pH of 2.4 to 2.6.
In both the serotonin and histamine assays, the OPT had to be made 
up immediately prior to use. It was found that the concentration of 
OPT used had to be increased approximately 20 fold over the published 
assays. Two blanks were used: a reagent blank (no amine sample)
and a sample blank (methanol without OPT was added).
-115-
2. Results
One complete set of results was obtained for each of the four 
amines from the five experimental groups. The chronic and withdrawn 
animals had been on methamphetamine for seven weeks. The results 
are summarized in Figures 8, 9, 10, 11. The values were subjected 
to a statistical analysis and the test for significance which was used 
was the unpaired 'student's* t test.
The significant changes (p < 0.05) seen in the amines on chronic 
treatment were found mainly in serotonin. Histamine appeared to change 
the most on injecting the animals, although this may be due to an 
increased concentration of histamine in the blood. The high standard 
deviations,seen especially with the dopamine results,would mask small 
changes in the amines and relatively large changes in dopamine levels. 
The high standard deviations reflect the problems encountered with 
this assay.
It can be seen from the tables that the values for the levels of 
the amines are very low and that they have not been corrected for 
recovery. This is due to the very low, and variable recoveries ob­
tained for the internal standards which were run at the same time as 
the samples. This was unexpected and casts doubt on the meaning of 
the results which were obtained.
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FIGURES 8-11 Summary of the regional amine levels
in the five experimental groups of rats 
after 49 days of treatment.
Figures 8 to 11 show the mean noradrenaline, 
dopamine, serotonin and histamine levels, 
respectively, in the various experimental groups. 
The error bars mark the standard deviation . The 
levels are not corrected for recovery.





Those values which were found to be significantly
different from the relevant control levels are marked
Significant
with an asterisk. # denotes a statistical^diff- 
erence between the controls and the injected controls,
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E. Comments on the route of administration of methamphetamine and
the methodology used to measure amine levels
The behavioural observations showed that when methamphetamine is 
given in the drinking water it is not possible to know with any pre­
cision how much methamphetamine each rat has consumed. In order to 
control this strictly, the rats would have to be housed individually 
with special drinking devices which measure the total amount consumed 
and how much of the total was spilt. Spillage of the drinking water 
is an especially important consideration when some of the animals are 
exhibiting stereotyped behaviour. When administering drugs which 
have a bitter or unpleasant taste in the drinking water, it is common 
to sweeten the water with sucrose. However it has been shown (Young 
& Landsberg, 1977) that sucrose given in the water to rats already 
given free access to food will result in voluntary overfeeding and a 
stimulation of the sympathetic nervous system. For obvious reasons, 
the addition of sucrose to sweeten the taste of the methamphetamine 
would only complicate the situation further.
The behaviours shown by individually-housed rats chronically 
treated with methamphetamine is radically different from those seen in group- 
housed rats. Groups will start to show abnormal social behaviours
e.g. increased fright and flight and little social grooming. Late 
stages show exaggerated fright or flight, f e a r - l i k s  startle responses 
and behaviours that result in their being chased by controls 
(Ellison et al., 1978).
-122-
The strikingly different behaviours ex­
hibited by individually-housed and group-housed animals would suggest 
that their biochemistry is also different.
The rating scales which are commonly used to quantitate subjective 
behavioural observations (Klawans et al., 1975; Ellinwood & Balster,
1974) were found to be impractical. I did not consider that this way 
of measuring behaviour was particularly meaningful in terms of corre­
lating my subjective (yet quantitative, therefore'objective') ratings 
with other research workers in the field. My original intention had 
been to correlate my biochemical results with a detailed behavioural 
study. The alternatives to this are to carry out a properly con­
trolled behavioural study of my own (which was clearly not feasible) 
or to correlate my biochemical data with results from behavioural 
studies by the administered dose. This has the drawback of group or 
individual variation to a particular dose.
It was clear that, on long-term treatment, the animals were 
receiving toxic doses of methamphetamine, and that the females were 
far more susceptible to the effects of methamphetamine (it is possible 
that the long-term effects were different for the two sexes).
In the light of the above observations it was decided to administer 
methamphetamine by intra-peritoneal injection, so ensuring that each 
rat received a known amount of methamphetamine. The amount of meth­
amphetamine received by each animal was also reduced, compared with 
that calculated to have been received in the drinking water in the 
first series of experiments. The result of this was to change the
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orientation of the research in the desired manner i.e. to correlate 
my biochemical data with published behavioural observations via dose 
rather than by behavioural assessment.
The acute group of animals was redundant as there can be no control 
for the acute effects of methamphetamine in chronically-treated rats 
even if the drug is administered by intra-peritoneal injection. As 
far as I am aware, the experiments which would be necessary to determine 
the amount of circulating and stored methamphetamine (or amphetamine) 
in rats which have been chronically treated with the drug, have not 
been done. These measurements would have to be carried out in order 
to set up a valid acute control.
The methodology used for the quantitation of regional amine levels 
was unsatisfactory for several reasons:-
(i) The separation and analysis of the four amines in five regions 
from twenty rat brains was tedious and impractical, as, to 
eliminate the possibility of inconsistent recovery at different 
stages in the procedure,it was preferable to run all the columns 
simultaneously and all the assays simultaneously.
(ii) The standard curves obtained for the fluorometric assays varied 
considerably even with consecutive assays, therefore a standard 
curve had to be carried out for every assay.
(iii)The recovery of the internal standards was variable and very low 
during the main experiment. This was unexpected and casts doubt 
on the meaning of the results. This also suggests that the 
published method for the purification and separation of the amines 
works only for the pure compounds and not for brain samples.
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The original paper used rat intestinal extracts for their internal 
standards, and showed a good recovery. However the endogenous levels 
given here were from rats on an L— DOPA administration trial. In 
retrospect, the data presented were not convincing evidence that the 
method was valid. A series of experiments using internal standards 
was carried out subsequently, and the results confirmed that the tissue 
extracts do not give the same results as the pure compounds. So, short 
of redesigning the procedure, with no certainty of obtaining a workable 
method, it was decided to abandon this method in which the amines are 
separated by ion-exchange chromatography and assayed fluorometrically.
The attraction of the alternative radioenzymatic techniques is 
their sensitivity and specificity. The fluorometric methods, even 
when the sensitivity of the assay was increased, were not sufficiently 
sensitive to measure the levels of all the amines in each region (even if 
the recovery had been high). Another point is that in an experimental 
study which involves long-term drug treatment of animals it is clearly 
desirable to try to obtain as much biochemical information as possible, 
simultaneously. This not only reduces the number of animals involved, but 
also allows biochemical 'pictures' of individual rats to be constructed. 
This is more valuable when considering individual variation in response 
to a dzrug.
In summary it was decided to administer methamphetamine by intra- 
peritoneal injection, and to use radioenzymatic techniques for the 
measurement of the amines, which allows other assays to be
carried out on the same homogenate.
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IV. ADMINISTRATION OF IvETHAMPHETAMINE BY INTRAPERITONEAL INJECTION
A. Treatment of Animals
1. Materials and Methods
The rats were 3 0 - 3 5  days old on commencement of treatment. They 
were housed in groups of five under constant conditions, i.e. light/ 
dark cycles (12h), temperature (21 - 23°C) and diet (Oxoid 41B).
Three experimental animal groups were set up as follows:
(i) 'Chronic'rats received methamphetamine by intra-peritoneal in­
jection (one injection every 12h). The initial dose was 5 mg/kg/ 
24h, increasing to 10 mg/kg/24h after 5 days and to 15 mg/kg/24h 
after 10 days. The rats were kept at this dose until the end
of the experimental period.
(ii) The 'withdrawn' animals were treated identically to those in the 
chronic group, except that they received saline injections 36h 
prior to death.
(iii)The 'control' animals received saline injections over the same 
time period.
All three groups were killed 12h after their last injection. The 
weights, drinking rates and food consumption were recorded at the same 
time each day (12.00 - 13.00 h).
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2. Results
Four sets of experimental animal groups were set up. The first 
set were male rats and were used to determine tyrosine hydroxylase 
activity and noradrenaline and dopamine levels. The second set were 
female rats which served as a comparison to the male rats in terms of 
weight gain, food consumption and drinking rates (this was felt to be 
important in the light of the results obtained in Section IIIA).
The third set were male rats, set up for an analysis of the regional 
amino acid levels. The final set of rats were also male and were 
used for the determination of tyrosine hydroxylase activity, the 
determination of noradrenaline, dopamine and their non-O-methylated 
metabolites, tryptophan and serotonin levels in brain regions, and 
the levels of tryptophan, phenylalanine and tyrosine in the plasma.
Figures 12 - 20 show the weights, food consumption and drinking 
rates from experimental sets 1 and 2, the weights and food consumption 
from experimental set 3 and the weights from experimental set 4.
From the graphs it can be seen that experimental sets 2 and 3 became 
tolerant to the anorexic effects of methamphetamine, whereas experi­
mental set 1 did not. A possible explanation for the first set of 
animals not developing tolerance to the anorexic effects of methamphetamine 
is stress. This set of animals showed signs of severe stress initially 
and also when the dose was increased (far more than any of the other 
experimental sets). My original intention had been to increase dose 
further, but because of the stress caused, I only increased it to 15 mg/ 
kg/24h. Stress was observed in all sets of control rats (again this 
was more pronounced in the first set) on commencing the injections.
It has been shown that amphetamine is stored in adipose tissue and 
released when the animal is stressed (S. Sparber, personal communication);
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there are also many reports in the literature of changes in catecholamine 
and serotonin metabolism with stress (Curzon, 1978; Ishii et al.,
1975).
The chronic rats in experimental set 1 also consumed significantly 
less water than the controls; this was not seen with experimental set 
2 or in the few measurements made for experimental sets 3 and 4.
Again, the only explanation which I can suggest is the increased 
stress seen in the animals of set 1.
In general the stress shown by the rats receiving methamphetamine 
was greater than that seen in the saline inj ected controls. There 
appeared to be no obvious way of establishing a control for this.
-128-
FIGURES 12-20 Graphs of the weights, food consumption 
and drinking rates of the 4 experimental 
sets of animals over 35 days of treatment.
Significant differences between the chronic
i ♦ ■--- ■group ( A A) and the control group (#—— #)
are indicated by an asterisk. { p < 0.05,
* * p  < 0.0001)
The error bars denote the standard error 
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B. Regional dissection of the brain
The rats were decapitated, the brains dissected over ice and
the regions dropped immediately into liquid nitrogen. The regions were 
then weighed and stored in liquid nitrogen until analysis. The time
from decapitation to the stage where all regions had been frozen in
liquid nitrogen was 4 - 5  min.
The dissection technique was modified from that described in 
Section III to give a more reproducible and accurate dissection of 
the nucleus accumbens, hypothalamus and amygdala. The method used 
is shown in Figure 21. Otherwise the technique was the same as that 
described previously. The order in which the regions were dissected 
was: cortical slice, tuberculum olfactorium, nucleus accumbens,
striatum, amygdala, hypothalamus, pons, medulla. Again the re­
producibility of dissection was monitored by weight; the average 
weights of the regions with the standard error ofgthe mean for one 
set of rats is shown in Table 3.
-139-
Fig. 21 Shows the modified dissection technique.
Fig. 21a shows a ventral view of the brain. Vertical 
sections were made at positions A to G .
Fig. 21b shows the sections from cuts A and B (1) 
and C and D (2) respectively (the relevant 
references to the Konig & Klippel (1963) stereo­
taxic rat brain atlas are given ) .
Cuts were made at the positions shown.
1. Shows the dissection of the accumbens and 
striatum (caudate nucleus)
2. Shows the dissection of the hypothalamus and 
amygdala. When the cuts shown were completed 
the section containing the hypothalamus and 
amygdaloid complex was turned to the ventral 
view when the demarcation of the hypothalamus 
could be seen and the hypothalamus cut out.
Key:
T - thalamic nuclei CN caudate nucleus
CC - corpus callosum HI - hippocampus
H - hypothalamus ac - accumbens
CAI - capsule interna OT - olfactory trace
- Ilird ventricle 
A - amygdaloid nuclei











Table 3. The average weights of the regions dissected from
the brain ± standard error of the mean, for 45 rats
Region Average weight the
(x) in mg ± standard error of 
mean (S.E.M.) n=45
Cortex X = 64.5 ± 1.6
Tuberculum _
olfactorium X 9.5 ± 0.4
N. accumbens X = 29.7 ± 0.7
Striatum X = 46.8 ± 1
Amygdala X = 72.8 ± 1.8
Hypothalamus X = 63.3 ± 1.2
Pons X = 114.8 ± 2.8
Medulla X = 116.2 ± 2.4
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C. Estimation of tyrosine hydroxylase activity
1. Materials and Methods
L- [side-chain-2,3-^^-Tyrosine (specific activity 13 Ci/mmol) 
and L-3,4-dihydroxy [ring-2, 5,5-^0-pheny 1-alanine (^ ĥ]-DOPA, specific 
activity 1.0 Ci/mmol) were obtained from the Radiochemical Centre,
Amersham. 6,7-Dimethy1-5,6,7,8 tetrahydropterin (DMPH^),bovine
serum albumin, tyrosine and Tris base (Trizma) were obtained from Sigma 
(London) Chemical Company Ltd. The alumina was a Merck product.
NSD 1055 (m-hydroxy-p-bromobenzyloxyamine)was obtained from Sander Ltd. 
The tetrahydrobiopterin was a gift from Dr. R.F. Long.
Methods
Tyrosine hydroxylase activity was measured by a modification of 
the method described by Hendry & Iversen (1971). The assay is based 
on the conversion of jside-chain-^H^-tyrosine to |side-chain-^H]-3,
4-dihydroxyphenylalanine ( |side-chain-^H]-DOPA) in the presence of an 
aromatic amino acid decarboxylase inhibitor (NSD 1055).
(i) Homogenization
The tissue was homogenized in 5 vol. or 10 vol. (depending on the 
activity of the enzyme in the particular region) of 5 mM Tris-HCl 
buffer, pH 6.0, at O^C.
(ii) Incubation
Tissue homogenate (10 yl) was added to tubes in an ice bath.
The blank tubes contained either 10 yl of homogenizing buffer 
or 10 yl of homogenate. Several tubes containing 10 yl of -
DOPA (20 yCi/ml) served to monitor Q^^j-DOPA recovery. Then 
10 yl of substrate-cofactor mix was added to all tubes except
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the DOPA recovery tubes and the homogenate blanks. The substrate- 
cof actor mix was made up as follows:
A few mg of dry alumina powder was added to a small tube followed 
by 200 yl of 5 ml*l Tris-HCl buffer, pH 8.6, and 100 yl (100 yCi) of 
L-[side-chain-^Hj-tyrosine. This was mixed well and kept at 
0°C. 6,7-Dimethyl-5,6,7,8 tetrahydropterin (0.5 mg) was weighed
into a small tube and 50 yl of B-mercaptoethanol was added. This 
was mixed until the cofactor had dissolved, then 500 yl of 0.8 M 
KH^PO^ Adjusted to pH 6.0 with NaOH then diluted to 0.8 M with 
distilled water) containing 0.4 mg/ml of NSD 1055 and 0.4 mM 
tyrosine was added to the cofactor. Finally equal volumes of 
-tyrosine and cofactor solution were mixed. The cofactor 
solution and the final mix were prepared immediately prior to 
incubation.
After the substrate-cofactor mix had been added to the tubes, 
they were mixed carefully and incubated in a shaking water-bath 
for 15 min. ,&Iodotyrosine was added to the substrate-cofactor mix 
to a final concentration of 0.1 mM for the homogenate blanks.
After incubation, 200 yl of 0.4 M perchloric acid containing 
L-DOPA (2 yg/ml) was added to the tubes, and they were stored 
frozen at -20°C.
(iii)Isolation of product
The alumina was prepared by washing repeatedly with distilled 
water to remove fine particles; it was then resuspended in 0.5 M 
potassium phosphate buffer, pH 7.4 (approx. 0.5 M KH^PO^ adjusted 
to pH 7.4 with NaOH and diluted to 0.5 M with distilled water), 
and added to columns plugged with cotton wool. The columns
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(i.d. 6mm) were filled with alumina to a height of 1 cm from 
the cotton-wool plug. The columns were then attached to glass 
reservoirs and washed with 5 mM Tris-HCl buffer, pH 8.6.
The contents of each tube were neutralized by adding 3.8 ml 
of a mixture containing 2 vol. 0.1 M Tris-HCl buffer, pH 8.6,
1 vol. 0.3 M NaOH and 1 vol. 0.2 M EDTA. The contents of the tube 
were then poured onto the column; the tube was rinsed with 5 mM 
Tris-HCl buffer, pH 8.6,and this was poured onto the columns.
The columns were washed with 40 ml of 5 mM Tris-HCl buffer, pH 
8.6. The pnJ-DOPA was eluted with 1.5 ml of 1 M acetic acid 
into scintillation vials, and 12 ml of triton X-lOO/toluene 
scintillant (3:7 (v/v) containing 0.5% (w/v) 2,5-diphenyloxazole). 
It was found to be advisable to wait 45 min before counting the 
samples, as initially the counts could be very high. The samples 
were counted in a Packard Tri-Carb scintillation counter (3385).
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Scintillation counting
In all experiments described in this section which involve scin­
tillation counting, any quenching of the radioactivity was monitored 
by the channel ratio method (Herberg, 1965) . A second channel was 
set to read approximately one-third of the counts obtained in the 
tritium channel -water was used as the standard and quench curves
(percentage efficiency against the ratio of the counts obtained in 
each channel) were constructed for each experiment, using carbon tetra­
chloride as the quenching agent. The maximum efficiency obtained 
from an unquenched [̂ h] -water standard was 37%. However, in general, 
it was found that experimental error was far greater than that due to
quenching, for this reason it was not considered necessary to convert 
the counts per minute obtained into disintegrations per minute.
A curve of counts per minute (c.p.m.) against the volume of 
scintillant was constructed to establish the volume of scintillant nec­
essary to give maximum counts; this curve flattened off around 10 ml. 
Experiments were also carried out to determine whether a secondary 
scintillant was necessary. It was found that there was no difference 
between the counts obtained in the presence or absence of 2,2-p-phenyl- 
enebis (5-phenyloxazole) (POPOP).
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Simpie kinetic studies on tyrosine hydroxylase in brain homogenate
The linearity of product formation with enzyme concentration and 
with time was tested and is shown in Figures 22 and 23. Several 
experiments were carried out to look at the product formation with 
increasing substrate concentration and it was found that, in the sub­
strate range employed (0.05 mM to 0.5 mM),v decreased with increasing 
indicative of substrate inhibition (Figure 24) . The kinetic 






V i  [Sj - Ki
assuming simple substrate inhibition where ^i = |Ê0 [s] / [e sJ
This was done by using a computer programme which calculates all the 
solutions of the simultaneous equations resulting from substitution 
of the individual v̂  , observations in the equation and finding the 
median after ranking the solutions in a manner analagous to that used 
to find Km and V by the direct linear plot (Eisenthal & Cornish-Bowden,
1974). Km was calculated to be approximately 0.04 mM, V = 39 mmol 
product formed/h/g wet wt. of tissue and Ki = 0.13 mM. These figures 
have to be considered as approximations as the data were not particularly 
good, and the values of were not corrected for endogenous tyrosine 
levels. As the values for Km and Ki are fairly low, the levels of 
endogenous tyrosine (65 nmol/g in striatum, the region used for these 
studies) would make the actual values lower than those quoted here.
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Due to the very low concentrations of tyrosine at which the 
optimal velocity is reached, the point at which it is reached in
brain homogenate will vary with endogenous tyrosine levels. The 
assay procedure was carried out at concentrations of tyrosine which 
would clearly be inhibitory, but rather than determine the mean tyro­
sine levels in each region together with the Vopt., it was decided 
to ’buffer' changes in endogenous tyrosine levels by adding cold 
tyrosine to a final concentration of 0.1 mM. Cicero et al, (1972) 
summarized the regional distribution of tyrosine hydroxylase activity 
in the brain using a tissue homogenate and a concentration of tyrosine 
of approximately 0.1 mM. A comparison between the values I obtained
for the various brain regions are compared with the values obtained 
by Cicero et al, (1972) in Table 4.
Preliminary experiments were carried out to see if the activity 
of the enzyme in an homogenate was affected by added catalase, iron
(Fe^ ), calcium,EGTA and using tetrahydrobiopterin instead of DMPH^.
2+The results indicated that adding catalase, Fe , calcium or EGTA to 
the incubation mix did not significantly affect the activity of 
the enzyme. Tetrahydrobiopterin increased the activity of the 
enzyme by at least 10 fold; v against and v against cofactor 
concentration plots suggested that the kinetic properties of the 
enzyme with this cofactor were also different.
My observations that neither calcium nor EGTA had any effect on 
the enzyme activity contradicts the findings of Morgenroth et al, (1975,
1975). My results do not conclusively disprove these papers, but 
reportshave been published recently by other researchers who are also 
unable to repeat the experiments of Morgenroth et al, (Lovenberg et al., 
1977).
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In the preliminary experiments I found that the enzyme showed 
very little activity when no cofactor was added. McGeer (1967) stated 
that no cofactor was required in the incubation; later (1971) he 
proposed that the cofactor requirement depended on the brain region. 
His rationale was: cell body containing regions were more readily 
disrupted, therefore dilution accounts for the activity in these 
regions increasing on adding cofactor. In nerve-terminal containing 
regions the enzyme is tightly bound and synaptosomes are formed on 
homogenization, which are not easily disrupted. This accounts for 
the lack of effect or inhibition of enzyme activity on the addition 
of cofactor.
This rationale seems unlikely, especially in the light of two 
observations which I have made during the course of my e5q>eriments:
(i) in homogenates of striatum (rich in nerve terminals), I found an 
absolute requirement for cofactor, (ii) in homogenate of striatum all 
the activity is recovered in the soluble high-speed supernatant 
(the homogenate was spun at 100,000 x g for 90 min in a Beckman ultra­
centrifuge (model L5-657))•
Tyrosine hydroxylase is a controversial enzyme. In this section 
I have briefly mentioned those aspects which I have assessed. The 
enzyme will be considered in more detail in the Discussion.
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FIGURES 22, 23 and 24
Graphs of velocity against enzyme 
concentration and velocity against 
time for tyrosine hydroxylase in a 
homogenate (1/5 w/v) of striatum. 












FIGURE 24. V  against - S using the direct linear
plot; this shows the characteristic pattern 
obtained with substrate inhibition in the 









2. Results: Regional tyrosine hydroxylase activity in experimental
animal groups
The results from the experimental groups from experimental set 
1 and experimental set 4 are shown in Figures 25 and 26, and Tables 
5 and 6, respectively. The groups of animals were killed after 15 
days and 30 days of chronic treatment respectively. The Lowry protein 
assay was used to measure the amount of protein present (Lowry et al., 
1951). The standard protein used was bovine serum albumin.
The changes in tyrosine hydroxylase activity in the brain regions 
from experimental set 1 after 15 and 30 days of chronic treatment are 
depicted graphically,as positive changes were seen. The results from 
experimental set 4 after 15 and 30 days of chronic treatment show no 
statistically significant change between the groups in any of the 
regions.
Table 4 shows the control levels of activity in the various regions, 
comparing the levels of activity found in each set of animals analysed.
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FIGURES 25 and 26. Tyrosine hydroxylase activity in
the various brain regions after 15 and 30 
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Table 4 Comparisons between the activity of tyrosine
hydroxylase obtained in the various brain regions 
from the control rats from each experiment and 
literature values for the regions using the 
same substrate concentrations (Cicero et al,, 1972).
The activity is in nmol product formed/h/g wet weight, 
± S.E.M.
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TABLES 5 and 6 Tyrosine hydroxylase activity in the
various brain regions from experimental 
set 4 after 15 and 30 days of treatment.
The activity is expressed in c.p.m./pg
protein x is the mean, a , is the standardn-1
deviation of the sample and n is the 
number of rats in the sanple. _
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15 days of treatment
REGION CONTROL CHRONIC WITHDRAWN
ACCUMBENS X  = 127.1 x = 100.2 x = 9 7
o T = 50 a , = 23.8 a , = 35.6n-1 n-1 n-1
n = 5  n = 5  n = 5
STRIATUM X  = 182.1 X  = 250.4 x = 294.3
a - = 80 a . = 46 a . = 99n-1 n-1 n-1
n = 5  n = 5  n = 5
AMYGDALA X  = 30.7 x = 44.1 x = 39.8
a = 9.5 a . = 25.6 a . = 9.5n-1 n-1 n-1
n = 5  n = 5  n = 5
HYPOTHALAMUS x = 31.3 X  = 30.9 x = 30.23
0 = 1 0 . 8  0 . =  6.5 0 ^ =  9.3n-1 n-1 n-1
n = 5  n = 5  n = 5
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30 days of treatment
REGION CONTROL CHRONIC WITHDRAWN













ACCUMBENS X = 81.6 X = 114.3 X = 93
^n-1 = 11.2 °n-l = 38.7 °n-l = 28.1
n — 4 n 4 n = 4
STRIATUM X = 195.8 X = 265.2 X = 234.2
on-1 = 46.4 °n-l = 113.9 ^n-1 = 27.6
n 4 n 4 n " = 4
AMYGDALA X = 21.9 X = 34.7 X = 35.2
°n-l = 6.9 °n-l = 9.6 ^n-1 = 0
n — 4 n 4 n 2
HYPOTHALAMUS X = 30.1 X = 31 X = 26.6
On-1 = 2.5 on-1 = 4 ^ n-1 = 4.5
n = 4 n = 4 n = 4
PONS X = 8.2 X = 8.3 X = 8.4
^n-1 = 2 °n-l = 1.9 °n-l = 2.1
n 4 n 4 n 4
MEDULLA X = 5.9 X = 7.7 X = 5.9
°n-l = 1.7 ^n-1 = 3 ° n - l = 2.8n 4 n 4 n 4
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D. Radioenzymatic measurement of noradrenaline, dopamine and their
metabolites 
1. Materials and Methods 
Materials
Dopamine hydrochloride (DA), noradrenaline bitartrate (NA), 
3-methoxytyramine hydrochloride (3MT), normetanephrine hydrochloride 
(NM), hompvanillic acid (HVA), vanillylmandelic acid (VMA), 4-hydroxy- 
3-methoxyphenyl glycol (MHPG), 3-methoxytyrosine, adrenaline bitartrate, 
metanephrine hydrochloride and S-adenosyl-L-methionine were obtained 
from Sigma (London) Chemical Company Ltd. Homovanillyl alcohol 
(HVET), 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4 dihydroxyphenyl- 
glycol (DHPG) and 3,4-dihydroxymandelic acid (DHMA) were obtained 
frcm Calbiochem. 3,4-D.ihydroxyphenethanol was obtained from Regis 
Chemical Company Ltd., and L-DOPA from Aldrich Chemical Company Ltd.
S-adenosyl-L-^ethyl-^fQ-methionine was obtained from the Radio- 
Chemical Centre, Amersham (specific activity 8 Ci/mmol ). This was 
diluted and stored in 100 yl aliquots at 20^C). The microcrystalline 
cellulose thin-layer chromatography plates were a Merck product.
Methods
Determination of noradrenaline and dopamine levels
The method was based on the radioenzymatic conversion of NA and DA 
by catechol-O-methyl transferase, in the presence of ^^H^-S-adenosyl 
methionine,to labelled NM and 3MT respectively. The products were 
separated by paper chromatography, cut out and counted (Cuello et ai., 
1973).
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The procedure followed was as follows:
(i) Purification of catechol-O-methyl transferase
The enzyme was purified according to the method of Nikodijevic 
et al. (1970). The activity of the enzyme preparation was deter­
mined by the method of McCaman (1965). The linearity of product 
formation with enzyme concentration was tested, then the enzyme
was stored at -20^C in 1 ml aliquots. The activity of the
-2purified enzyme was found to be 4.4 - 5.4 x 10 nmol product 
formed/min/mg protein. The protein concentration was 4 0 - 4 5  
mg/ml.
(ii) Homogenization
The brain regions were homogenized in 5 mM Tris-HCl buffer, pH 
6.0, at 0°C. An aliquot was removed for a protein assay and for 
the assay of tyrosine hydroxylase activity. Then perchloric 
acid (1 M), containing 1 mM EDTA and 10 mM ascorbic acid, was 
added to a known volume of homogenate (which had been placed in 
microfuge tubes at 0°C), to give a final concentration of 0.1 M 
perchloric acid. The homogenates were mixed and centrifuged in 
a microfuge (Beckman microfuge B) at 8730 x g (11,600 rev/min) 
for 3 min, at 4°C. The supernatant was pipetted off and stored 
at -20°C overnight; the next day the supernatants were thawed 
to 4°C and re-centrifuged. The supernatants were then stored 
at -20^C until the day of assay. Internal standards were put 
in on homogenization in order to monitor the recovery.
A number of assays were performed on the same brain region and 
in order to clarifity the sequence of events a diagrammatic summary 
of the procedure is shown in Figure 27.
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(iii) Incubation
The •incubation mix' consisted of 50 yl of catecho1-0-methyl 
transferase, 10 yl of 20 mM ethylene glycol-bis-( 6-amino-ethyl 
ether) N,N-tetra acetic acid (EGTA), 30 yl of [^H^'S-adenosyl 
methionine (250 yCi/ml), 10 yl of pargyline (16 mg/ml) in 10%
6-mercaptoethanol, 63 yi of 1 M Tris-HCl buffer, pH 9, containing 
3 mM magnesium chloride.
Tissue supernatants (10 yl) were placed in conical glass 
centrifuge tubes, in an ice bath. 'Incubation mix' (25 vl) was 
added to each tube, mixed and incubated at 37°c for 40 min.
(iv) Extraction
SaTUfaftzdAfter incubation, 30 yl of a mixture of 5 vol. of^borate buffer, pH 
10, and 1 vol. of a mixture of NM and 3MT (10 mg/ml) was added to
the incubation mixture. This was mixed and 0.5 ml of toluene/ 
isoamyl alcohol (3:2 v/v) added. This was mixed on a vortex 
mixer for 30 s, then centrifuged at half speed (3,000 rev./min;
8 X 15 ml head; 2065 x g) in a bench centrifuge (BTL bench 
centrifuge, Baird & Tatlock (London) Ltd.).
(v) Back extraction
400 yl of the toluene/isoamyl alcohol was transferred to a clean 
conical centrifuge tube containing 25 yl of 0.1 M HCl. This was 
mixed on a vortex mixer for 30 s, then centrifuged in a bench 
centrifuge as before. The organic phase was removed carefully.
(vi) Chroma tography
Three 5 yl aliquots of acid phase were spotted onto Whatman 3 mm 
chromatography paper (the origins were previously spotted with 5 yl 
of a mixture of NM and 3MT (10 mg/ml) containing 0.1% sodium 
metabisulphi te.
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The papers were developed by descending chromatography with 
methylamine (25/30% w/v in water)/t-amyl alcohol (1:4 v/v) for 
at least 24h. The spots were visualized by spraying the paper 
with ammonia followed by dilute Folin's reagent (1:4 v/v).
The spots were cut out and eluted overnight in 3 ml of ethanolic 
ammonia (ethanol/concentrated ammonia, 100:22 v/v). This was then 
counted as has been described previously.
Initially internal and external standard curves were run for 
each assay, however, as it was found that the two were identical, 
only an external standard curve was run routinely (Figure 28).
In practice the standard curves varied minimally between assays.
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Determination of DOPA, noradrenaline, dopamine and their non-0- 
methylated metabolites
The method is identical to that already described, except that 
after incubation of the samples, 5 yl of 8 M formic acid was added to 
the incubation mixture, mixed and the tubes placed in an ice-bath.
The compounds were then separated by the thin-layer chromatographic 
procedure described by Fleming & Clark (1970). Immediately prior to 
spotting, 5 yl of carrier methoxyamine mix was added to the mixture 
(NM, 3MT, HVA, VMA, MHPG, HVET and 3-methoxytyrosine; 1 yg/yl). The
thin-layer plates were then spotted with 15 yl of incubation mixture 
and run in two dimensions. The first dimension was in butanol: 
methanol: 1 M formic acid (3:1:1,by vol.), and the second dimension 
was in chloroform:methanol:1 M ammonia (12:7:1, by vol.). The 
running time was approximately 3h and 2h respectively. The spots were 
visualized with p-nitroaniline spray, this was made up from three 
solutions; (i) 0.1 g of p-nitroaniline dissolved in 2 ml of concentrated 
HCl and made up to a final volume of 100 ml with water, (ii) 0.2% 
sodium nitrite (iii) 10% potassium carbonate. Immediately prior to 
use, 1 vol. of (i) , 1 vol. of (ii) and 2 vol. of (iii) were mixed.
The spray had to be used within 90 s of mixing. The spots were scraped 
off the plate, eluted with 0.1 ml of 0.1 M formic acid in a scintillation 
vial and counted. Figure 29 shows the chromatographic separation of 
DOPA, NA, DA and their non-O-methylated and 0-methylated metabolites by 
the method described above.
Several problems were encountered on trying to combine the thin- 
layer chromatographic separation technique with the radioenzymatic 
method already described. Firstly the pH of the incubation mixture had
-169-
to be brought down to a pH of about 2, if the spots were to separate 
clearly. The only acid which could be used was formic acid (others 
tried were: perchloric acid, trichloroacetic acid and hydrochloric 
acid). The second problem was to precipitate the protein,as this 
could also interfere with the separation. Two other protein préci­
pitants were tried (ZnSO^ / NaOH and tungstic acid) and mercaptho- 
ethanol was also tried. It was found that ZnSO^/NaOH and mercapto- 
ethanol were about equally effective. However if the activity of 
the catechol-O-methyl transferase is sufficiently high it can be 
diluted so that the amount of protein present is not great enough 
to interfere with the assay (2 mg/ml protein).
Metanephrine was found to chromatograph to a position which over­
lapped both the NM and the 3MT spots, therefore the method could not 
be used to measure adrenaline.
In order to test the specificity of the assay, each compound was 
incubated separately and chromatographed with the 'methoxyamine mix'.
Each spot was scraped off and counted; Table 7 shows the results of 
these experiments. Interference was found to occur between NA and 
DA; this is almost certainly due to the NM and 3MT spots running 
close to each other. This is not obvious from the plate shown, but 
in practice, with repeated numbers of plates, sometimes these two 
spots are so close as to be touching each other. Therefore the NA/DA 
interference is probably due to overlap of spots (which can be eliminated 
if great care is taken on running the plates). The only other inter­
ference noted was with DHPG; most counts were, as expected, on the 
MHPG spot? however a significant number of counts were found on the
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HVET spot. From looking at large numbers of plates, I feel it is 
reasonable to rule out overlap as being the cause. The only explanation 
I can think of is a chemical breakdown of DHPG to DHPET before, or 
during incubation. The experiment was repeated several days later 
using the same solution of DHPG, and more counts were found on the 
HVET spot (although the total number of counts in both spots was the 
same, suggesting a fairly specific breakdown).
The recovery of the radioactivity was monitored by measuring the
percentage of the total counts (as measured in 5 yl of incubation mixture)
recovered in the 'dry counts' (measured by spotting 5 yl of incubate on
the top-right hand corner of the plate). The total counts recovered
in all the spots was measured, and the counts remaining at the origin
2(the origin was defined by scraping a 2.25 cm square of cellulose
from around the origin; the individual spots were all less than 1 cm
in diameter). These figures are shown in Table 8.
The standard curves for each compound are shown in Figures 30 - 36. 
The reproducibility of the assay ( seen from the standard deviations),
and the sensitivity of each amine in the assay (this is the concentration 
which gives 2 to 4 times blank levels of radioactivity, depending on 
the standard deviations)are shown in Table 8.
The levels obtained for each amine in the various regions compares
favourably with literature values obtained using other techniques.
Finally, the published changes observed in those amines which have been 
measured after chronic treatment with methamphetamine are in the same 
direction as my results.
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Further experiments which would establish the above method as 
valid together with an assessment of current methods used to measure 
the catecholamines will be considered in the Discussion. The shape of 
the standard curves will also be discussed.
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FIGURE 27 Diagram of the procedure by which measurements 
of cerebral tyrosine hydroxylase activities, 
amine and tryptophan levels, and plasma tryptophan, 
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FIGURE 28 Standard curves for NA (■— — ■) and DA 
(#— — #) . The scale on the ordinate for 







Figure 29. Chromatographic separation of DOPA, 3-methoxy- 
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Table 7. Percentage change in blank values on incubating 5 ng of 
each amine individually (n.s. indicates no significant 
change).
Amine 3 MeTyr NM 3MT
SPOT
VMA HVA MHPG HVET
DOPA 275 n. s. n. s. n.s. n.s. n.s. n.s.
NA n. s. 188 39 n.s. n.s. n. s. n.s.
DA n. s. n.s. 149 n.s. n.s. n.s. n.s.
DHMA n.s. n.s. n. s. 233 n.s. n.s. n.s.
DOPAC n.s. n.s. n.s. n.s. 10880 n.s. n.s.
DHPG n.s. n.s. n. s. n.s. n.s. 1534 47
DHPET n.s. n.s. n.s. n. s. n.s. n.s. 6617
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Figures 30-36 Standard curves for NA, DA, DHMA, DOPAC,
DHPG and DHPET. Figure 30 shows a linear 
relationship between c.p.m. and concentration 
for NA and DA, figure 31 shows that, at lower 
concentrations the slope changes. Subsequent 
standard curves give the curves obtained at 
low and high substrate concentrations.
Key:
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Table 8. Distribution of radioactivity on thin-layer chromatography 
plates.
Blank plate
"dry counts" = 67% of "wet counts" 
origin = 7 ? of "dry counts"
counts recovered on spots = of "dry counts" 
radioactivity unaccounted for = 9^ % of "dry counts"
= l^l^pOO c.p .m.
Approximate sensitivity of the assays :
NA: 20 pg DOPAC: 10 pg
DA: 200 pg DHPG: 20pg
DHMA: 20 pg DHPET: 10 pg
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2. Results: Regional amine levels in experimental animal groups
The levels of noradrenaline and dopamine were determined in the 
three groups of experimental set 1 after 30 days of chronic treatment.
The results are shown in Figure 37. In all the regions analysed there 
were decreased average levels of noradrenaline and dopamine; signi­
ficant decreases were found in NA and DA all regions in either the 
chronic or withdrawn animal groups except for NA in the nucleus 
accumbens.
Using the modified radioenzymatic method, results were obtained 
for two regions (striatum and hypothalamus) in the three groups from 
experimental set 4 after 30 days of treatment. These two regions were 
selected as amphetamine is thought to act primarily on the nigroneostriatal 
dopaminergic pathway and the hypothalamus is rich in noradrenaline and 
dopamine, therefore any differential effect of amphetamine on the two 
transmitters in terms of the levels of NA and DA and their metabolites 
would be seen. The results are shown in Table 9.
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Figure 37. Noradrenaline and dopamine levels in selected




^ significantly different from control 















































Table 9. Levels of noradrenaline, dopamine and their 
non-O-methylated metabolites in the striatum 
and hypothalamus from experiment Set 4, after 
30 days of chronic treatment. Levels are in mg/g 
wet wt. of tissue ± standard deviation.
Key:
NA - noradrenaline 
DA - dopamine
DHMA - 3,4-dihydroxymandelic acid 
DOPAC - 3,4-dihydroxyphenylacetic acid 
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E . Determination of brain tryptophan levels
1. Materials and Methods
Tryptophan was measured by virtue of its native fluorescence 
under strongly alkaline conditions (Udenfriend, 1962); the fluores­
cence intensity is greatest at pH 10.9. , The brain regions were homo­
genized in Tris-HCl buffer and the protein precipitated with 0.1 M 
perchloric acid. The tryptophan assay was carried out on the resulting 
supernatant; consequently the fluorescence measured corresponds to 
the free tryptophan and the tryptophan present in proteins. As no 
extraction step was employed there is likely to be non-specific inter­
ference .
n-Butylamine buffer, pH 11.0 (24.56 ml of 0.2 M n-butylamine,
18.46 ml of 0.1 M HCl, made up to 200 ml with distilled water) (900 yl) 
was added, on mixing,to 100 yl aliquots of samples or standards, and 
allowed to stand at room temperature for 30 min. The samples or 
standards were read at an excitation wavelength of 287 nm and an 
emission wavelength of 376 nm (uncorrected values). All glassware 
used in this assay was soaked in 15% HCl overnight, then rinsed 4 
times with distilled water, and dried.
The characteristic spectrum of tryptophan is shown in Figure 38.
The external standard curve is shown in Figure 39; the sensitivity of 
the assay was about 10 ng (twice blank value). The internal standard 
curves (Figure 40) were less sensitive and more variable, as can be 
seen from the two internal standard curves shown. An internal standard 
curve was run for every assay.
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The reproducibility of the assay was assessed by measuring 
tryptophan levels in 23 cerebellar samples from 2 rats. The standard 
deviation was found to be 2 to 4 ng.
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2. Results: Regional tryptophan levels in the experimental animal
groups
The results obtained for the various brain regions from the 
experimental animal groups are shown in Table 10. The values are not 
corrected for recovery; the average recovery was 83%. No significant 
differences can be seen between the three experimental groups after 
15 and 30 days of treatment in experimental set 4. In the 15 day 
animals the control group showed significantly lower levels of trypto­
phan in the cortex compared to the striatum (p < 0.005) and hypothalamus 
Cp < 0.001) and significantly lower levels in the medulla as compared 
to the striatum (p < 0.002). These regional variations were not seen 
in the 30 day rats.
The 35 day rats from experimental set 1 do show significant 
differences between the experimental groups. There is a depletion 
of tryptophan in the striatum and mesolimbic regions (nucleus accumbens 
and amygdala) in the chronic group of animals. On withdrawal the 
levels are between those of the control and chronic groups, but not 
significantly different from either. There is a trend towards a 
depletion in the hypothalamus in the chronic group and an apparent 
partial recovery on withdrawal but this did not reach significance 
owing to the high standard deviation. The pons and medulla appear 
to show opposite trends i.e. an increase in tryptophan levels in the 
chronic group, but again this did not reach significance.
As with the 15 day rats from set 4 the levels of tryptophan were 
lower in the cortex and medulla compared with the other regions. The 
cortical levels of tryptophan in the controls were significantly lower
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than the levels in the striatum (p < 0.05), nucleus accumbens (p <
0.05) and amygdala (p < 0.01). The control levels in the medulla 
were significantly lower than the levels in the nucleus accumbens 
(p < 0.05), striatum (p < 0.05) and the amygdala (p < 0.02).
The large standard deviations seen in the table probably reflect 
a large variation between individual rats. In most methods for 
measuring tryptophan levels in brain tissue there is an extraction step 
(usually using a buffered cation exchange resin or by partitioning 
between two phases of solvent mixtures), before the measurement of 
tryptophan fluorometrically. Some of the methods have been reviewed 
by Gaitonde (1974), and he presents the levels of tryptophan obtained 
in whole brain and specific regions of the brain, found by various 
research workers. These values varied from 12.5 to 65.1 nmol/g of 
tissue. The levels of tryptophan which I have reported here vary 
between 28 and 38 nmol/g of tissue for experimental set 4, which had 
much lower standard deviations than the first experiment on the 35 day 
rats from experimental set 1 (these values varied from 22 to 61nmol/g). 
Therefore this method gives values similar to those obtained when an 
extraction step is included and has the advantage of being simple and 
rapid. The method described here is, however, not very sensitive and 
would not detect any small regional changes in tryptophan. By 
comparing the published methods which include an extraction step with 
mine it is not possible to tell whether these methods are more sensitive,
The changes observed between experimental groups in experimental 
set 1 after 35 days of chronic treatment are compatible with the 
results of the tyrosine hydroxylase activity and amine levels in that
-197-
this experimental set appeared to react more, in biochemical terms, 
than did experimental set 4.
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FIGURE 38 Excitation and emission spectrum of 
50 ng of L-tryptophan, pH 11.0, 25^0 
F is the intensity (uncorrected)
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FIGURE 39 External standard curve for tryptophan assay, 
pH 11, 25°C




FIGURE 40 Internal standard curves for tryptophan 
assay. Blank values were 0.42 (curve a) 
and 0.51 (curve b). F - intensity 
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Table 10 Levels of tryptophan in the various brain
regions after 35 days of chronic treatment
in experimental set 1, and after 15 and 30
days in experimental set 4. The table gives the
mean (x), the number of observations (n) and the
standard deviation (a ); * denotes that the results. n-1
in the experimental group were significantly different 
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F. Measurement of brain serotonin levels
1. Materials and Methods
Materials
Acetyl coenzyme A (acetyl CoA) and serotonin creatinine sulphate 
(5-HT)'were obtained from Sigma (London) Chemical Company Ltd. A 
stock solution of serotonin creatinine sulphate was stored in 0.1 M HCl 
in the deep freeze. Under these conditions it was stable for 2 to 
3 weeks.
S-adenosyl-L-|methyl- ]0 - methionine (^^I^-SAM ; specific activity
[“ 141 - c j -acetyl coenzyme A (specific activity 50 mCi/ 
mmol) were obtained from the Radiochemical Centre, Amersham.
Methods
The method used was identical to that described by Saavedra et 
al. (1 9 7 3 ). This radioenzymatic assay is based on the following 
reactions :




The melatonin is extracted, and the amount of melatonin
formed should be directly proportional to the amount of 5-HT in the 
original sample.
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(i) Purification of N-acetyl transferase
N-acetyl transferase was purified from rat liver by a modification 
of the method described by Weissbach et ai. (1961). All purification 
procedures were carried out at 4^C. Rat livers (50 g) were homo­
genized in 100 ml of 0.1 M sodium phosphate buffer, pH 7.2, and 
centrifuged at 100,000 x g for 1 h in a Beckman Ultracentrifuge (model 
L5-65). The supernatant was saturated to 40% with solid ammonium 
sulphate, allowed to stand for at least 15 min, then centrifuged for 
20 min at 18,000 rev./min (36,000 x g) in an M.S.E. 18 centrifuge.
In all steps which involve the addition of solid ammonium sulphate, 
it was added slowly with constant stirring. The precipitate was 
dissolved in 10 ml of 20 mM sodium phosphate buffer, pH 7.2. Ammonium 
sulphate was added to give 65% saturation and this was centrifued 
for 20 min at 36,000 x g. The precipitate was dissolved in 10 ml 
of 20 mM sodium phosphate buffer, pH 7.2,and dialysed three times (3h 
each) against 2,000 ml of this buffer. After dialysis a precipitate 
formed in the dialysis residue which was centrifuged (in a bench 
centrifuge at 3,000 rev./min (2065 x g) ) and discarded. The enzyme 
was stored with 10% ethylene glycol, neutral EDTA (0.1 mM) and 1 mM 
mercaptoethanol (Riddle and Jenks, 1971). The enzyme was stored in 
200 yl aliquots at -20°C. Under these conditions it was found to 
be stable for 6 months.
The activity of the enzyme was assayed by the method of Deguchi 
& Axelrod (1972). The activity of the enzyme was found to be 
700 - 800 nM product formed/h/ml. The velocity was linear with 
enzyme concentration.
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Purification of hydroxyindoIe-O-methyl transferase
Hydroxyindole-O-methyl transferase was partially purified from 
bovine pineal glands by a modification of the method described by 
Axelrod & Weissbach (1961). All purification procedures were carried 
out at 4°c. Frozen bovine pineals (10 g) were homogenised in 1.1% KCl. 
The homogenate was centrifuged at 100,000 x g for 1 h. To the soluble 
supernatant fraction, solid ammonium sulphate was added to 35% saturation; 
the supernatant was allowed to equilibrate for 1 h and was then centri­
fuged at 18,000 rev./min (36,000 x g) for 20 min. Solid ammonium 
sulphate was added to the soluble supernatant fraction to reach 65% 
saturation; it was added as before and left to stand for 1 h. This 
was centrifuged at 18,000 rev./min (36,000 x g) for 20 min. The pellet 
was dissolved in 5 ml of 50 mM sodium phosphate buffer, pH 7.9, and 
dialysed three times (each for 3h) against 1 litre of this buffer.
After dialysis the enzyme was stored in 200 yl aliquots at -20°C. It
was found to be stable for about 6 months.
The activity of the enzyme was assayed by the method described 
el oj
by Saavedraji^(1973) . The activity of the enzyme was 250 nmol product 
formed/h/ml. (this is below the values reported SciCLV̂ clrcv et q)
CIS 7 The velocity was
linear with enzyme concentration.
Assay for serotonin
The frozen brain regions were homogenised in 0.1 M perchloric 
acid (containing ascorbic acid and EDTA as before), or 0.1 M HCl 
(1:10 w/v). The homogenate was frozen and thawed before centrifuging
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in a microfuge and assaying for serotonin. The assay was performed 
in 3 stages :
(i) N-acétylation. 25 yl of samples (standards or tissue samples) 
were placed in stoppered glass tubes; 45 yl of’incubation mix' was 
added and the tubes incubated at 37°C for 30 min. The reaction was
stopped by transferring the tubes to an ice bath. The ^incubation
mix' consisted of 25 yl of a solution made with 10 ml of 0.2 M sodium 
phosphate buffer,pH 7.9,and 1.1 ml of 1 M sodium hydroxide, 10 yl of 
N-acetyl transferase and 10 yl of acetyl CoA (this has to be made up 
freshly , immediately prior to use.)
(ii) 0-methylation. After stage (i), 22 yl of a mixture containing
10 yl of hydroxyindole-O-methyl transferase,- 2.0 yl of ^ ĥ]-S-adenosyl- 
L-methionine (8,0 Ci/mmol) and 10 yl of 0.2 M sodium phosphate buffer, 
pH 7.9, was added.
The reaction was stopped with 0.5 ml of 0.5 M borate buffer, pH 
10.0 (10 volO plus melatonin (1 vol. of 1 mg/ml in 25% ethanol.)
(iii)Extraction. 6 ml of toluene was added to the incubation mixture, 
which was then mixed on a vottex mixer for 30 s, and centrifuged at 
half-speed on a bench centrifuge (2065 x g) for 2 min. The toluene 
extract (5 ml) was transferred to clean glass scintillation vials 
containing 3ml of fresh toluene. These were incubated overnight at 
80°C in an oven.
It was noted that, in this stage of the procedure ,the temperature
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of the oven was crucial. It was important for the temperature to 
be homogeneous, and that the temperature should not exceed 80°C other­
wise the melatonin will break down.
The product was identified by thin-layer chromatography. The 
-melatonin was dissolved in 75 yl of ethanol, and 30 yl applied to 
activated (heated at 100°C for 1 h) silica gel plates (home-made).
The melatonin was separated by ascending chromatography in toluene: 
acetic acid:ethyl acetate: water (80:40:20:4, by vol.). The melatonin 
was seen as a bright orange spot under ultra-violet light.
The thin-layer chromatography step can be included in the assay 
in order to obtain maximal sensitivity. In these experiments it 




The procedure described by Saavedra1973) employs HCl only in 
the homogenization step. This is unusual, as most methods for the 
measurement of brain amine levels use a protein precipitating agent 
such as perchloric acid or trichloroacetic acid. Firstly a standard 
curve was obtained for the procedure exactly as outlined (Figure 41), 
then the tissue was homogenized in perchloric acid. For the assay to 
work in perchloric acid the buffer for the N-acetylation stage had to 
be altered. (10 ml sodium phosphate buffer, pH 7.9 plus 0.6 ml
IM NaOH) . KCL the pH at this stage in the reaction was found
to be 7.6; using perchloric acid and using the modified buffer it 
was found to be pH 7.0. The standard curve was found to be linear 
(Figure 42), however the modified method could not be used on tissue 
samples as the buffer for the N-acetylation stage did not give a 
constant pH. As the same kind of variation in pH occurred if the 
samples were homogenized in water before adding the hydrochloric 
acid to 0.1 M, it seems that the buffer must be inadequate. The 
reason for wishing to modify the assay was so that all the assays 
described in previous sections could be carried out on the same brain 
sample. In order to take this line of investigation further, the 
first parameter which ought to be tested is the buffer for reaction 
(i). HEPES would be a more efficient buffer at the pH opt. of N- 
acetyl transferase.
L
As it proved to be difficult to combine this assay with the 
others, more rats from experimental set 4 were killed after 30 days 
of chronic treatment. After dissection of the brain and freezing 
in liquid nitrogen, the assay was carried out exactly as that 
described by Saavedra et ai. (1973).
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The results are shown in Table 11. It can be seen that after 
30 days of chronic treatment there is no significant change in the 
serotonin levels in any of the regions from the three experimental 
animal groups, except in the amygdala.
-214-
Figures 41 and 42 Internal standard curves for serotonin
using 0.1 M HCl and 0.1 M Perchloric acid 
respectively, as the homogenizing medium. 
The graphs show c.p.m. against the 



















Table 11. Levels of serotonin in the three experimental
groups of animals from Set 4. in ng/g wet wt. 
of tissue
Key:
* indicates the value is significantly different 
from control.
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Region Control Chronic Withdrawn
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n = 3
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G. Determination of amino acid levels in brain regions
1. Materials and Methods
The frozen brain regions were weighed and homogenised in 3%
sulphosalicylic acid (10 ml/g). The sulphosalicylic acid contained
55.6 nM of norleucine/ml, to give a final concentration of 50 nM/ml.
Norleucine is used as an internal standard for the amino acid analyzer.
The homogenates were left in ice for about 30 min, then spun at 6,000
rev/min (4335 x g) for 30 min in a Christ microfuge (V.A. Howe Ltd.).
The supernatant was filtered through an 8 y millipore filter , to
oremove fats, and stored at -20 C.
The animals used in this experiment were killed after 15 and 30 
days of treatment. It was necessary to pool -the samples ; consequently 
the two time intervals have only two samples of each region per 
experimental group.
The samples were run on a Chromaspek auto amino acid analyser 
(Rank-Hilger Ltd., Margate, Kent). This analyser separates the amino 
acids by ion-exchange chromatography. The pH gradient for elution 
is continuous and provided by means of an electronic gradient programmer, 
The composition of the acidic and basic buffers are as follows: the
acidic buffer contains anhydrous lithium chloride (0.84% w/v), citric 
acid (1.05% v/v) and isopropanol (1% v/v), pH 2.2; the basic buffer 
contains lithium hydroxide (0.84% w/v), boric acid (0.31% w/v) and 
citric acid (1.05% w/v), pH 12.0. The amino acids are reacted with 
ninhydrin as they come off the column, heated in an oil bath maintained 
at 90°C, cooled and a photocell measures the intensity of colour 
formed in the reaction with each amino acid; this is then recorded.
— 220—
The Chromaspek which I used was connected to a computer which was 
set to integrate the areas under the peaks.
The supernatants were run at two dilutions; 1 in 10 and 1 in 100, 
The first dilution resolved the neutral and basic amino acids, and 
the second dilution resolved the acid amino acids.
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2. Results
The levels of amino acids were calculated using the norleucine 
internal standard. This was used as the measure of recovery of the 
amino acids. A standard mixture of amino acids was run every 3 or 4 
samples; this provided a standard value for the particular amino acid 
from which, knowing the recovery, the concentration of each amino acid 
present could be calculated.
Table 12 shows the levels of amino acids in the pooled regions 
from the 3 groups of rats after 15 and 30 days of treatment.
-222-
Table 12a Regional levels of tyrosine, phenylalanine
and tryptophan in various brain regions from 
experimental set 3 after 15 and 30 days of chronic 
treatment, as measured by a Chromaspek auto 
amino acid analyser
Table 12b This shows the changes in the other amino acids 
which were measured (only a representative 
selection of all the results is shown here). 
Asparagine does not appear to be present in 
brain tissues, or .is it present in such low 
amounts in all brain regions that it is below 
the sensitivity of the auto amino acid analyzer,
For both tables the levels are in yM, or ymoles/O.l g wet 
wt. of tissue. The mean ± the standard deviation is shown 
where no standard deviation is given, n = 1.
Key: $ significantly different from control
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H. Determination of total and free tryptophan levels, phenylalanine 
and tyrosine levels in plasma
I. Materials and Methods
Blood was collected, on decapitating the rats, in calcium-heparin 
(2 I.U./ml) tubes. This was centrifuged immediately (3,000 x g for 
10 min at 4°c) and the plasma transferred immediately into plain 
plastic tubes. The plasma was then frozen in liquid nitrogen.
(i) Total and free plasma tryptophan
Equilibrium dialysis of plasma samples was carried out as
described by Wood et al. (1977) MutK the dialysis ' carried
out at room temperature) equilibrium was attained after 4 h, when
the samples were extracted. The plasma total and free tryptophan
was measured fluorometrically by a modification of the method
described by Eccleston (1973). The method was modified in the following
ways: 4 ml of 10% (w/v) trichloroacetic acid, 0.5 ml of 1.8% (w/v)
-4formaldehyde and a final strength of 1.5 x 10 M FeCl^ were used.
The samples were centrifuged at 3,000 x g for 10 min at 20°c and 
the ferric chloride solution was added to the samples immediately 
prior to incubation in a boiling water bath. The samples were 
put in to the incubation bath within 15 min of being centrifuged 
(Wood et ai., 1977).
(i) Plasma phenylalanine
Plasma phenylalanine levels were measured using a method based 
on that of McCamanr* & Robbins (1962) in which the phenylalanine is 
measured by virtue of the fluorescence obtained when phenylalanine 
is reacted with ninhydrin in the presence of a sensitizing peptide
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(L-leucyl-L-alanine). The success of the method depends on the 
strict control of pH (5.8 ± 0.1) by means of a succinate buffer; this 
optimizes fluorescence and maximises specificity. The method is 
described in Sigma Tech. Bulletin No. 60F/70F (7-74): the reagents
were obtained from Sigma (London) Chemical Company Ltd. in the form 
of a 'kit'.
(iii) Plasma tyrosine
Plasma tyrosine was measured by the method of Wong et ai. (1964). 
The basis of the assay is the formation of a fluorescent derivative 
formed by the reaction of tyrosine with l-nitroso-2-napthol after the 
mixture is heated in the presence of nitric acid. The reagents 
were provided in a kit form by Sigma (London) Chemical Company Ltd.




It has been shown that the freezing of plasma samples does not 
affect the total and free tryptophan levels in plasma (K. Wood, 
personal communication). The measurements were carried out on animals 
which had been chronically treated with methamphetamine for 30 days 
and the results are shown in Tables 13 and 14. It can be seen that 
there is no change in total tryptophan between the groups. The % 
free tryptophan is significantly lower in the chronic group compared 
with the controls. The free tryptophan levels are significantly 
lower in the chronic group compared with the controls and the 
withdrawn animals. There is no significant difference between the 
groups in bound tryptophan levels.
The phenylalanine and tyrosine results show no significant 
differences between the groups.
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Tables 13 and 14 Table 13 shows the total, free and bound
levels of tryptophan in the plasma (in yg/ml) 
from rats from experimental set 4 after 30 days 
of chronic treatment.
Table 14 shows the levels of phenylalanine 
and tyrosine (in yg/ml) in plasma from the 
same rats. The % of free amino acid is also 
given.
X is the mean 
is the stanc
n is the number
a . ndard deviation n-1
The figures were analysed statistically using 
Satterthwaite's approximation and the "student's" 
t test .
* indicates a significant difference from the 
control group 
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1. Levels of phenylalanine and tyrosine in the plasma and in 
the brain
The levels of phenylalanine and tyrosine in the plasma were 
unchanged in all three experimental groups. The binding of other 
amino acids, apart from tryptophan, to serum proteins is not usu­
ally considered as playing any regulatory role: it was interesting
that about 10% of the phenylalanine is bound to serum proteins 
although this did not change in any of the experimental groups.
That the levels of these amino acids are unchanged on chronic 
treatment with, or withdrawal from, methamphetamine is a good 
indication that their nutritional status is the same in all the groups 
Consequently any change observed in the levels of amino acids in 
the brain is unlikely to be due to a nutritional deficit caused by 
the anorexic effects of methamphetamine which is subsequently 
compensated for on withdrawal.
The levels of phenylalanine and tyrosine in the various regions 
of the brain did not appear to change on chronic treatment with 
methamphetamine but increased dramatically on withdrawal in the regions 
examined.
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2. Tyrosine hydroxylase activity
The results obtained for the activity of tyrosine hydroxylase show, 
in the case of experimental set 1, a decrease in both the 15 and 30 day 
animals after chronic treatment followed by a complete or partial re­
covery on withdrawal. After 30 days the decrease in activity on ch­
ronic treatment was so great that it was below the sensitivity of the 
assay. However, experimental set 4 did not show any significant 
change in tyrosine hydroxylase activity in any of the experimental groups. 
P. Vaughn (personal communication) has found, with studies on synap- 
tosomes, that the effect of amphetamine on tyrosine hydroxylase activity 
in vitro depends on the control levels. If these are high then amphet­
amine tends to decrease the activity and vice versa. The table of
control levels of tyrosine hydroxylase in the various experimental groups 
(Table 4) does not support this fact for my in vivo studies.
The graphs of the drinking rates, weights and food consumption 
(Figures 12 - 20) for the four experimental sets show that the chronically- 
treated animals from experimental set 1 differed fron the other three 
experimental sets in not developing tolerance to the anorexic effects 
of methamphetamine and they drank significantly less water. Subjective 
observations indicated that they were under considerably greater stress 
than the other sets. Stress had already been shown to correlate with 
alterations in catecholamine metabolism (Ishii, 1975; Curzon, 1978) 
and to increase the effect of methamphetamine on amine depletion 
(Beauvallet et al., 1962b, 1967; Moore & Lariviere, 1963, 1964; Salama 
& Goldberg, 1969). Stress also releases amphetamine which was stored 
in rats chronically treated with amphetamine (S. Sparber, personal 
communication). Consequently the measurements from the first experi­
mental set will be considered separately.
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Ellison et al. (1978), using pellet implantation to treat 
rats chronically with (+)-amphetamine found, after sectioning the 
brains and visualizing the amines with formaldehyde vapour, that 
there was a reduced fluorescence in the forebrain after 2 days and 
"diffusion around cortical axons". After 5 days, they found that the 
axons in the caudate nucleus had become swollen, which is very 
similar in appearance to the caudate after lesions have been made 
by partial aspiration (Andén et ai., 1955). The implication is 
that continous amphetamine treatment damages the dopaminergic 
terminals in the caudate. The swollen axons are thought to reflect 
an accumulation of amines in the remaining axons. On withdrawing 
the rats from amphetamine for 5 to 33 days, a gradual and partial 
reappearance of the background fluoresence and finer axons was 
usually seen, but bright and extremely swollen axons were still 
present in some regions. Ellison et al. (1978) measured tyrosine 
hydroxylase activity in several brain regions and found that in 
the caudate the activity had dropped to 50% of control levels and 
that it had not returned to control (74%) 110 days after withdrawal, 
although the activity was elevated in some regions. This supports 
the results from the fluorescence studies in that amphetamine, 
administered by pellet implantation, causes selective alterations 
in nigrostriatal dopaminergic fibres. In order to show that 
chronic .amphetamine administration by pellet implantation is not 
the same as i.p. injections and is a better model for amphetamine 
use in man, where chronic users develop patterns where, for several 
days they are in a permanent state of intoxication, Ellison et al. 
(1978) carried out a similar study to that already described 
except that they administered the same dose (3.2 mg/kg/24h.)- i:p.
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once a day for 30 days and found that the activity of tyrosine 
hydroxylase did not decrease.
Thus, one possible theory which would explain the disparate 
results obtained for tyrosine hydroxylase in my experiments is that 
the first experimental set were in a permanent state of intoxication 
with the drug. I administered the drug by 2 i.p. injections per 
day in order to make my model resemble the human state more closely. 
The animals in experimental set 1 were stressed, therefore it seems 
possible that the amount of circulating drug which would otherwise 
be stored in adipose tissue was continually being mobilized. It 
is also possible that these animals may have been more sensitive 
to the effects of amphetamine. It has been observed, using 
operant conditioning, that individual rats can behave completely 
differently to the same dose of amphetamine (L.H. Possum, personal 
communication).
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3. Levels of catecholamines and their metabolites in various 
brain regions
In experimental set 1 only noradrenaline and dopamine levels 
were measured in the cortex, nucleus accumbens, amygdala and hypo­
thalamus. In all regions the levels of noradrenaline and dopamine 
tended to decrease on chronic treatment; this decrease reached 
significance inthe noradrenaline levels in the cortex, dopamine 
levels in the nucleus accumbens and noradrenaline and dopamine 
levels in the hypothalamus. On withdrawal the levels of nor- 
: adrenaline and dopamine in the cortex in the amygdala were 
significantly decreased. The levels, of noradrenaline and dopamine 
tended to recover in the nucleus accumbens and the hypothalamus but 
only the dopamine levels in the hypothalamus were significantly 
above the chronic levels.
The modified radioenzymatic assay method which allows nor­
adrenaline, dopamine and their non-O-methylated metabolites to be 
measured simultaneously was used for experiment set 4. No 
significant change in any of the amines or their metabolites was 
found. In order to get an idea of the changes which had occurred 
in the metabolites in the samples from experimental set 1, I 
examined a chronic and a control sample from the hypothalamus 
from this set of animals after 30 days of chronic treatment.
The decrease in noradrenaline, dopamine and their non-O-methylated 




3,4-dihydroxymandelie acid: no change
3,4-dihydroxyphenylglycol: 78%
Dopamine : no change
3,4-rdihydroxyphenylacetic acid: 47%
3,4-dihydroxyphenethanol: 53%
Tentatively it would appear that, in the hypothalamus, nor­
adrenaline was affected more than dopamine but the metabolites of 
dopamine were affected more than the noradrenaline metabolites.
This is the reverse of what would be predicted from the MAO in­
hibition studies (ffentle et ai., 1976). However if MAO inhibition 
is physiologically significant, an explanation for this apparent 
discrepancy could be that the concentration of dopamine in the 
hypothalamus is not significantly different from the control values 
whereas noradrenaline is only 23% of control values. The hypo­
thalamus contains a higher endogenous level of noradrenaline, but 
if we are only dealing with intraneuronal deamination this is not 
an important consideration. Consequently any intraneuronal in­
hibition of MAO will affect dopamine more than noradrenaline.
The results of the amine levels in the experiment set 1 and 
experimental set 4 agree with the theory put forward in section 
2 above to explain the different results obtained for tyrosine 
hydroxylase. Ellison et al. (1978) found decreased levels of 
dopamine in the striatum on chronic treatment by pellet implantation 
and decreased levels of noradrenaline in the cortex, hypothalamus 
and brain stem. There were increased levels of dopamine in the
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brainstem on chronic treatment. On withdrawal, the levels returned 
to control.
It is worth mentioning here that although I do not consider the 
results from Section III to be reliable due to the problem of the 
internal standards noted previously, rats with electrolytic lesions in 
the medial Raphe nuclei have been found to engage in the same "mud- 
walking" (C. Pycock, personal communication) which I saw in the animals 
described in Section III. The Raphe nuclei are serotonergic 
tlierefore these lesions would be expected to decrease the levels of 




Experimental set 1, owing to a high level of stress, resembled 
the model of chronic amphetamine treatment which is produced by 
pellet implantation, i.e. the animals may be in a permanent state 
of intoxication induced by the drug. The extent of the decrease of 
tyrosine hydroxylase increases with the duration of treatment which 
is in keeping with the hypothesis that structural damage may be occurring. 
In my studies the enzyme activity returned to control values in the 
cortex, striatum, nucleus accumbens and amygdala, but was still 
significantly lower than control in the tuberculum olfactorium, 
hypothalamus, pons and medulla after 30 days of treatment, and only 
returned to control levels in the striatum and hypothalamus after 15 
days of treatment.
The levels of noradrenaline tended to return to control values 
in only two of the regions studied (nucleus accumbens and hypothalamus). 
The noradrenaline and dopamine levels in the cortex and amygdala 
were significantly decreased on withdrawal.
These findings can be explained in two ways: (1) assuming
structural damage to dopaminergic neurons (ii) assuming that the only 
changes are metabolic.
Damage to the neurons by lesioning causes a loss in tyrosine hydroxy­
lase activity due to damage of cell bodies (Creese & Iversen, 1975) 
and a supersensitivity of the receptors (Ungerstedt, 1971aD to that 
amine; therefore as the levels of the amine return to control levels 
on withdrawal, this supersensitivity may persist, resulting in a feedback
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inhibition of tyrosine hydroxylase. On withdrawal the situation 
starts to return to normal.
The actual situation is probably a combination of (i) and (ii).
To shed more light on the situation I would have to study withdrawal 
over a longer period of time.
In experimental set 4 amine metabolism appears to be unaffected 
by the treatment, in keeping with the hypothesis that in experimental 
sets 2 and 3 the stress was low and the animals did not seem to be 
permanently intoxicated with the drug. This agrees with my subjective 
observations. Ellison et ai. (1978) has shown that permanent and 
intermittent intoxication with amphetamine during a period of chronic 
treatment are qualitatively(and quantitatively)different. However in 
experimental sets 2 to 4 biochemical changes are occurring in the 
amino acid levels in the brain. Phenylalanine and tyrosine increased up to 
18 fold in some brain areas on withdrawal and this effect is not due 
to nutritional factors as shown by the constant levels of these amino 
acids in the blood. Tolerance to the drug appears to have developed 
and, whatever adaptive metabolic process has occurred, perhaps at the 
transport stage is disturbed by the withdrawal of the drug, resulting 
in the increase of brain phenylalanine and tyrosine. Other possible 




1. Levels of tryptophan in the plasma and in the brain
The total level of tryptophan in the plasma was unchanged in
all three experimental groups. The percentage of free tryptophan 
and the concentration of free tryptophan is significantly lower in 
the chronic animals (Satterthwaite's approximation for % free 
tryptophan f = 7, d = 2.408, p < 0.05. For the concentration of 
free tryptophan f = 6, d = 3.271, p < 0.02). The concentration 
of free tryptophan in the withdrawn group is significantly higher 
than the chronic group (p < 0.001). As free tryptophan decreases 
with stress (Curzon, 1978) it is difficult to know whether this 
finding is a concomitant of stress or an effect of chronic treat­
ment with methamphetamine. As I have mentioned earlier, using 
injected controls does not control for the stress induced in rats 
chronically treated with methamphetamine by i.p. injection.
The levels of tryptophan found in the brain did not change 
significantly in any of the animals from experimental set 4. 
Experimental set 1 did show significant changes; in this set of 
animals a decrease of tryptophan was found in the striatum, nucleus 
accumbens and amygdala in the chronic group. The overall tendency 
appeared to be a decrease of tryptophan in the nerve-terminal 
containing regions (striatum, nucleus accumbens and amygdala), 
and an increase in the cell body containing regions.
Measurement of tryptophan on the Chromaspek autoamino acid 
analyser is unreliable (M. Grant,personal communication). In a few 
cases (15 day hypothalamus, 15 day amygdala, 15 day pons and 15 and
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30 day medulla) the levels of tryptophan appeared to increase on 
withdrawal. In summary it is probably better to consider only 
those results obtained using fluorometry and bear in mind that 
changes in the levels of tryptophan probably are occurring, but 
the assay is not sufficiently sensitive to detect them.
It is important to question the assumption that the free trypto­
phan in the plasma regulates the concentrations of tryptophan in 
the brain and that the transport of tryptophan into the brain is the 
rate limiting step in the synthesis of serotonin Brain serotonin 
concentration and metabolism have been shown to be affected by the 
uptake of tryptophan into the brain (Green et al., 1952; Moir & 
Eccleston, 1968; Grahame-Smith, 1971; Fernstrom & Wurtman, 1971; 
Yuwiler, 1973; Gal & Drews, 1962). This is explained as reflect­
ing the relatively high Km of tryptophan hydroxylase which 
approximates to the normal brain tryptophan concentration. This 
is thought to be the rate-limiting enzyme for the synthesis of 
serotonin in the brain (Fernstrom & Wurtman, 1971; McKeen et al., 
1968; Eccleston et ai., 1970). Thus basal serotonin synthesis 
is thought to be both substrate and enzyme dependent with a basal 
rate approximating ^V. Since the tryptophan in the brain is taken 
up from the blood, research has tended to concentrate on the 
"free" tryptophan in the blood as being an indicator of brain levels 
and hence the rate of serotonin synthesis. This is based on the 
assumption that the Kd for tryptophan bound to the serum proteins 
is sufficiently low that most of the bound tryptophan is not going to 
dissociate-as- the tryptophan is being transported into the brain.
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The existence of a saturable aromatic amino acid carrier system 
has been well documented (Lajtha & Toth, 1961; Neame, 1964; Tsu- 
kada et al., 1963). Oldendorf (1971) has shown that most neutral 
amines can interfere with tryptophan transport to the brain. 
Perez-Cruet. et al. (1972) speculated that this was of physiological 
importance in regulating brain tryptophan concentration, which was 
confirmed by Fernstrom & Wurtman (1972) .
McMenemy & Oncley (1958) reported that tryptophan exists 
in the free form and bound to albumin in the blood. The binding 
is pH-sensitive and tryptophan can be displaced from albumin binding 
sites by agents such as free fatty acids (Curzon et al., 1973).
Both total blood tryptophan and free tryptophan have been correlated 
with brain serotonin changes following various treatments (Tagliamonte 
et al., 1973; Curzon & Knott, 1973; Fernstrom & Wurtman, 1971).
As tryptophan binding to albumin is a pH-dependent equilibrium, 
it seems likely to be influenced by the pH difference.between 
venous and arterial blood. Also the microcapillary bed has a 
small diffusion pathway, therefore the rate of uptake in the micro­
capillary bed of the brain might not be reflected in the bulk 
equilibrium conditions and between free and bound tryptophan in 
the blood.
Yuwiler et al. (1977) showed by experiments which manipulated 
the!levels of free and bound tryptophan that the bound tryptophan 
contributes to the tryptophan taken up by the brain. They also 
found that other amino acids may strongly influence the uptake of 
tryptophan into the brain. They argue that a considerable portion
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of the bound tryptophan is dissociated from the albumin during its 
passage through the capillary bed in the brain. They calculated 
the "effective" tryptophan concentration in albumin-tryptophan 
mixtures from the measured uptake into the brain and found that the 
"effective" tryptophan concentration greatly exceeds the measured 
free tryptophan.
Yuwiler et al., (1977) also calculated that, at normal blood 
concentrations, other neutral amino acids inhibit tryptophan 
uptake in the order leucine > tyrosine > threonine > phenylalanine 
= histidine > isoleucine = methionine > valine. This is of 
importance when considering the large increases in phenylalanine 
and tyrosine in the brain on withdrawal, and with reference to the 
other amino acid levels in the brain.
The assumption that the sole role of tryptophan in increasing 
serotonin formation is as a substrate is questionable. Firstly 
the effective half-saturation constant for tryptophan transport 
into neurons is likely to be considerably greater than 60.yM since 
it has been shown that several amino acids interfere with tryptophan 
transport at such concentrations (Grahame-Smith & Parfitt, 1970). 
This would tend to linearize the relationship between blood trypto­
phan and the rate of tryptophan hydroxylation. Secondly, the 
concentration of tryptophan at the neuronal uptake site and the 
hydroxylation site may not reflect the mean concentration of this 
amino acid in brain. If these concentrations were higher than 
the mean, the effectiveness of changes in available blood tryptophan 
would be minimized whereas, if lower, the effectiveness would be
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magnified. Finally tryptophan may do more in influencing the 
rate of 5-hydroxytryptophan synthesis than merely act as a 
substrate. By analogy with the tryptophan oxygenase system, 
tryptophan may help stabilize the hydroxylase, may influence co­
factor binding, or may help maintain the integrity and function of 
the pteridine reductase system (Etioineet ai., 1976; Yuwiler et ai., 
1977).
Peripheral considerations
Peripheral administration of tryptophan is a 'stressor', as 
evidenced by elevated adrenal corticoids and some 'stressors' lead 
to elevations in brain serotonin (Barchas & Freedman, 1963; Thierry 
et ai., 1963), but not all (Yuwiler, 1971) 'stressors' result in 
an elevation of brain serotonin, presumably as a complex function 
of hormonally-induced enzyme changes, alterations in central nervous 
system activity and even such factors as stress-induced changes in 
feeding behaviour. Thus adrenal corticoids are reported to elevate 
enzymic activity of mid brain tryptophan hydroxylase in adrena- 
lectomized animals (Azmitia & McEwen, 1969) and of aromatic amino 
acid decarboxylase (Davis, 1963), hepatic tryptophan pyrrolase 
(E.C. 1.11.1.4) and tryptophan amino transferase (Knox, 1963). in 
intact animals. The first two could facilitate conversion of 
tryptophan to serotonin and the latter could redirect tryptophan 
to alternative metabolic pathways.
The amount of free tryptophan in the blood is frequently 
correlated with the levels of brain tryptophan and brain serotonin.
The explanations put forward however have to be made with all the afore-
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mentioned factors in mind, especially when considering, as I am, 
the chronic administration of a drug which has central and peripheral 
actions by intra-peritoneal injection.
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2. Brain serotonin
There were no significant changes in the levels of serotonin 
in any of the regions from experimental set 4» except in the amygdala 
where the levels were significantly increased.
In summary the significantly lower levels of free tryptophan 
in the chronic and withdrawn animals do not correlate with the levels 
of brain tryptophan or serotonin. Brain tryptophan and serotonin 
levels either do not change, or decrease in the nerve-terminal 
containing regions and increase in the cell body containing regions. 
The low free tryptophan is not related to a nutritional deficit as 
the total plasma levels of tryptophan remain unchanged.
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C. Amino Acid Uptake
There was no clear pattern in the groups of amino acids which
were increased in the brain on withdrawal. Most of the amino acid
Uilyicfi
concentrations increased with the exception of (3\BAjwas not considered 
as the levels of this amino acid are known to increase dramatically 
post-mortem owing to the high activity of glutamic acid decarboxylase. 
Consequently it was not possible to interpret the data in terms of 
known carriers for groups of amino acids (e.g. neutral, basic, acidic, 
aromatics; see Oldendorf & Partridge, 1977).
The generalized changes in amino acid levels suggest that there 
may be a change in some metabolic pathway which is common and 
essential to the transport of all amino acids e.g., the y-glutamyl 
cycle (Meister, 1973) which has been suggested to be involved.
Another possibility is a general effect on the subsequent metabolism 
of these amino acids e.g. the availability of pyridoxal phosphate, 
a cofactor which is essential for many of the enzyme catalysed 
reactions in amino acid metabolism, or changes in the activity of 
the transaminases in the brain.
To investigate these metabolic parameters was not the aim of 
this work therefore the possible explanations for the increased 
concentrations of amino acids in the brain seen on withdrawal will 
not be considered in any more detail.
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D. Radioenzymatic Assays
The catecholamines and indoleamines are usually measured 
fluorometrically, radioenzymatically, by gas-liquid chromatography 
or using high-pressure-liquid chromatography. Of these methods 
only the last three were sufficiently sensitive for my needs and 
only the radioenzymatic assays were practical under my circumstances.
There are a number of radioenzymatic assays which have been 
published for the measurement of the catecholamines and indoleamines, 
all of which are based on the conversion of the amine to its 0-methyl- 
ated derivative in the presence of catechol-O-methyl transferase 
(COMT; E.C. 2.1.1.6) with - or methyl-$-adenosyl methionine
as the methyl donor.
For the measurement of noradrenaline and dopamine ,I used the 
method of Cuello et al. (1973). More sensitive assays for nor­
adrenaline and dopamine have been reported by Palkovits et al.,
(1974) and Gauchy et al. (1976) and modifications by Chiueh & Kopin
(1978) and Martin et al. (1978).
Assays which measure noradrenaline, dopamine and adrenaline 
simultaneously have been reported (Da Prada & Ziircher, 1976; Ben- 
Jonathan & Porter, 1976; Peuler & Johnson, 1977). Of the im­
provements and modifications reported, only two stand out. These
are: the use of sodium tetraphenylborate as a complexing agent
for the extraction of the 0-methylated amines and the use of thin- 
layer chromatography instead of paper chromatography.
Hefti & Lichtensteiger (1976) reported a method for the measure-
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ment of DOPA, and Argiolas et al. (1977) and Kebabien et al. 
have published methods for the measurement of 3,4-dihydroxyphenyl- 
acetic acid.
2+It has been reported (Gauchy et al., 1976) that Ca salts 
inhibit the reaction and refuted by Chiueh & Kopin (1978), therefore 
the alumina step employed by Gauchy et al. (1976)is probably un­
necessary. In all these publications on the radioenzymatic measure­
ment of catecholamines no one has looked for a thin-layer chromato­
graphic procedure which is capable of measuring DOPA, noradrenaline, 
dopamine and their non-O-methylated metabolites simultaneously. The 
method which I have described in Section IV is potentially capable 
of measuring all these compounds simultaneously.
However I believe that there is still more work to be done on 
this assay. The use of sodium tetraphenylborate to increase the 
sensitivity could be examined; the pH opt. of COMT isolated from 
rat brain is 7.2 - 7.4 (P. Gulliver & K. F. Tipton, personal communi­
cation) but in all the methods reported a Tris buffer was used and 
the pH varied from 8.6 to 10.4. I used a Tris buffer, pH 9.0,
but I did find that the pH of the incubation mixture was not constant ̂t
varied
between 7.8 and 8.2). I feel that it would be advisable to try 
using a phosphate buffer, pH 7.2 to 7.4.
The standard curves which I obtained for noradrenaline and 
dopamine using the method of Cuello et ai. (1973) and my thin-layer 
chromatographic method were not linear. In general I found it to 
be linear below 1 ng and above 1 ng (see figures 28 and 30 to 36).
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The gradient of the line was lower above 1 ng suggestive of in­
hibition of the enzyme or an insufficient enzyme concentration or 
S-adenosyl methionine. The most likely of these possibilities is 
inhibition of the enzyme by S-adenosyl homocysteine formed by the 
action of COMT. This can be removed by the use of adenosine 
deaminase, purified from Takadiastase (Kaplan, 1955) , which converts 
S-adenosyl homocysteine to S-inosyl methionine. Adenosine deaminase 
from Takadiastase has the advantages of having a broad specificity, 
broad pH optimum and being stable (Kaplan, 1955).
The sensitivity of my method for measuring noradrenaline, 
dopamine and their non-O-methylated metabolites is in the pg range. 
The reproducibility of the assay determined from the standard 
deviations of the mean c.p.m. obtained for each concentration of 
amine was not very reproducible. The amine levels were calculated 
from the standard curve which was run with every assay (Figures 
30 - 36 show the standard curves obtained from one assay).
The radioenzymatic assay which I used to determine the levels 
of serotonin (Saavedra, 1974) was inadequately buffered at the 
first reaction step i.e. the N-acétylation of serotonin. Again 
I think alternative buffers ought to be tried (the pHopt for sero­
tonin quoted by Weissbach (1961) is 7.5 - 8.5) e.g. N-2-hydroxyethyl- 
piperazine-N'-2-ethane sulphonic acid (HEPES) or triethanolamine 
hydrochloride-NaOH.
It has been proposed that a sulphomucopolysaccharide may be 
involved in the binding of catecholamines inside vesicles (Unvas,
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1973). It is reasonable to assume that the amines are in a bound 
form in the nerve terminal. Some work has been done on the hypo­
thesis that a sulphomucopolysaccharde is involved in the binding 
of catecholamines in the adrenal medulla. However little work 
has been done on the brain and that which has been done has been on 
whole brain. Pycock et al. (1975) reported a study in which adult 
rats which had treated at birth with 6-hydroxydopamine were in­
jected with ^^S-labelled sodium sulphate. Synaptosomes were 
prepared from various regions and it was found that the ^^S content 
of each synaptosomal preparation correlated with the decreases in 
catecholamine content brought about by 6-hydroxydopamine treatment. 
Sucrose gradient centrifugation studies showed that ^H-noradrenaline
labelled synaptosomes showed similar equilibrium characteristics
35as the distribution of S on the gradient. Their results showed 
that the main sulphomucopolysaccharides occurring in the synaptosome 
pellet were chondroitin sulphate and heparan sulphate.
The results of the study by Pycock et al. (1975) suggest to me 
the possibility of binding of the amines to chondroitin
sulphate or heparan sulphate in synaptic vesicles. Although this 
is purely hypothetical the question which would follow this is 
what fraction ac. 'pool' of amines is being measured by the various 
assay techniques available? This is, I believe an important question 
which ought to be investigated.
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E. Behavioural Correlates
As the concepts of drug addiction, tolerance and withdrawal are 
all behaviourally defined, I am going to describe a behavioural 
study on rats which were on a similar drug regime for a similar period 
of time and in which withdrawal was studied. This will be prefaced by 
a summary of the background to behavioural studies of this sort. For 
reviews on the behavioural analysis of amphetamine intoxication and be­
havioural theories on the effects of amphetamine see Lyon & Robbins
(1975) and Ellinwood et al. (1972).
Stereotypy and the approaches used to determine a biochemical mechanism 
Behavioural studies have indicated that treatment with amphetamine 
produces a sensitization to its central stimulant effects, i.e. the dose- 
response curve for stereotypy moves to the left (Hitzemann et ai., 1973). 
Stereotypy has been shown to be mediated by dopaminergic mechanisms. 
Stereotyped behaviour can be seen in most species of animals if they are 
given a sufficient dose of amphetamine. The topography of the stereo­
typed behaviour patterns differs between species and it should be 
emphasized that the responses characterised by stereotyped behaviour are 
not outside the animals'^general repertoire, but are observed in caged 
animals under a variety of conditions, although they ordinarily occur at 
a much lower rate. They are classified as stereotyped when their rate 
increases and therefore the rate of other types of behaviour decreases 
(e.g. eating and drinking). In rats stereotyped behaviour is character­
ized by repetitive licking and sniffing, periodically interrupted by 
gnawing on the cage floor or the rats own forelegs (Randrup &
Munkvad, 1968; Scheel-Krliger, 1971). The rat often assumes a 
characteristic crouched posture against the side of the cage. The 
frequencies of another behaviours such as eating, drinking, grooming
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and forward locomotion are greatly diminished.
Psychomotor stimulants which elicit stereotypic behaviour fall 
into two groups (Randrup & MunkVad, 1970? Scheel-Kriiger, 1972) .
In the first group the occurrence of stereotypic behaviour can be 
blocked by a-methy1-p-tyrosine but not by reserpine. This group 
includes amphetamine, methamphetamine and phenmetrazine. In the 
second group the occurrence of stereotypic behaviour can be blocked 
by reserpine but not a-methy1-p-tyrosine; this group includes 
pipradol and methyl phenidate. It was therefore suggested that 
the former group released catecholamines from the newly synthesized 
pool, while the latter group releases catecholamines from storage 
sites depleted by reserpine.
The conclusion that the activation of dopamine receptors in the 
corpus striatum appears to be responsible for amphetamine induced 
stereotyped behaviour is based on three experimental approaches :
(i) Drug-drug interactions; (ii) neurotoxin-drug interactions;
(iii) lesion-drug interactions. (These approaches epitomize the 
way in which biochemical theories of types of behaviour are con­
structed. The global nature of this kind of investigation leads 
to 'simplistic' biochemical explanations, i.e. the words used are 
the same but the concepts are not).
(i) Drug-drug interactions:
Many of these types of study were cited in the Introduction, 
here they are being looked at from a different viewpoint.
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It was noted that a-methy1-p-tyrosine blocks amphetamine- 
induced sterotypy, while reserpine does not. From this finding 
it was suggested that amphetamine-induced stereotypy is 
dependent on the newly synthesized pool of catecholamines.
L-DOPA can antagonize the blockade of amphetamine-induced 
sterotypy produced by a-methyl-p-tyrosine, suggesting that 
dopamine plays an important role in stereotypic behaviour. 
Administration of a dopamine-6-hydroxylase inhibitor does not 
antagonize the effects of L-DOPA, suggesting that noradrenaline 
is not required for amphetamine-induced stereotyped behaviour. 
That noradrenaline does not play a role in stereotypic behaviour 
is further supported by experimental data showing that neither 
a- nor g-adrenergic blocking agents have an effect on stereo­
typy. On the other hand, either i.p. administration of large 
doses of L-DOPA or direct injection of dopamine into the 
caudate nucleus elicits stereotypy. The importance of 
dopamine in stereotyped behaviour is also supported by evidence 
which indicates that dopamine acts at post-synaptic sites to 
produce stereotypic behaviour. The methylated metabolite of 
dopamine has been shown to increase after an effective dose of 
amphetamine in both reserpine-pretreated and normal animals 
(Randrup & Munkvad, 1970).
(ii) Neurotoxin-drug interactions:
Creese & Iversen (1973) used the neurotoxin, 6-hydroxy­
dopamine, in a series of experiments designed to examine the 
importance of the nigrostriatal dopaminergic system in the 
.mediation of amphetamine-induced stereotypy in rats. 6-
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Hydroxydopamine is presumed to destroy presynaptic catecholamin- 
ergic terminals. Rats were treated with 6-hydroxydopamine 
intraventricularly at 5, 7 and 9 days of age. Control rats 
were injected in the same manner, but with the 6-hydroxydopamine 
vehicle. Although special feeding procedures were necessary 
after weaning, the 6-hydroxydopamine rats were at normal body 
weight with a normal diet when tested. When control rats 
were given 5 mg/kg of (+)-amphetamine, stereotypic behaviour 
occurred throughout the 2 h experimental session, whereas when 
the 6-hydroxydopamine treated rats were given the same dose 
of (+)-amphetamine, stereotypy did not occur. Similarly, a 
10 mg/kg dose of (+)-amphetamine elicited stereotypy in controls, 
but very little, if any, in 6-hydroxydopamine treated animals.
On the other hand, apomorphine, a putative dopaminergic 
agonist, elicited stereotypic behaviour in 6-hydroxydopamine 
treated rats which was 2 to 5 times greater than control rats. 
Biochemical data showed that, following 6-hydroxydopamine 
treatment, tyrosine hydroxylase was only 2% of control levels 
in the striatum and dopamine levels were so low they could 
not be measured. Tyrosine hydroxylase activity and noradrenaline 
levels in the hypothalamus were 58% and 35% of control resp­
ectively. These data indicate that dopamine plays a major 
role in the expression of stereotypy. The increased stereo­
typy seen in 6-hydroxydopamine-treated rats following apo­
morphine suggests that the dopamine receptors were intact and 
functional, following 6-hydroxydopamine, and that they may be 
supersensitive owing to the destruction of presynaptic dopam­
inergic terminals. The results also indicate that (+)-amphet-
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amine-induced stereotypy depends on intact presynaptic 
dopaminergic neurons and is mediated by dopamine release.
(iii)Lesion-drug interactions:
Evidence from selective brain lesions also indicates that 
dopamine plays an important role in stereotyped behaviour in 
adult rats. Creese & Iversen (1975) made lesions in the 
substantia nigra that caused a 99% decrease in striatal tyro­
sine hydroxylase activity and completely blocked amphetamine- 
induced stereotypy, whereas partial nigra lesions that caused 
only an 80% decrease in tyrosine hydroxylase activity enhance 
amphetamine-induced stereotypy. Lesions in the dorsal and 
ventral noradrenergic tracts caused no modification of 
drug-induced stereotypy. The markedly different effect of 
amphetamine depending on whether the lesion produced 80% or 
99% depletion of tyrosine hydroxylase suggests that the small 
remaining pool of catecholamines may be of functional importance 
(Fibiger et al., 1973.)
On the basis of discrete lesions in the dopaminergic 
system, Asher & Aghajanian (1974) concluded that only lesions 
which reduced levels of dopamine in the caudate (i.e. nigro­
striatal lesions) blocked stereotypy. Other evidence questions 
whether the nigrostriatal dopaminergic system is necessary 
for stereotypy. Costall et al. (1972) lesioned the substantia 
nigra electrolytically and found no change in amphetamine- 
induced stereotypic behaviour; moreover the response to 
apomorphine was decreased.
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It is argued by many authors (e.g. Seiden, 1978) that as Costall 
et al. (1972) did not report dopamine levels, it is impossible to 
draw conclusions concerning the functional state of the dopaminergic 
system. Costall et al. (1972) provide morphological evidence 
concerning the precision of the lesion anatomically; Creese &
Iversen (1975) do not. The argument is in terms of pathways, there­
fore surely the anatomical evidence is crucial.
This global and rather destructive set of approaches towards 
a biochemical mechanism for the behavioural action of a drug, although 
highly regarded is, in my opinion, crude and of little value to 
the neurochemist. More important I believe that many neurochemical 
concepts have been arrived at in this fashion. This is especially 
true with the biochemical actions of amphetamine. One further 
comment is that, throughout,the interpretations of these studies 
attribute a causal relationship to the biochemical explanation. 
Temporally the cause has to precede the event.
The behavioural study where the treatment of the rats was 
very similar to mine was one by Hitzemann et al. (1977). They 
injected rats s.c. with 3, 6 and 12 mg/kg of (+)-amphetamine twice 
daily on a weekly increasing "staircase" schedule. On days 1, 7,
14 and 28 after the last injection of amphetamine the animals 
were challenged with 1 and 3 mg/kg of (+)-amphetamine and their 
behaviour observed.
Stereotypy, measured by a rating scale, and exploratory activity 
by square-crossing, showed that for at least 28 days after with­
drawal from chronic amphetamine treatment, the dose of amphetamine
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necessary to induce stereotyped behaviours in the rat is considerably 
reduced. Square-crossing and rearing activities were depressed 
from control levels in the withdrawn animals administered 3 mg/kg 
of (+)-amphetamine. However there was an increase in these be­
haviours if the withdrawn animals were administered 1 mg/kg of 
(+)-amphetamine. This inverted U shaped dose-response curve is 
also seen in control animals (Hitzemann & Loh (1974), although higher 
doses are required to depress the square-crossing activity. Thus, 
in the withdrawn rats the dose-response curve moves to the left.
While reserpine pretreatment markedly potentiates both amphetamine- 
induced square-crossing and stereotyped behaviours in normal animals, 
reserpine pretreatment had little or no effect on these behaviours 
in the withdrawn animals. The authors suggest that the storage 
of dopamine may have been altered by the chronic drug treatment 
causing dopamine to be more easily displaced by (+)-amphetamine.
Hitzemann et al. (1977) found that a-methyl-p-tyrosine blocked 
the (+)-amphetamine-induced increase in square crossing and stero­
typy, but only 20 - 30 min after administration of the amphetamine; 
between 0 - 1 0  min a-methyl-p-tyrosine potentiated these behaviours. 
a-Methyl-p-tyrosine blocked the (+)-amphetamine-induced stereotypy 
at both time intervals in the withdrawn rats, i.e. the effect of 
the drug, at this dose, depends on the unirterrupted synthesis of 
catecholamines. a-Methy1-p-tyrosine was not effective in blocking 
the effects of 3 mg/kg of (+)-amphetamine in the withdrawn animals; 
in fact the square crossing activity was potentiated during the 20 - 
30 min interval. This suggests that the effects of amphetamine 
at this dose are no longer dependent on catecholamine synthesis.
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Thus, behavioural studies have shown that there are long-term 
behavioural changes after chronic amphetamine administration in 





As has been mentioned before it was not possible to set up 
adequate controls for this experiment. Firstly the injected control 
group, after the first week, were not apparently upset by the 
injections. The chronic group reacted to every increase in dose 
with increased stress for several days. At best they were still 
more stressed than the control group. Secondly it was not possible 
to set up a control for the acute effects of methamphetamine as 
methamphetamine is stored in the body and mobilized by stress. Thus, 
one would have to determine the dose equivalent to the circulating 




The term 'enzymic adaptation' was first introduced by Karstrom 
ifi 1930 - 38 in order to describe the development of an enzyme 
activity by micro-organisms only when the relevant substrate was 
provided (see Richmond, 1968, for a general account). It has 
been shown that tolerance occurs at least to the anorexic effects 
of methamphetamine in my experiments, and that in those animals 
there is a change in amino acid levels in the brain on withdrawal, 
suggesting that metabolic adaptation had taken place. Logically 
I would expect any metabolic adaptation in the central nervous 
system to occur at the tyrosine hydroxylase step, however my results 
seem to indicate that it may be occurring at the level of transport 
of amino acids into the brain. However it is impossible to tell 
whether the in vitro activity of tyrosine hydroxylase is representative 
of its in vivo activity. It is possible that the results may have 
been affected by post mortem changes in the activity of the enzyme 
as the dissection time of set 1 was slower than that for the other 
sets. (6 to 7 min. as compared to 4 min.)
-268-
3. Tyrosine Hydroxylase
The literature on the kinetic properties of tyrosine hydroxylase
is diffuse and contradictory (see Mandell, 1978 for a review).
Four problems which make generalizations about the enzyme difficult
are:
(i) The purification of the enzyme using either proteolytic 
digestion, detergents (Kuczenski, 1973a; Kuczenski, 1973b)
or affinity chromatography (Poillon, 1971), provide contradictory 
results on the kinetic properties of the enzyme.
(ii) The kinetic properties of the enzyme appear to differ depending 
on the source e.g. adrenal medulla (Petrack et ai., 1968; 
Musacchio et ai., 1971); rat striatum (Kuczenski, 1973)and 
dopaminergic and noradrenergic neurons and sympathetic 
ganglia (Joh & Reis, 1975).
(iii)The cofactor used to assay the enzyme. Usually 6,7-dimethy1- 
pterin or 6-monomethyl pterin is used. These are not, however 
the natural cofactors for the enzyme.. The use of what is 
considered to be the natural cofactor (biopterin) gives 
completely different kinetic parameters and suggests alternative 
regulatory roles for tyrosine hydroxylase (Black, 1975; 
Mandell, 1978).
(iv) Purification of the enzyme from different sources show that 
the enzyme aggregates, therefore exists in more than one form 
in vitro (Poillon, 1971; Petrack et ai., 1968).
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4. Alterations in the "blood-brain barrier” on amphetamine treatment 
Carlsson & Johansson (1978) have suggested that amphetamine 
causes blood brain barrier "dysfunction" in rats. The theory is 
based on the altered permeability of Evans blue dye into the brain. 
This type of experimental design which is used to demonstrate 
alterations in the blood-brain barrier is adequately criticized by 
Dobbing (1968). However, that there may be alterations in the 




In this thesis I believe that I have studied the metabolic 
changes in what are, essentially two animal models of chronic 
methamphetamine administration.
Experimental set 1 closely resembled a model in which the 
animal is in a constant state of intoxication with methamphetamine.
In this group the progressive decrease in the levels of activity 
of tyrosine hydroxylase with the duration of treatment together with 
the decrease in the levels of noradrenaline indicates either an 
enzymic adaptation to methamphetamine, a feedback inhibition due to 
the increased activity of the dopaminergic and noradrenergic 
neurons, or damage to the catecholaminergic neurons.
The results from experimental sets 3 and 4 were completely 
different behaviourally and biochemically. The only changes ob­
served were in amino acid levels. The levels of free tryptophan 
in the plasma which were decreased on chronic treatment are difficult 
to interpret as there was no 'stressed' control. The increase in 
amino acid levels in the brain on withdrawal from methamphetamine 
strongly indicate a metabolic adaptation at the level of transport 
of essential substrates into the brain or on their subsequent 
metabolism. If the blood-brain barrier is damaged by amphetamine, 
as has been suggested (Carlsson & Johansson, 1978), the metabolic 
control in the brain may be completely altered. However the changes 
in amino acid levels in the brain did not appear to be altered on 
chronic treatment, only on withdrawal from the drug.
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Tolerance to the anorexic effects of methamphetamine only 
occurred in experimental sets 2 to 4. Therefore I am proposing 
that metabolic adaptation to the effects of methamphetamine occurs 




This thesis has covered a fairly wide range of biochemical 
variables rather than investigating one in detail. I feel that this 
overview was a necessary prelude to more detailed work. A few 
suggestions which emerge as a direct consequence from this work are:
I. An investigation into the changes in amine levels or tyrosine 
hydroxylase activity using pellet implantation as the means of 
administering methamphetamine, and comparing the results with 
the same dose administered intraperitoneally.
2. A more detailed investigation into the inhibition of tyrosine 
hydroxylase which it is possible to induce on chronic amphetamine 
treatment. Mixing the homogenates from the chronic and control 
rats would provide some information on the nature of the in­
hibition. Further kinetic studies could elucidate whether
the change in activity is a metabolic adaptation or due to 
feedback inhibition.
3. Full use was not made of the method which evolved for the 
measurement of DOPA, noradrenaline, dopamine and their non-0- 
methylated metabolites. Only a partial study was possible.
The method should be improved as suggested in Section 4 of 
the Discussion by using adenosine deaminase to remove the 
inhibitor S-adenosylhomocysteine.
4. The amino acid results were interesting as they were completely 
unexpected. Further work ought to be done in order to repeat
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this and obtain more statistically significant results. As 
well as providing fresh data on the biochemical actions of 
amphetamine it may well provide insights into the amino acid 
transport mechanisms frcxn the blood into the brain.
5. An investigation into the changes in amino acid uptake into 
the brain over a longer period of withdrawal.
6. A determination of the circulating and tissue levels of 
methamphetamine and its metabolites over a course of chronic 
treatment. A suitable experiment could be designed where 
the animal is subjected to mild and moderate stress and the 
circulating and tissue levels redetermined. From this one 
can attempt to set up a suitable acute control.
— 274”
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